The Development of Nanostructured Calcium Phosphate Biomaterials for Bone Tissue Regeneration by Wilcock, Caroline
 
 
The Development of Nanostructured 
Calcium Phosphate Biomaterials for 
Bone Tissue Regeneration 
 
Caroline Joanne Wilcock 
 
A thesis submitted towards the degree of  
Doctor of Philosophy 
 
 
 
Faculty of Medicine, Dentistry and Health 
University of Sheffield 
June 2015 
  
Caroline Wilcock - Abstract 
2 
 
Abstract  
Relatively little progress has been made in the preparation of new nanoscale calcium 
phosphates that have been modified to introduce improved properties when used as 
injectable bone graft substitutes.  The aim of this research was therefore to 
investigate the preparation and properties of injectable nanoscale hydroxyapatite 
(nHA) materials that were modified by either substitution of calcium for strontium, or 
doping with silver.  Wet precipitation and sol-gel fabrication of nHA were investigated 
in order to select and further optimise the methods which may be most suitable for 
the production of nanoscale hydroxyapatite pastes and gels, whilst also considering 
which methods would be most suited for the production of chemically modified 
nHA.  Materials characterisation results using X-ray diffraction, transmission electron 
microscopy and X-ray fluorescence demonstrated the successful formation of a range 
of strontium-substituted nHA (0 – 100 at. % strontium content), and a range of silver-
doped nHA (0 – 10 at. % silver content). In vitro biocompatibility results suggested 
that the majority of strontium-substituted nHA pastes and gels had no detrimental 
effects on cellular viability. Silver-doped nHA pastes were shown to have potent 
antibacterial activity against two microorganisms associated with bone 
infection, Staphylococcus aureus and Pseudomonas aeruginosa. In conclusion, this 
research has optimised manufacturing processes for the preparation of nHA, 
described new methods for the preparation of substituted and doped nHA, and shown 
that these modifications introduce additional properties including antimicrobial 
activity. The further commercial translation of these new materials with superior 
performance has the potential to benefit millions of patients worldwide. 
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1. Introduction 
Annually, millions of patients worldwide require bone augmentation materials to fill 
defects caused by trauma or congenital deformities. When bone healing is 
compromised, there can be a great impact on a patient’s quality of life as well as 
increased treatment costs. The current gold standard bone augmentation material is 
an autologous bone graft typically taken from the iliac crest of the patient. However, 
harvesting of the bone has significant disadvantages in terms of donor site morbidity, 
pain suffered by the patient and graft availability. The most commonly used bone 
augmentation material is allograft bone, which carries the risk of viral infections and 
undergoes deterioration in its osteoconductive and mechanical properties due to its 
processing [1]. Therefore, there is a great interest in the use of synthetic biomaterials 
for bone tissue regeneration. The ideal bone augmentation material should be 
osteoconductive to aid the regrowth of bone tissue, and be available in a suitable form 
to allow for the surgeon to easily implant it into the defect site. Synthetic bone 
augmentation materials have the potential to overcome the disadvantages of naturally 
derived bone graft substitutes summarised above.  
Synthetic calcium phosphates such as hydroxyapatite (HA) have been widely used in 
medicine and dentistry, in part due to their similarity to the mineral found naturally in 
bone and tooth enamel. Calcium phosphates have typically been used in the form of 
powders, granules or as coatings on the surface of implants. However, the 
development of nanoscale HA has encouraged alternative forms of bone graft 
substitute to be investigated. One promising technology that has been developed 
relatively recently is a paste based upon the combination of nanoscale calcium 
phosphate with water. Preliminary clinical data for the first generation of nanoscale 
calcium phosphate paste products is encouraging, suggesting that they are capable 
of promoting bone tissue regeneration [2, 3]. The reasons underpinning their good 
clinical performance are not known, but this may be due in part to the extremely high 
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surface area to volume ratio and biomimetic nature of nanoscale calcium phosphates. 
The improvement and wider clinical use of nanoscale calcium phosphate pastes may 
be worthy of greater consideration for a number of reasons. Firstly, these systems 
are injectable thereby facilitating minimally invasive surgeries. Secondly, nanoscale 
calcium phosphate may be chemically modified to enhance their clinical performance. 
For example, the production of a paste with enhanced bioactivity may beneficially 
decrease the time for successful bone tissue regeneration. Additionally, the use of an 
antibacterial calcium phosphate paste has the potential to reduce the incidence of 
bone infection.  
Despite this potential, modified nanoscale calcium phosphates have had little impact 
on the market or clinically. There is also a lack of laboratory studies that have 
considered the substitution of other chemical elements into injectable nanoscale 
calcium phosphate systems. Due to the vast array of elements that may be 
substituted into HA, there are many substitutions which might beneficially affect the 
bone healing response. Hence it is of great importance to investigate chemical 
substitutions, particularly those which are likely to have a potent effect on bone tissue 
regeneration.  
Furthermore, although there are an increasing number of publications regarding the 
production of nHA, it is often difficult to draw conclusions due to the mixed quality of 
the papers and the wide variety of process parameters described. Therefore there is 
a need for a more systematic review of the nHA production methods, ideally combined 
with laboratory study, in order to select the processes that are best suited to the 
production of chemically modified nanoscale calcium phosphate pastes. Given the 
potential improvement in versatility and clinical usefulness, the aim of this research 
was therefore to investigate and develop methods which could be used for the 
production of injectable substituted nHA products, with enhanced biological 
properties. The specific focus of this project was to develop nanoscale ceramics due 
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to the potential increase of bioactivity with the use of nanoscale over microscale 
hydroxyapatite, and because nanoscale mineral may form a cohesive pastes or gels 
to a better degree than microscale powders. These aims and objectives are outlined 
in more detail in Chapter 3, but before this it is important to review the literature to 
consider current progress and future potential.   
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2. Literature Review 
2.1 Bone Function and Structure 
In order to design and optimise biomaterials to encourage bone tissue healing, it is 
first necessary to understand the function and structure of bone tissue to comprehend 
how biomaterials may interact in vivo. Throughout the body, bone has a variety of 
functions including providing support and protection of vital organs as well as allowing 
for movement and hearing. Bone tissue is also responsible for mineral and growth 
factor storage and blood cell formation [4]. All these functions contribute significantly 
to a person’s quality of life. Therefore, considerable suffering can occur when bone 
healing is compromised.  
Bone tissue contains a highly organised structure which is in the constant process of 
being remodelled to repair frequently occurring microfractures. Wolff’s law states that 
the form which bone takes is a result of the biomechanical loads which are applied to 
it [4]. As a consequence, bone is found in different forms throughout the body which 
are highly specialised to achieve their required function; bone tissue is generally 
classified as cortical or cancellous (see Figure 2.1 A). Cortical or compact bone is 
found on all external layers of bones throughout the body, and is densely packed with 
structural units known as osteons (Figure 2.1 B). Osteons are made of hollow tubes 
of bone matrix called lamellae and surround blood vessels and nerve fibres in an 
arrangement known as the Haversian system. Within the osteons, osteocytes reside 
in lacunae at junctions between lamellae, and are connected to other osteocytes via 
narrow canals called canaliculi. The embedded osteocytes arise from osteoblasts 
which have become entrapped during the process of bone mineralisation. Cancellous 
bone is otherwise known as spongy bone and is located around the central cavity of 
most bones. It is made up of small struts called trabeculae, between which red or 
yellow marrow may reside. The trabeculae are aligned in response to external 
stresses exerted on the bones, in accordance with Wolff’s law [4]. 
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Figure 2.1. Hierarchical structure of bone tissue. (A) Schematic representation of a 
long bone cross section displaying the macroscopic organisation of the outer cortical 
bone layer and inner cancellous bone (Image from Wellcome Library, London). 
Cortical bone contains osteons (B) which are composed of layers of lamellae with 
collagen fibres (C) alternating direction between adjacent layers. Fibres contain 
collagen fibrils which have smaller structural units named microfibrils (D). Biological 
apatite crystals reside in between the collagen microfibrils. (E) TEM micrograph 
displaying arrangement of biological apatite crystals in sheep bone. (F) TEM 
micrograph of isolated biological apatite crystals. TEM imaged reproduced with 
permission from [5].  
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Bone tissue contains four main types of cells. Firstly, osteogenic cells residing in the 
periosteum and endosteum are the stem-like cells which provide a population of 
osteoblasts. Osteoblasts are responsible for secreting osteoid, which in turn is 
mineralised to provide structural strength to the bone tissue. Osteoclasts are 
responsible for the resorption of damaged bone. Lastly, osteocytes are responsible 
for monitoring the stresses exerted on the bone and communicate with other 
osteocytes through cellular extensions. When microfractures occur, a bone 
multicellular unit (BMU) is formed. A BMU is made up of osteoclasts which resorb the 
damaged bone, followed by osteoblasts which deposit osteoid. When the osteoid is 
mineralised and remodelled the bone once again possesses the necessary strength 
to withstand the applied loads. The combined activity of osteoblasts and osteoclasts 
therefore allow bone to maintain its structural strength by the removal of old, damaged 
bone and the formation of new bone tissue. 
Bone is generally considered to have capacity for self-regeneration, providing that the 
injury site is not too large and that the defect site remains relatively free of soft tissue 
invasion. Conventional fracture healing generally follows these stages: haematoma 
formation, fibrocartilagenous callus formation, bony callus formation and remodelling. 
Briefly, blood vessels which are torn by the fracture cause local bleeding which is 
stabilised by the formation of a haematoma. After a few days new blood vessels grow 
into the fracture site and fibroblasts and chondrocytes produce collagen and cartilage 
matrix respectively. Bone trabeculae begin to grow into the fibrocartilagenous callus 
over a period which can last up to 2 months. Finally the bony callus is remodelled to 
achieve bone tissue which has appropriate mechanical properties [4]. This type of 
fracture healing is based on the endochondral ossification of bone tissue which uses 
a hypertrophic cartilaginous template to form the bone as observed during the 
embryonic development of long bones. The other type of embryonic bone tissue 
formation is termed intramembranous ossification, which occurs in flat bones such as 
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the cranium and sternum. The process begins in the fibrous connective tissue 
membranes where an ossification centre is formed, consisting of mesenchymal stem 
cells differentiating into osteoblasts. In turn the osteoblasts secrete osteoid which is 
mineralised within a few days. The formation of osteoid around the blood vessels 
results in woven bone trabeculae and the periosteum surrounding the bone forms 
from condensing mesenchyme. The thickening of the trabeculae close to the 
periosteum results in a structure with a compact bone collar, with red marrow residing 
in trabecular spaces [4].  
The extracellular constituents of bone tissue can be divided into organic and inorganic 
categories. The organic component is termed osteoid and is comprised of 
proteoglycans, glycoproteins and type I collagen fibres, all of which are produced by 
osteoblasts. The inorganic phase of bone consists mainly of non-stoichiometric 
carbonated hydroxyapatite crystals that are in the form of nanoscale platelets residing 
between collagen microfibrils (see Figure 2.1 D and E). Apatite crystals have been 
reported to nucleate and grow in two different environments in the collagen network; 
the plate-like crystals grow in larger holes between the ends of collagen microfibrils 
and in smaller pores lateral to collagen microfibrils. The apatite crystals tend to be 
aligned with the c-axis parallel to the microfibril long axis. [6]. There is evidence that 
the mineralisation of developing bone occurs at the nanoscale, with 30 – 40 nm sized 
mineral in found in neonatal mouse bone [7]. Estimates for the size of mature 
biological apatite crystals include 50 x 30 x 2 nm [6] and 50 x 25 x 3 nm [8].  
Natural apatite is composed of non-stoichiometric carbonated hydroxyapatite, which 
has the general formula Ca10-x-y[(HPO4)(PO4)]6-x(CO3)y(OH)2-x. A variety of different 
elements are also present in bone (Table 2.1) as well as a variety of trace elements 
including silicon (500 ppm), zinc (39 ppm) and smaller amounts of chromium, cobalt 
and manganese [9]. The elements present in bone mineral may either be absorbed 
onto the crystal surface or substituted into the calcium phosphate lattice [9].  
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Therefore, there are a variety of biomimetic elemental substitutions which can be 
considered including carbonate, sodium, potassium and strontium. It should be noted 
that considerable variations in apatite composition can be found between individuals. 
For example the carbonate content in bone has been reported to be between 2.3 and 
8 wt. % [10, 11]. There are conflicting reports regarding the nature of the carbonate 
substitution. Some reviews claim that the carbonate groups are generally accepted 
to substitute for the phosphate groups, termed a B-type carbonate substitution [12]. 
Whilst it was reported by Tampieri et al. that B-type substitution was predominant in 
young bones, substitution of hydroxyl groups for carbonate groups (A-type) was 
increasingly present in bones belonging to older individuals [10]. The presence of 
carbonate groups decreases the crystallinity and thermal stability of the nHA 
compared to stoichiometric HA, whilst increasing the solubility. These changes in 
material behaviour may be partly attributed to the weakness of the calcium-carbonate 
bond when compared to the calcium-phosphate bond [12]. 
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Table 2.1. Elemental composition of the inorganic components of bone, enamel and 
dentine in weight percent [13].  
Wt. % Bone Enamel Dentine 
Ca 36.6 37.6 40.3 
P 17.1 18.3 18.6 
CO2 4.8 3.0 4.8 
Na 1.0 0.7 0.1 
K 0.07 0.05 0.07 
Mg 0.6 0.2 1.1 
Sr 0.05 0.03 0.04 
Cl 0.1 0.4 0.27 
F 0.1 0.01 0.07 
Ca/P molar ratio 1.65 1.59 1.67 
 
It has been reported that biological apatite has a low degree of hydroxylation. A 
mechanistic model to explain this has been reported by Wopenka et al. [12]; the 
smaller the crystallite size and the greater degree of atomic disorder progressively 
cause a less energetically favourable state for the incorporation of hydroxyl ions. 
Therefore the nanoscale nature of biological apatite leads to a large number of 
distorted bonds at the edges of the crystal, which inhibits the occupation of the 
channel sites by the hydroxyl groups. It has also been hypothesised that the hydroxyl 
site vacancies exist to accommodate the charge vacancy caused by the carbonate 
substitution for phosphate [6]. Indeed it may be a combination of these two effects 
that results in relatively low levels of hydroxyl groups in biological apatite.  
The combination of collagen fibres and the mineral phase provides bone with its 
structural strength alongside its flexibility and durability [14]. In terms of material 
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structure, the complex organisation of bone tissue is inhomogeneous and anisotropic. 
It has been reported that cortical bone has a remarkable tensile strength between 90-
230 MPa [15] which is comparable to steel, whereas the compressive strength of 
healthy bone is half as strong as steel [4]. The strength of bone is highly dependent 
on the volume of bone matrix present and its microarchitectural distribution, as well 
as the degree of mineralisation of the bone tissue. The mineralisation of bone begins 
to occur 5-10 days after the osteoid is deposited by osteoblasts, and can be described 
in two stages. Primary mineralisation progresses at a linear rate, followed by a slow 
gradual secondary mineralisation. It is believed that during primary mineralisation, 
matrix vesicles containing crystals or high concentrations of ions are delivered to the 
mineralisation front by osteoblasts. The matrix vesicles contain a number of proteins 
which allow for initial mineralisation to occur such as alkaline phosphatase and 
pyrophosphates. These proteins may allow for initial crystal nucleation to commence 
inside the vesicle before the mineral and protein contents are delivered via exocytosis 
to the extracellular matrix. Heterogeneous mineralisation can then occur with the 
presence of a nucleating substance allowing for crystal formation and growth. Gap 
zones at the end of collagen molecules are known sites of initial mineralisation. They 
are first filled with proteoglycans which bind calcium ions. The proteoglycans are then 
enzymatically degraded whilst phosphoproteins bind to the collagen. Alkaline 
phosphatase then dephosphorylates these molecules to make phosphate ions 
available for crystal growth. This whole process is highly regulated and controlled. 
For example, non-collagenous proteins can control the dimensions of the crystals by 
inhibiting crystal growth on particular faces [16]. During secondary mineralisation 
there may be an increase in the amount of crystals, or an increase in crystal size, or 
an improvement in the perfection of the crystal arrangement or any combination of 
the above [17].   
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The mineralisation of bone tissue also requires a degree of water content to allow for 
the diffusion of ions required during crystal growth. The surface of the hydroxyapatite 
crystal is surrounded by a layer of water known as the hydration shell. For the crystals 
to mature and grow, ions are required to diffuse from the surrounding fluid into the 
hydration shell. The ions can then either become deposited on the surface of the 
crystal or can flow into the crystal structure where substitution into the apatite 
structure can occur.  As a result of this situation, biological apatite permits a variety 
of ionic substitution, exchange or absorption which is highly dependent upon its 
surrounding environment [16].  It has also been hypothesised that water is an 
essential component of bone mineral due to the stabilising effect of water molecules 
in the apatite channels. As discussed previously, biological apatite contains hydroxyl 
site vacancies, possibly to compensate for the charge imbalance arising from 
carbonate group (CO32-) substitution into phosphate group (PO43-) sites. It has been 
proposed that the structurally incorporated water molecules support the hydroxyl 
vacancies in order to stabilise biological apatite [6]. 
2.2 Clinical Need for Bone Augmentation Materials  
Every year hundreds of thousands of patients in the US and millions of patients 
worldwide undergo bone graft procedures [18], with bone being the second most 
transplanted tissue after blood. The most recent estimate found for the number of 
bone grafting procedures performed worldwide is 2.2 million in 2006 [19, 20], however 
this number is likely to have increased considerably due to the aging population. 
Common procedures that require the use of bone grafts include treatment of fracture 
non-union, spinal fusions, filling voids left from the sites of bone tumour resection, or 
correction of congenital deformities. As well as in orthopaedics surgeries, bone graft 
materials are commonly used in maxillofacial surgery to repair areas of bone loss.  
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Bone has some capacity to heal itself as described in section 2.1 Bone Function and 
Structure. However, if the space in the bone tissue is above a particular size then it 
will not heal without surgical intervention; these are known as ‘critical size defects’. In 
particular, non-union fractures present a challenge to surgeons, as well as incurring 
considerable costs due to the long lasting therapies frequently required. For example, 
it has been estimated that a ‘best-case scenario’ humeral non-union fracture may cost 
over £15,000. Furthermore in the same study it was reported that the results of these 
long term treatments are often unrewarding [21]. This certainly highlights a need to 
produce materials which can rapidly and effectively aid bone healing.  
Another application which can require bone augmentation materials is to repair 
lesions left from the resection of cancerous bone tumours. Although primary bone 
cancer originating from the bone itself is rare, most commonly these osteosarcomas 
arise in young people, which often have devastating consequences on their quality of 
life. Furthermore, bone is a very common site for the metastasis of tumours. 65-80 % 
of patients with metastatic bone tumours have developed these as a result of breast 
or prostate cancer [22, 23], which are among the most prevalent cancers for women 
and men respectively. Bone metastases often greatly reduce the chance that a patient 
can be cured of cancer [24]. The current standard care for bone tumours are drugs 
which promote the activity of osteoclasts. Since 30-50 % of patients using these 
therapies develop further bone metastases more effective therapies are clearly 
required [24].  Promisingly, it has been reported that nanoscale hydroxyapatite 
exhibits inhibitory effects on osteosarcoma cells, whilst stimulating mesenchymal 
stromal cells [25]. Although no extensive research has been carried out into this area, 
this may present an alternative therapy which could be used in conjunction with 
current methods to potentially improve the prognosis for cancer patients.    
Another large segment of the bone biomaterial market consists of spinal fusion 
products. In the US, fusion was reported to be the 19th most common inpatient 
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procedure in 2003 and had experienced a sharp rise from being the 41st most 
common inpatient procedure in 1997 [26]. Spinal fusions are often required to treat 
trauma cases and degenerative disc disease. During the last century, autogenous 
bone grafting has been employed to enhance the success of spinal fusion 
procedures. The osteoconductivity of hydroxyapatite has also resulted in the use of 
this material in these operations. However concerns regarding the suitability of current 
hydroxyapatite materials have been raised, particularly due to their brittle nature and 
low shear strength for solid formations of HA used in load bearing applications [27].  
2.2.1 Materials used for Repair and Regeneration of Bone Defects  
As described in the previous section, bone augmentation materials are required for a 
variety of applications. The ideal bone augmentation material should possess 
osteoconductive and osteoinductive properties as well as being biocompatible and 
bioresorbable. Osteoconductivity refers to the capability of the material to assist the 
growth of new bone; importantly the material should allow the ingrowth of blood 
vessels and support the growth of osteoprogenitor cells. Osteoinduction describes 
the ability of a material to recruit pluripotent mesenchymal stem cells and to allow the 
differentiation of these cells into osteoblasts [28]. For the surgeon the material must 
be easy to use, and for society it is beneficial if the material is cost-effective, in terms 
of reducing the socio-economic costs associated with these types of injuries, diseases 
and deformities.  
The current gold standard bone augmentation material is autologous bone typically 
taken from the iliac crest of the patient. The living cells present on the resorbable 
bone matrix provides a bone substitute with no risk of rejection. It has been described 
to have the greatest osteogenic capacity of all bone augmentation materials. However 
the harvesting of autologous bone has major disadvantages such as donor site 
morbidity and graft availability [1]. The most common patient complaint is pain at the 
donor site, with less frequent complications including nerve injury, infection and 
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fracture at the donor site caused by the removal of bone [28]. Considerable costs are 
also amounted for the requirement of extra surgical time. Due to these disadvantages, 
allograft bone transplants are the most often used bone graft, but these materials 
have reduced osteoinduction and osteogenesis when compared to autograft 
transplantations. Also, allografts carry the risk of infections such as HIV and hepatitis 
B and C. The processing of allograft bone to reduce its immunogenicity has 
detrimental effects on the properties of the bone, particularly its mechanical strength 
and osteoinductive properties [1]. Similarly, xenogenic bone from animals must be 
processed before implantation to remove cells and proteins which would trigger an 
immune response. Human, bovine or equine bone can also be used to produce 
demineralised bone matrix (DBM), which is a sponge-like collagen scaffold, is 
prepared by decalcification and sterilisation of bone samples. DBM is mainly used as 
a bone graft extender due to its poor mechanical properties. As well as promoting 
revascularisation this material has been found to have osteoconductive and 
osteoinductive properties.   
The considerable disadvantages associated with the use of natural bone have 
encouraged the development of synthetic bone augmentation materials (see Table 
2.2). Although synthetic materials have a lower osteoconductivity than autografts and 
allografts, they can be prepared to be readily available ‘off the shelf’ products with no 
risk of disease transmission or immune rejection. Even though a wide variety of 
materials have been investigated for use in bone augmentation, the properties of a 
single material tend to be insufficient to recapitulate the natural composite material 
properties of bone. Indeed many composite materials based on combinations of the 
materials listed in Table 2.2 have been investigated in order to optimise material 
properties and characteristics. 
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Table 2.2. Classes of synthetic bone augmentation materials [29-31]. 
Class of material Examples 
Ceramics 
Hydroxyapatite  
β-tricalcium phosphate  
Bioactive glasses (Glass-ceramic) 
Metal Titanium 
Polymers 
Poly(lactic acid) 
Poly(glycolic acid) 
Poly(lactide-co-glycolide) 
Cements 
Calcium phosphate 
Glass ionomer 
Calcium sulphate 
Poly(methyl methacrylate)  
 
For example, polymers are generally combined with other materials such as ceramics 
or bioglasses in order to better match the mechanical properties of natural bone. For 
instance, the biomimetic use of collagen in bone graft substitutes imparts ductility to 
improve the mechanical properties. Problems associated with the use of natural 
collagen include ethical and disease transmission regarding the collagen source 
which is commonly derived from animals. Synthetic polymers such as PLA and PGA 
have also been extensively researched for use as composite bone augmentation 
materials. Advantages include the ability to control the degradation rate by altering 
the co-polymer ratio. However the acidity of the degradation products has to be 
considered to ensure a biocompatible response [29].  
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Table 2.3. Advantages and disadvantages of synthetic bone augmentation materials 
in clinical use.  
Material Form Advantages Disadvantages References 
Bioactive 
glass 
Granules  
Blocks 
Paste 
-Ability to form 
chemical bond with 
bone and 
osteoconductive 
properties 
-Degradation rate 
can be controlled by 
varying proportions 
of the reactants 
-Not 
osteoinductive 
-Poor 
mechanical 
properties 
[19, 32] 
Calcium 
phosphates 
(generally 
HA and β-
TCP) 
Powder 
Granules 
Blocks 
Cements 
Pastes 
-Inherently 
biocompatible due 
to similarity to 
mineral phase of 
bone 
-Osteoconductive 
-Degradation rate 
can be controlled by 
altering the      
HA:β-TCP ratio 
-Not 
osteoinductive 
-Poor 
mechanical 
properties 
[19, 30] 
Calcium 
sulphate 
Pre-set 
beads 
Cements 
-Rapid resorption 
rate  
-Good 
biocompatibility  
-Provides scaffold 
for bone growth 
-Readily provides 
calcium ions to 
promote bone cell 
activity 
-Relatively 
inexpensive 
-Not 
osteoinductive 
-Properties 
dependent of 
preparation 
technique 
-Blood may 
interfere with 
setting time 
-Poor 
mechanical 
properties 
[33] 
 
In contrast to resorbable polymers and ceramics, metals such as titanium have been 
used for bone tissue augmentation due to its good biocompatibility. The high strength 
of titanium has promoted its widespread use for joint replacement implants which are 
required to bear load. However, titanium is not resorbable and stress shielding effects 
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can cause the detrimental resorption of natural bone surrounding a titanium implant 
[34].  
Popular bone augmentation materials are listed in Table 2.3. For example, calcium 
sulphate was one of the earliest materials used for bone augmentation which was first 
used for the filling of bony defects reported in 1892 (reported by Peltier [35]). Calcium 
sulphate is a well-tolerated biocompatible bone augmentation material in vivo which 
undergoes complete and rapid resorption, generally with no significant inflammatory 
response encountered. However, the rapid resorption rate can be a disadvantage if it 
does not match the bone regeneration rate [33].  
Bioactive glasses were developed by Larry Hench in the 1960s and were the first 
material developed specifically for use in bone augmentation. When in contact with 
physiological aqueous solutions, a silica-rich gel layer forms on the surface which 
allows the material to form a direct bond with bone tissue [36]. Despite its’ apparent 
ability to stimulate a greater amount of bone regeneration than the other bioactive 
ceramics (e.g. HA and β-TCP), bioactive glass is not as widely used in bone tissue 
regeneration as calcium phosphate. One proposed reason for this was the difficulty 
of producing a porous form of bioactive glass from the original formulation (45S5). 
However, recent advancements have allowed this challenge to be overcome [32].       
Hydroxyapatite has been used widely in medical ceramic applications for decades. 
Due to its similarity to the mineral found naturally in tooth enamel and bone tissue, 
this calcium phosphate is inherently biocompatible and also displays good 
osteoconductive properties.  Even though this material has been extensively studied 
over the last 40 years, there are an increasing number of publications focussed on 
improving the bioactivity of this material, potentially due to its’ lack of osteoinductive 
and osteogenic potential [1]. Improvements in these properties may be possible with 
use of bone morphogenetic proteins or other bioactive factors. However, these 
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biological additions contribute to increased costs. Ceramic bone substitutes have 
recently been considered as the best alternative for autologous bone in orthopaedics 
surgery due to their safety, efficacy and low cost [30].   
A recent review by Kolk specified that autologous bone grafts were still the optimal 
material for the repair of craniofacial defects [29] despite the limited availability and 
significant disadvantages for the patient and surgeon associated with the harvesting 
of autologous bone. Similarly, for orthopaedic bone augmentation procedures the use 
of autologous and allogeneic bone are considered to be suitable materials for use 
[30] despite the risk of disease and prion transmission associated with allogeneic 
material [29]. This clearly highlights the need for superior synthetic bone 
augmentation materials to be developed.  
Future perspectives for bone augmentation materials highlight the need for improved 
materials which can allow for minimally invasive surgical intervention [37]. There is 
much interest in the use of growth factors to stimulate an optimal biological response. 
However, the high costs associated with these and other biological factors raise 
concerns that these developments are unsuitable for wide scale use. Alternatively, a 
more biomimetic mineral approach may impart beneficial biological properties, whilst 
providing a cost effective product. For instance, nanoscale calcium phosphate 
materials mimic the mineral found in bone tissue and therefore have attracted 
considerable interest for the development of superior biomaterials.    
2.3 Clinical Challenge of Deep Bone Infection  
In addition to the clinical need for the regeneration of bone tissue discussed in section 
2.2 Clinical Need for Bone Augmentation Materials, the treatment of deep bone 
infection remains a significant unmet clinical need. Osteomyelitis is a bone disease 
which may present as an infection of the medullary cavity, cortex or periosteum. The 
infection leads to the destruction and necrosis of bone tissue [38]. As well as causing 
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significant morbidity to bone tissue, the recurrence rate of osteomyelitis is particularly 
high [39]. There are three recognised routes for an organism to cause infection in 
bone. Firstly, the organism may be directly introduced to the site of infection which 
may occur at the time of injury or during surgery [40]. Alternatively, infection may 
spread from a local source, for example from a skin ulcer, which is known as a 
contiguous route of infection. Lastly, it is possible for organisms to travel through the 
blood to infect the bone which is known as the haematogenous route [40]. 
Osteomyelitis can be caused by a variety of pathogens; although pyogenic (pus 
forming) bacteria are usually present [38], mycobacteria and fungi may also be found 
at the site of bone infections. The Staphylococcus species account for most 
osteomyelitis cases, followed by Enterobacteriaceae and Pseudomonas species [41]. 
Staphylococcal infections are considered one of the most difficult infections to treat 
with problematic factors including antibiotic resistance [38]. Specifically, 
Staphylococcus aureus and Staphylococcus epidermidis are the cause of over 50 % 
of osteomyelitis cases [39].  
The management of bone infections remains a major challenge in orthopaedics and 
dentistry. The socio-economic costs associated with bone infections are particularly 
high due to increased lengths of hospitalisation and often the need for revision 
surgeries. The introduction of a biomaterial into the body unfortunately presents an 
opportunity for bacterial colonisation. For example, it was found that the minimum 
infection dose of S. aureus was reduced 100,000-fold for implant associated 
infections [42]. Indeed, it was suggested by Tavakoli et al. that the increased rates of 
bone infections are largely due to the increased use of prosthetic devices [38]. This 
may be caused by a decreased ability to kill phagocytosed bacteria in the presence 
of an orthopaedic implant due to a local polymorphonuclear cell defect [41]. Once 
bacteria have colonised an implant surface, the formation of a biofilm protects the 
bacteria from host defences and antibiotics. A biofilm is usually composed of 
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exopolysaccharides that are secreted by adhered microorganisms which act to 
protect the microbial community [43].  
Once bone has become infected, rapid and thorough treatment is required to prevent 
the death of bone tissue (chronic osteomyelitis) caused by the devascularisation of a 
large area of bone [39]. If chronic osteomyelitis occurs, a three step treatment 
program is used which consists of surgical debridement, systemic antibiotic treatment 
and local antibiotic delivery. The administration of high doses of oral and intravenous 
antibiotics are often required when treating osteomyelitis usually with a 6 week 
treatment period. Considerable costs are associated with these treatments; 
intravenous delivery of antibiotics often requires a long period of hospitalisation and 
infectious relapses are not uncommon [39]. For instance, systemic antibiotic 
treatment can costs hundreds of US dollars per day for outpatients and considerably 
more when a hospital stay is required [44]. As well as the protective biofilm, it is 
particularly problematic to treat bone infections using oral or intravenous antibiotics 
due to the difficulty of achieving an effective antibiotic concentration in the infected 
site. This problem is often compounded by low blood supply [45].  
2.3.1 Materials used to Treat Deep Bone Infections  
Local antibiotic delivery systems which are used to treat osteomyelitis can be 
classified into two classes: non-biodegradable and biodegradable. The main 
advantage of a local delivery system is the maintenance of a high concentration of 
antibiotics at the infected site for a long period of time [46]. Furthermore, the local 
administration of antibiotics actually reduces costs and avoids systemic toxicity issues 
associated with the intravenous administration of antibiotics. Non-degradable PMMA 
cement beads have been widely used for the treatment of chronic osteomyelitis. For 
example, gentamycin loaded PMMA beads Septopal® have been available for over 
35 years [47]. However, the requirement to remove the beads after treatment is a 
major drawback. Furthermore, this approach can lead to the undesirable colonisation 
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of the carrier surface by resistant bacteria during the later stages of low level antibiotic 
release [46]. The use of antibiotic impregnated PMMA beads is considered as the 
gold standard treatment despite their poor biocompatibility and cytotoxic effects [39]. 
Biodegradable systems provide the major advantage of not requiring removal. 
Collagen sponges, lactic acid polymers, calcium sulphate and calcium phosphate 
ceramics have all been investigated as biodegradable antibiotic delivery systems. 
The similarity of calcium phosphates to the mineral component of bone and their 
osteoconductive properties are advantages to their use. As such there are several 
reports of antibiotic loaded hydroxyapatite composites, typically involving the use of 
antibiotic loaded porous hydroxyapatite blocks [48] or tricalcium phosphate beads 
[49]. However, due to the rise of antibiotic resistant bacteria, it is becoming ever more 
important to seek alternative treatment options. As highlighted in a recent review, the 
increasing prevalence of antibiotic-resistant bacteria is considered a global health 
crisis. Furthermore the genes for antibiotic resistance are able to transfer between 
bacteria [50]. If a vancomycin-resistant Staphylococcus aureus were to evolve, this 
could cause infections that are resistant to all currently available antibacterial 
treatment [38].  
2.4 Nanoscale Hydroxyapatite Bone Augmentation Pastes 
There are currently three nanoscale hydroxyapatite pastes established on the market: 
Ostim® (aap Implantate AG, Berlin, Germany), SINTlife (Finceramica Faenza S.p.A, 
Italy) and ReproBone novoTM (Ceramisys Ltd., Sheffield, UK). Although there are 
several reports in the literature on the behaviour of Ostim® in vivo, fewer reports exist 
on investigations involving SINTlife and ReproBone novoTM. The majority of the 
reports published on nHA pastes have been published within the last 7 years, thereby 
highlighting the current interest in this novel class of materials.   
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Ostim® is prepared through a wet precipitation reaction involving the addition of 
orthophosphoric acid into a calcium hydroxide suspension [51] and has been reported 
to contain a range of nanoscale hydroxyapatite mineral content from 35 wt. % [51] to 
59.6 wt.% [52] in combination with water. Transmission electron micrographs of dried 
Ostim® paste display needle-like HA particles with a high aspect ratio (length of 
particle / width of particle). The particles have been reported to be 100 x 20 x 3 nm in 
size [53]. Several papers have reported the particle size as 18 nm [54] but this is an 
incorrect interpretation of Rietveld refinement results obtained from X-ray diffraction 
data that can only provide crystallite sizes which may be present in much larger 
particles.  
SINTlife is a nanoscale hydroxyapatite paste substituted with magnesium ions with 
particle sizes of 30-40 nm [55]. The preparation of the material involves the addition 
of calcium nitrate, magnesium nitrate and ammonium dihydrogen phosphate 
solutions into a dilute solution of ammonium hydroxide to maintain the pH above 9 for 
the duration of the reaction [56]. The solution is stirred in a carbon dioxide-free 
environment to reduce carbonate substitution into the HA. This is followed by a 
hydrothermal treatment at 120 °C followed by filtering, washing and drying stages. 
For more information regarding magnesium-substituted hydroxyapatite see section 
2.5.1.1 Substitutions Intended to Enhance the Bioactivity of Hydroxyapatite.  
In the past decade, Ostim® and SINTlife have been investigated for a wide range of 
bone regeneration applications to enhance healing throughout the body. These 
nanoscale hydroxyapatite pastes have been tested against conventional bone graft 
materials in a variety of procedures. Firstly, the biocompatibility of Ostim® has been 
investigated in vitro. However, one set of in vitro tests provided poor viability results 
for primary human osteoblast and mesenchymal stem cells cultured on Ostim®. It was 
suggested that the high water content of the material was likely to have reduced the 
osmotic potential of the culture conditions, thereby resulting in cell death [54]. Ostim® 
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has been extensively tested in a range of animals including rabbits, goats, pigs, 
minipigs and hamsters. In these animal trials Ostim® was generally found to possess 
potent osteoconductivity. It was reported in several papers that the rapid and thorough 
osteointegration of Ostim® may have hindered the complete resorption of the material 
[57]. Although Ostim®  was found to resorb at an early stage after implantation [58], 
there are reports that showed the cessation of Ostim®  degradation 4 weeks [59] and 
6 weeks [60] after implantation. Indeed, many animal investigations have described 
the incomplete resorption of Ostim®  after 12 weeks [59, 61] and 1 year [57]. In 
contrast, Thorwarth et al. [62] reported the complete resorption of Ostim®  6 months 
after implantation into critical size porcine calvarial defects. In the same study, when 
Ostim® was combined with autogenous bone, complete resorption occurred in 12 
weeks.  
Many studies observed favourable results for Ostim® compared with other materials. 
Ostim® was found to reduce cement penetration in acetabular bone impaction grafting 
[58] and Busenlechner et al. [2] found that the use of Ostim® led to a higher degree 
of bone formation compared to particulate deproteinised bovine bone mineral (Bio-
Oss®). The presence of Ostim® was also found to be beneficial for treating critical size 
rabbit defects compared with the use of a bovine derived porous HA scaffold 
(Cerabone®) [3]. Laschke et al. [51] reported evidence to suggest that Ostim® guided 
vascularisation during degradation after 14 days in vivo in dorsal skinfold chambers 
of Syrian golden hamsters.  
Similar promising results have been found with the use of Ostim® in clinical trials. 
Ostim® has been investigated as a material for use in a variety of bone fracture 
situations such as void filling of tibial compression fracture zones [63], complicated 
metaphyseal radial fractures [64], comminuted distal radial fractures [65] and 
calcaneal fractures [53]. Ostim® has also been tested in various maxillofacial 
surgeries including sinus floor augmentation [66, 67], intrabony peri-implantitis 
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defects [68], periodontal intrabony defects [69, 70], alveolar bone healing following 
tooth extraction [71] and lateral alveolar ridge augmentation [72]. In these applications 
Ostim® was generally found to be a suitable material due to its easy handling 
characteristics and its good biocompatibility and osteoconductivity thereby 
encouraging beneficial bone formation. Strietzel et al. [72] and Zaffe et al. [67] 
reported only a small amount of Ostim® presence 6 months after implantation for 
alveolar ridge augmentation and 12 months after implantation for sinus floor 
augmentation respectively.  
Clinical trials performed using SINTlife paste have included treatments for tibial 
osteotomy [55] and sinus grafts [73]. In these applications, SINTlife showed a limited 
resorption capacity. An improved resorption capacity was observed when SINTlife 
was mixed with allogeneic lyophilised human bone chips to form DBSint [55]. The 
nanocomposite DBSint showed significantly higher osteointegration than the 
lyophilised bone chips. It was also noted that the radio density of SINTlife was 
different from that of mineralised bone [55] thereby providing a useful means of 
monitoring the presence of the bone substitute. 
ReproBone novoTM is a nanoscale hydroxyapatite paste with a particle size of 30 – 
50 nm and a mineral content of 38 wt. % [74]. Although ReproBone novoTM has not 
been investigated as widely as Ostim® or SINTlife, early reports suggest that it has 
the ability to encourage bone tissue healing in the same way as other nanoscale 
hydroxyapatite pastes. When ReproBone novoTM paste was combined with 
hydroxyapatite and β-tricalcium phosphate biphasic granules to fill tooth extraction 
sockets in dogs, the nanoscale hydroxyapatite paste was completely resorbed within 
8 weeks. At this time point, remnants of the granules still remained. In this study, the 
granulated ReproBone novoTM construct presented superior biological results when 
compared to the self-hardening bone cementum group which displayed fibrous tissue 
encapsulation and a lower degree of bone tissue regeneration [75, 76].  
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Despite very encouraging experimental and clinical data, more general concerns exist 
regarding the safety of materials at the nanoscale. A review on the use of nanoscale 
materials in orthopaedic surgery conceded that the health effects of nanoscale 
materials are essentially unknown [77]. Safety considerations include the potential 
release of nanoparticles during in vivo degradation, and the subsequent transport and 
metabolism via the blood. Investigations involving the injection of nHA into mice 
concluded that the target organs of the blood-borne particles were the lungs, liver and 
spleen [78]. These investigations into the long term safety involved the repeated 
injection of nHA particles every 2 weeks over a 2 year period, with no chronic damage 
or long term side effects reported. The study concluded that nHA particles may be an 
effective drug carrier in appropriate concentrations as the lethal dose of the nHA 
suspension was caused by the blockage of capillaries [79]. The general consensus 
is that more studies need to be carried out in order to fully understand the potential 
risks associated with the use of nanoscale materials in vivo. However, the studies to 
date on nanoscale hydroxyapatite pastes have showed promising results with no 
specific concerns raised regarding the harmful migration of nHA throughout the body.    
Therefore based on the current evidence in the literature, it can be concluded that 
nanoscale hydroxyapatite paste-like materials present a promising new class of bone 
augmentation materials which may be superior to current clinical treatments. In 
particular the combination of these pastes with granules or bone chips generally 
provides superior handling characteristics and a better biological response, than the 
use of granules or bone chips alone. For information regarding the manufacture and 
characterisation of nHA see section 2.5.2 Nanoscale Hydroxyapatite Production 
Methods.  
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2.5 Hydroxyapatite Chemistry 
Before considering the methods to produce nanoscale hydroxyapatite, it is important 
to understand the chemistry and structure of hydroxyapatite (HA) and elemental 
substitutions which may impart favourable properties. Hydroxyapatite is a calcium 
phosphate mineral with the formula Ca10(PO4)6(OH)2. Therefore the stoichiometric 
calcium: phosphorus ratio for HA is 1.67. HA has been widely used in medical and 
dental applications during the last few decades due to its similarity to the mineral 
phase of bone and tooth enamel. Moreover, HA has excellent bioactivity and 
biocompatibility. It is considered as an osteoconductive material due to its ability to 
provide a beneficial environment for new bone apposition [28]. 
HA possesses the highest stability, density and insolubility of the calcium phosphates. 
In bone and tooth enamel, hydroxyapatite is present in its hexagonal crystal structure 
form. An alternative crystal structure for HA also exists, namely the monoclinic form 
in which the hydroxyl groups are stacked in a column and point in the same direction; 
in hexagonal HA the adjacent hydroxyl groups point in opposite direction [80]. Since 
the stability of the monoclinic form is sensitive even to a small amount of foreign ions 
[9], it is the hexagonal structure HA that is commonly prepared using precipitation and 
sol-gel techniques. Hexagonal HA has a P63/m space group with the unit cell 
dimensions of a = b = 0.9432 nm, c = 0.6881 nm [81]. Two different calcium cation 
sites exist in the crystal structure: Ca(I) and Ca(II), see Figure 2.2. In a unit cell of HA, 
4 Ca(I) atoms are tightly bound to 6 oxygen atoms, whilst sharing 3 weaker oxygen 
bonds. The Ca(I) atoms are arranged parallel to OH- channels and are aligned in 
precise columns. Deviation in the metal-oxygen interactions for the Ca(I) affect the 
entire lattice.  Meanwhile 6 Ca(II) are enclosed by 7 oxygen atoms. The Ca(II) atoms 
are staggered, belonging to consecutive layers, which allows for random local 
displacements without affecting the entire unit cell structure [9].  
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Figure 2.2. Hydroxyapatite crystal structure viewed along the c-axis. Note the different 
positions of Ca(I) and Ca(II). Reproduced with permission from reference [9]. 
The stages in the precipitation of hydroxyapatite have been investigated from 1965 
[82]. This report demonstrated the importance of an ageing step in the production of 
crystalline HA. Firstly an amorphous product was formed which slowly crystalizes until 
an apatite structure is observed. The final stage is characterised by a gradual 
increase of crystallinity caused by an enlargement of particle size and a reduction of 
the concentration of dissolved calcium in the solution. The growth of the crystals is 
said to occur through Ostwald ripening, where smaller soluble crystals are re-
deposited of the surface of the larger crystal. It is believed Posner clusters 
(Ca9(PO4)6), described as the growth unit of hydroxyapatite, may be involved in the 
process of Ostwald ripening. Specifically, it has been reported that Posner clusters of 
0.8 nm in height may partake in selective hexagonal packing during the formation of 
HA [83]. Posner clusters exist in the known precursors of hydroxyapatite, namely 
octacalcium phosphate and amorphous calcium phosphate [83, 84]. The Ostwald 
ripening process is considered as thermodynamically favourable due to the reduction 
of Gibbs free energy in the system; smaller particles are considered to have a high 
surface energy as a result of their large surface area to volume ratio. Therefore the 
reduction of surface area forms more stable, larger particles.    
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Hydroxyapatite undergoes thermal decomposition into β-tricalcium phosphate (β-
TCP). There are reports of the thermal decomposition of HA ranging from 1050 °C to 
over 1450 °C [85]. It was reported by Cihlar et al. that the most generally accepted 
mechanism of HA thermal decomposition [85] is:  
Ca10(PO4)6(OH)2 ↔ 2β-Ca3(PO4)2+Ca4(PO4)2O+↑H2O 
However there are also reports providing an alternative decomposition reaction [86-
88]: 
Ca10(PO4)6(OH)2 ↔ 3β-Ca3(PO4)2+CaO+↑H2O 
In particular, calcium-deficient HA [89] and nanoscale HA [90]  have been found to 
decompose to β-TCP at lower temperatures than stoichiometric HA. For example, 
Bianco et al. [90] reported the appearance of a β-TCP phase when nanoscale HA 
powders were sintered above 800 °C.    
2.5.1 Substituted Hydroxyapatites 
Apatite is considered to be a very flexible mineral in its ability to allow for a vast range 
of elemental substitutions. Indeed, apatite is able to around accommodate half of the 
elements in the periodic table [12]. Some possible substitutions of biological interest 
are listed in Table 2.4. The substitution of different elements into the HA crystal lattice 
affect the unit cell structure. These changes affect many material properties including 
crystallinity, crystal strain, hardness, thermal stability and solubility [12]. Furthermore, 
if the substitution does not balance the charge of the original ion, vacancies are 
created within the crystal structure. Cationic substitutions can occur over the whole 
range of occupation (e.g. substitution of Sr2+, Cd2+, Pb2+ for Ca2+) [9], or to a limited 
extent for smaller ions which inhibit crystal nucleation and growth e.g. Mg2+ and Zn2+ 
[56, 91, 92]. Similarly, the anionic substitution of Cl- or F- can replace all the OH- ions 
in the HA crystal structure. Carbonate substitution has also been reported to inhibit 
the growth of crystals resulting in poorly crystalline products with an increased 
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solubility. On the other hand, the substitution of F- resulted in a product with increased 
crystallinity and a lower solubility. Advantageously, these substitutional effects allow 
for the tailoring of material properties, which can allow for the material to be optimised 
for a range of different biological functions. For example, the use of fluoride in 
toothpaste and drinking water creates a degree of fluorine substituted apatite on the 
tooth surface which is more resistant to corrosion in an acidic environment [93, 94].     
Complications can arise when trying to distinguish if the ions have successfully 
substituted into the crystal structure or if the ions are present in an amorphous phase 
or adsorbed onto the crystal surface. Unfortunately there is discrepancy in the 
literature regarding the terms ‘substitution’ and ‘doping’ when describing chemical 
modifications to hydroxyapatite. Some researchers use the term interchangeably, 
whereas others regard substitution as the replacement of an atom in the crystal cell 
structure, whereas doping is the adherence of ions or particles on the surface of the 
crystal cell. Certainly in some cases it is not known which eventuality has occurred. 
Many researchers investigate the change in unit cell parameters to determine whether 
the introduction of a smaller or larger ion has caused a change in the unit cell 
dimensions. With the view to improve the bioactivity of hydroxyapatite, several 
elemental substitutions have been reported in the literature. 
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Table 2.4. Hydroxyapatite substitutions of biological interest; general formula 
M10(XO4)6Y2 [9, 12]. 
M XO4 Y 
Ca2+ PO43- OH- 
Sr2+ CO32- F- 
Ba2+ VO43- Cl- 
Cd2+ AsO43- Br- 
Pb2+ SiO44-  
Zn2+ SO42-  
Mg2+   
Mn2+   
Ni2+   
Cu2+   
Co2+   
Ag+   
Na+   
K+   
Al3+   
Y3+   
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2.5.1.1 Substitutions Intended to Enhance the Bioactivity of Hydroxyapatite 
Silicon-substituted Hydroxyapatite 
Silicon is the most prevalent HA substitution published in the literature. Historically, 
silicon-containing Bioglass was the first synthetic material to bond with living tissue 
and was discovered by Larry Hench in 1969 [95]. Silicon is a biologically relevant 
substitution as it was found to have a significant effect on the early stages of bone 
matrix production when cockerel chicks were fed silicon-deficient diets. In this study, 
bones from chicks fed silicon-deficient diets were found to have considerably less 
collagen present than chicks fed a silicon-enriched diet. Furthermore the silicon-
deficient chicks developed shorter and narrower skulls with abnormal areas 
displaying fewer trabeculae and less calcification [96]. Silicon has also been located 
in the unmineralised osteoid regions in young bones of mice and rats suggesting that 
it has an important role in the mineralisation of bone [97]. 
It has been reported that the maximum amount of silicon that can be successfully 
substituted into the HA crystal is 5 wt. % [97]. It should be noted that the maximum 
amount of silicon which could theoretically be incorporated into the HA crystal by 
replacing all of the phosphorus is approximately 20 wt. %. Due to the non-
isoelectronic substitution of SiO44- for PO43- the hydroxyapatite crystal can 
accommodate the extra negative charge by creating new anionic vacancies [97]. 
Therefore, the substitution of silicate ions into HA is not energetically favourable 
during crystal growth and it has been proposed that silicate ions only substitute with 
subsequent thermal treatment at 900 °C to displace residual carbonate ions [98]. The 
substitution of the silicate ion is also responsible for a decrease in the surface charge 
which in turn will allow a higher dissolution rate [97]. This has been proposed as an 
explanation for the difference in in vivo activity.  
The most popular method to synthesise silicon-substituted HA has been via 
precipitation methods [97] which use silicon sources such as silicon acetate [99]. 
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Balas et al. [100] demonstrated the importance of a basic pH during the precipitation 
of silicon-substituted HA. Silicon-substituted hydroxyapatite synthesised at a pH 
lower than 11 was found to decompose into β-TCP at a temperature of 950 °C. A 
review article by Boanini et al. [9] states that XRD is not a sensitive enough technique 
to distinguish between silicon and phosphorus due to their very similar isoelectronic 
states. Instead neutron diffraction is suggested to provide a clearer understanding on 
the presence and position of these atoms. 
Although there is evidence to suggest that silicon substitution enhances the bioactivity 
of HA [99], little is understood on the precise mechanisms by which the presence of 
silicon affects bone cells. A critical view by Bohner [101] suggests that silicon ions 
may be released by the materials and then have an active and direct effect on cellular 
behaviour. Another proposed theory is that the chemical and physical difference 
induced by the presence of silicon has an indirect effect on the cells when they interact 
with the surface of the modified biomaterial. Bohner concluded that it is still not clear 
whether the presence of silicon has a positive effect on the biological response of 
silicon-substituted calcium phosphates. However, Bohner also concedes that there is 
converging evidence that the addition of silicon to calcium phosphates such as HA 
and α-TCP modifies the in vivo behaviour of the material. For example, an in vivo 
study by Patel et al. [102] found a significantly greater bone ingrowth for 0.8 wt. % 
silicon-substituted HA granules compared to phase pure HA granules which had been 
implanted in the femoral condyle of rabbits.    
Interestingly, silicon-substituted hydroxyapatite was found to be osteoinductive in an 
ectopic ovine model. It should be noted that the stoichiometric HA was also found to 
be osteoinductive in this model which is unusual, since HA is not commonly accepted 
to have osteoinductive properties. However, significantly more bone formation and 
bone attached to the implant surface was observed in the silicon-substituted HA group 
[103].  
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Magnesium-substituted Hydroxyapatite 
Magnesium is another substitution which has been investigated in the literature due 
to its biological relevance; biological apatite is known to contain a higher amount of 
magnesium at the start of the calcification process which then decreases as 
calcification progresses [104]. Although magnesium is a known inhibitor of HA 
nucleation and growth, a limited amount of substitution is possible. 
Interestingly, Bigi et al. [56] recognised that an apatite phase could not be formed 
when magnesium was present between 35 – 50 at. %. In this range the product was 
found to be completely amorphous due to the ability of magnesium to inhibit the 
crystallisation of HA. Below this range, increasing the amount of magnesium causes 
a decrease in crystal size. Above this range, different crystalline phases are formed 
displaying the inability of the HA crystal lattice to accommodate the magnesium atoms 
at a level higher than 7 at. %. The amount of magnesium able to substitute into the 
lattice is limited by the inability of the magnesium atom to substitute into the Ca(I) 
position. Instead magnesium atoms are only able to substitute into the Ca(II) sites 
which form the channels surrounding hydroxyl ions (see Figure 2.2). This has been 
attributed to the shorter metal oxygen distance provided by these sites. Magnesium 
was found to preferentially adsorb onto the crystal surface when it was fully 
accommodated by the HA lattice. This has promoted research regarding magnesium-
doped hydroxyapatite which has been found to have a higher solubility than 
hydroxyapatite potentially through a reduction in crystallisation in conjunction with 
increased surface hydration [105]. 
It can be difficult to confirm the effective substitution of magnesium using conventional 
XRD analysis due to the decrease in HA crystallinity. Furthermore, low temperature 
precipitation methods can be prone to multi-substitutions such as carbonate-
substitution in conjunction with magnesium-substitution which can further complicate 
XRD patterns. The presence of magnesium in HA has been found to cause thermal 
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instability; it was reported by Bigi et al. [56] that the presence of magnesium causes 
the thermal decomposition of the magnesium-substituted HA to a magnesium-
substituted β-TCP above 500 °C. 
Magnesium-substituted hydroxyapatite has been found to have promising results 
regarding its in vivo activity. For example a study by Crespi et al. [106] compared the 
use of magnesium-enriched HA and autologous bone in maxillary sinus grafting. 
Although the autologous bone group displayed higher vital bone levels, ex vivo 
osteoblast expansion revealed that the magnesium-enriched HA had caused higher 
expression of osteoblast differentiation markers and bone formation markers which 
are also associated with a lower osteoclastic activity. Unfortunately, no details are 
given regarding the amount of magnesium present or the source of the material which 
makes it difficult to understand whether this material is magnesium-substituted or 
magnesium-doped HA. For more information regarding the in vivo behaviour of 
nanoscale magnesium-substituted HA paste (SINTlife) see section 2.4 Nanoscale 
Hydroxyapatite Bone Augmentation Pastes.  
Carbonate-substituted Hydroxyapatite 
As described earlier, the substitution of carbonate ions into hydroxyapatite is of 
particular interest due to the carbonate content of bone mineral. Indeed, bone apatite 
is said to contain between 2.3 and 8 wt. % carbonate [11]. For this reason, carbonate-
substituted HA is a biomimetic substitution which has attracted attention due to its 
potential to encourage bone tissue regeneration. Carbonate ions (CO32-) are able to 
substitute into two sites within the HA crystal structure. A-type carbonate substitution 
is when carbonate ions substitute into the hydroxyl ion site, whereas the carbonate 
ion occupancy of the phosphate group site is known as B-type substitution. The most 
biologically relevant substitution is a mixed A- and B-type which corresponds to the 
distribution of carbonate in biological apatite [11]. The presence of carbonate reduces 
the crystal growth and crystallinity of HA. These factors may account for the increased 
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solubility of carbonated hydroxyapatite, which has been proposed to contribute to its 
increased bioactivity [9].  
A recent in vitro study concluded that the effects of carbonated HA on the behaviour 
of human osteoblast-like cell line MG63 were not dose dependent on the amount of 
carbonate. Differentiation, osteoprotegerin and vascular endothelial growth factor A 
(VEGF-A) levels were all decreased with carbonated HA (3.88, 4.85 and 5.82 wt. %) 
when compared to conventional HA [107].  In contrast the activity of osteoclasts was 
stimulated on carbonated HA [108], and in fact osteoblast activity increased after the 
osteoclastic presence on carbonated HA [109].  
In vivo studies have concluded that carbonated HA has enhanced bioactivity due to 
its higher solubility and ability to stimulate osteoclastic resorption; indeed these two 
factors are intrinsically linked. For instance, Porter et al. investigated the behaviour of 
carbonated HA granules in an ovine model. The carbonate-containing HA (1.2 and 
2.05 wt. %) was more soluble than the HA with no carbonate content. Furthermore, 
the bone surrounding the carbonated HA displayed a higher degree of organisation, 
including the presence of collagen fibrils. It was concluded that the increased solubility 
of the carbonated HA may have activated osteoclasts, which in turn further 
accelerated the material breakdown [110]. In order to better understand the 
mechanisms regarding the increased bioactivity on carbonated HA, Spence et al. 
investigated the dual effect of carbonated HA and the osteoclast suppressing drug 
zoledronate. It was concluded that osteoclast activity was responsible for the 
increased osteoconductivity observed for carbonated HA implants [111].  
Strontium-substituted Hydroxyapatite 
Strontium substitution into hydroxyapatite is of particular interest due to the use of 
strontium compounds in the treatment of osteoporosis [112]. Osteoporosis is a 
common metabolic bone disease among post-menopausal women that causes the 
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weakening of bone tissue through over resorption of existing bone tissue and a 
decrease in bone deposition. This often results in fractures which can require patients 
to undergo traumatic joint replacement procedures. Oral dosage of strontium 
compounds, such as strontium ranelate, have been used successfully in the treatment 
of osteoporosis. It has been found that these strontium compounds have the ability to 
increase bone deposition whilst reducing bone resorption [112, 113] which has the 
positive effect of increasing the strength of bone, thus reducing the occurrence of 
fractures. More specifically, strontium ranelate has been found to increase pre-
osteoblast replication, osteoblast differentiation, collagen type I synthesis and bone 
mineralisation whilst reducing osteoclast differentiation [114]. This has led to interest 
in the field of strontium-substituted hydroxyapatite. Even in this form, strontium has 
been found to have a beneficial effect on bone formation, namely by stimulating 
osteoblast-like cells whilst inhibiting osteoclastic activity [115]. However, only a limited 
amount of papers have been published regarding the production and characterisation 
of Sr-HA which are discussed in detail below. 
Although the exact mechanisms of strontium action on bone cells are not fully 
understood, several theories have been proposed. Due to the use of the drug for 
reducing fractures in osteoporotic patients, research regarding the effect of strontium 
on bone cells usually investigates the effect of strontium ranelate on bone cell 
cultures. In this form, strontium is said to have a pharmacological effect on bone cell 
activity i.e. strontium directly exerts a biochemical or physiological effect. Furthermore 
the molecular mechanisms of strontium on bone cells have also been investigated 
[116]. The action of strontium on bone cells, particularly osteoblasts and osteoclasts, 
directly affects the rate of bone formation. Firstly, strontium reduces osteoclast activity 
and differentiation, thereby reducing bone resorption levels; this effect manifests 
through various actions including increased osteoclastic apoptosis and disruption to 
osteoclast adhesion [117]. Secondly, strontium stimulates osteoblast differentiation 
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and activity which increases bone deposition [117]. Finally, strontium has also been 
found to reduce the adipogenic differentiation of mesenchymal stromal cells, thereby 
effectively encouraging osteoblastic differentiation [118].  
The cellular effects listed above are caused by various molecular mechanisms which 
activate multiple signalling pathways. Namely, strontium can act through the calcium-
sensing receptor to increase the proliferation of osteoblastic cells. Osteoclast 
apoptosis and reduced osteoclastic differentiation is also stimulated by the effect of 
strontium on the calcium-sensing receptor. However, studies on knock-out animals 
with no calcium-sensing receptor, have shown that other pathways are also 
stimulated by strontium. For instance, the stimulation of the nuclear factors of 
activated T-cells (NFATc) pathway upregulates the expression of osteoblastic 
differentiation genes [119], although the precise mechanism by which NFATc is 
activated by strontium is unknown. Furthermore, strontium has been found to have 
an effect on the receptor activator of nuclear factor kappa-B (RANK) / receptor 
activator of nuclear factor kappa-B ligand (RANKL) / osteoprotegerin (OPG) system 
[116]. RANK is a cell membrane receptor present on the surface of osteoclast cells 
and their precursors. When RANKL binds to RANK osteoclast formation is stimulated 
as well as the activity and longevity of mature osteoclast cells. OPG inactivates 
RANKL by binding to it, thereby reducing its effect on osteoclast cells. Specifically, 
strontium increases OPG and decreases RANKL production which reduces 
osteoclast production and activity; this in turn reduces the resorption of bone tissue 
[120]. Furthermore, a study investigating strontium-substituted bioactive glasses 
reported the genetic upregulation of alkaline phosphatase, collagen type 1 α-chain 
and osteocalcin for strontium-containing samples [121].  
The higher atomic number of strontium when compared to calcium results in the 
higher radiopacity of strontium-containing materials. For instance, studies regarding 
strontium HA bone cement [122] and strontium calcium phosphate bone cements 
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[123] reported higher radiopacity for the materials containing greater amounts of 
strontium. This could beneficially aid in vivo placement and monitoring of implants.  
Strontium can be substituted into hydroxyapatite over the whole range of composition 
which causes a linear expansion of the lattice parameters [124, 125] due to the larger 
ionic radius of strontium (0.12 nm) when compared to calcium (0.099 nm). At low 
concentrations strontium has been found to display a preference for the Ca(I) site, 
whereas at higher strontium concentrations a slight preference for the Ca(II) site has 
been observed [125]. Low levels of strontium substitution cause a decrease in 
crystallinity. At higher strontium concentrations, increases in the size of crystals and 
the crystallinity of the material have been observed [125]. A computational study by 
Matsunaga et al. [126] indicated that for biological apatite mineralisation, strontium 
ions can be more favourably substituted into octacalcium phosphate (OCP) by ion 
exchange rather than straight into hydroxyapatite. Since OCP is a known precursor 
to hydroxyapatite, this provides an insight as to how strontium-substituted 
hydroxyapatite may be synthesised in wet chemical reactions.   
Strontium-substituted hydroxyapatite has been prepared by various methods 
including wet precipitation and sol-gel methods. Typical strontium precursors used 
include strontium nitrate and strontium hydroxide. Low temperature wet precipitation 
methods have used to produce strontium-substituted hydroxyapatite powders [115, 
125, 127], with one study preparing strontium-substituted-HA powders over the whole 
range of possible composition (0-100 at. %) [124]. It should be noted that these 
studies did not involve high temperature sintering stages, potentially due to the 
thermal instability of substituted apatites.  
Several papers regarding the sol-gel synthesis of strontium-substituted 
hydroxyapatite reported the thermal instability of strontium-substituted HA samples. 
Hanifi et al. [128] reported the emergence of a β-TCP phase after sintering at 600 °C. 
It was proposed by Renaudin et al. [129] that strontium-substituted β-TCP was being 
Caroline Wilcock - Literature Review 
55 
 
synthesised in the thermal decomposition of strontium-substituted HA. This was 
confirmed by Rietveld refinement studies investigating the changes in unit cell 
parameters of HA and β-TCP with strontium substitution into the two materials. 
Strontium HA has also been investigated in the form of coatings applied using 
sputtering techniques. Recent analysis of Sr-HA coatings by Boyd et al. demonstrated 
the changes in XRD patterns and FTIR spectra for coatings with increased amount of 
strontium [130, 131]. 
Strontium-substituted hydroxyapatite has been found to have a marked biological 
effect on osteoblasts at a relatively low level of substitution (3-7 at. %) [115]. 
Increased levels of alkaline phosphatase activity, collagen type I production and 
osteocalcin production were observed for osteoblasts cultured on Sr-HA samples. 
Furthermore osteoclast numbers were found to be reduced on the strontium-
containing samples, even at 1 at. % strontium incorporation. As an explanation as to 
how strontium-substituted HA promoted bioactivity, it was proposed that the presence 
of strontium causes a destabilising effect which in turn increases the solubility of 
strontium-substituted hydroxyapatite. Increases in solubility will result in a higher 
concentration of ions to interact with the bone cells. A study by Zhang et al. concluded 
that 10 at. % strontium-substituted HA promoted the highest levels of alkaline 
phosphatase activity and MG63 viability compared to 0, 40 and 100 at. % strontium-
substituted HA [132]. Interestingly it was also reported that the effect of Sr alone was 
not enough to stimulate the higher levels of proliferation and ALP activity observed 
for MG63 cells on strontium-substituted HA pellets; instead it was proposed that a 
joint effect between the strontium, calcium and phosphorus could be responsible for 
the biological effects observed [133]. Recently, it was reported that strontium-
substituted hydroxyapatite gels promoted proliferation and the differentiation of 
mesenchymal stem cells in an osteogenic manner. Specifically, alkaline 
phosphatase, osteopontin and osteocalcin markers were upregulated demonstrating 
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the enhanced osteogenic differentiation. However, due to the change in particle 
morphology when different amounts of strontium were present, it could not be 
concluded whether the changes in in vitro response were due to the direct effect of 
strontium or due to an indirect effect of particle morphology, or a combination of the 
two effects. Furthermore, only strontium-substituted nHA gels of up to 20 at. % Sr 
content were investigated; by considering strontium content only up to one fifth, an 
optimal Sr concentration may have been overlooked [134].  
Few in vivo studies are available concerning the response of SrHA. However, in one 
study, 10 at. % SrHA cement was found to interact differently than HA with cancellous 
and cortical bone in a rabbit hip replacement model. The SrHA cement induced the 
formation of a 70 µm apatitic layer when in contact with cancellous bone, whereas a 
layer of only 1 µm thickness was formed on the cement in contact with cortical bone. 
Furthermore, the different compositions of the apatite layers suggested different rates 
of cement dissolution had occurred at the different sites. It was proposed that these 
differences may be due to the presence of active osteoclasts at the cancellous bone 
site whereas no osteoclasts were observed at the cortical bone site [135]. 
2.5.1.2 Antibacterial Hydroxyapatite Substitutions 
As well as substitutions to increase the bioactivity of HA, some researchers have 
performed substitutions to impart antibacterial properties. Ions such as zinc, copper 
and silver have been investigated for this purpose. Although not fully understood, the 
broad mode of action of antibacterial ions reduces the likelihood of bacterial 
resistance developing. For example, as well as disrupting ATP production and DNA 
replication, it has also been suggested that antibacterial ions induce changes in cell 
membrane permeability and affect the transportation of protons. Furthermore, the 
production of reactive oxidative species affects several components of the cell wall, 
membrane and other intracellular components, ultimately causing cell death [136].  
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Zinc-substituted Hydroxyapatite 
Zinc is regarded as an essential biological element and has a particularly vital role in 
bone metabolism, since it is known to be present at the active sites of hundreds of 
enzymes [136]. For example, an increase in alkaline phosphatase activity and bone 
DNA content was observed when rats were given a low dose of zinc [137]. Therefore 
the development of zinc-substituted HA has been considered for bioactive and 
antibacterial purposes. Zinc has been shown to inhibit osteoclastic differentiation and 
stimulate osteoblast activity, thereby promoting bone formation [138]. Murine pre-
osteoblast cells cultured on zinc-substituted HA surfaces were found to display 
significantly increased cell proliferation, alkaline phosphatase activity and osteocalcin 
production [139]. Few published articles are available detailing the in vivo response 
of zinc-substituted hydroxyapatite. However, an in vivo experiment by de Lima et al. 
concluded that zinc-substituted HA granules were found to increase the rate of 
angiogenesis and were resorbed at a faster rate than stoichiometric HA [140]. 
Although zinc is a fairly potent inhibitor of HA crystal growth [92] it is still possible to 
perform zinc substitution using wet precipitation reactions [91, 92, 141]. So far it has 
been suggested that the successful substitution of zinc ions for calcium ions in the 
HA crystal occurs up to approximately 20 at. %. In a similar fashion to other ions such 
as magnesium, zinc preferentially substitutes into the Ca(II) site. The incorporation of 
zinc is associated with a decrease in HA crystallinity and thermal stability with partial 
decomposition to zinc-substituted β-TCP reported after sintering at 500 °C [92].  
The antibacterial activity of zinc-substituted HA has been reported  [142] and a zinc 
content of 1.6 wt. % was found to exhibit antibacterial properties whilst enhancing 
bioactivity [143]. Investigations regarding a zinc-doped β-TCP and HA composite 
ceramic reported the increased bioactivity of osteoblast cells when the zinc level was 
0.6 – 1.2 wt. %. However, a zinc content higher than 1.2 wt. % was found to have 
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cytotoxic effects due to zinc release, which highlighted the sensitivity of cells to small 
changes in metallic composition [144].   
Copper-substituted Hydroxyapatite  
Copper is involved in a variety of metabolic processes and has been known for its 
antibacterial properties since the Egyptian times. It was discussed that as well as the 
disruption to the bacterial structures and functions previously discussed for 
antibacterial ions, copper ions also increase macrophage ability to inactivate bacteria 
[145]. 
Reported synthesis methods of copper-substituted hydroxyapatite include 
hydrothermal [146], ion exchange [147] and wet precipitation methods [142, 148]. In 
these methods copper nitrate [146, 148] , acetate [147] and oxide [142] have all been 
used as copper sources.  The ion exchange method described by Li et al. involved 
the precipitation of HA followed by subsequent drop wise addition of the metal salt 
solution into the HA slurry. This study suggested that the substitution process involved 
initial rapid formation of surface complexes followed by the partial dissolution of HA 
whereupon the copper ions would exchange with the calcium HA ions [147]. The 
attempted substitution of copper by Stanic et al. resulted in a reduction in the 
stoichiometric ratio ((Ca+Cu)/P) for HA demonstrating the probable formation of a 
copper-substituted calcium-deficient apatite [142].  
Conflicting reports exist on the antibacterial efficacy of copper-substituted HA. Kim et 
al. reported that the antibacterial effect of copper and zinc were difficult to observe 
whereas clear antibacterial effects were observed for silver-substituted samples 
[148]. Conversely, it was reported by Stanic et al. that copper- and zinc-substituted 
HA samples showed clear antimicrobial activity against Escherichia coli, 
Staphylococcus aureus and Candida albicans [142]. High antibacterial activity was 
also observed against E. coli for copper-substituted HA. However, the same paper 
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concluded that copper-substituted HA coatings were unsuitable for implants due to 
the cytotoxicity of copper ions to osteoblasts [147].  
Silver-substituted Hydroxyapatite 
Few detailed reports have been published on the synthesis and antibacterial activity 
of silver-doped nHA research to date. The majority of reports which have been 
published mainly focussed on a substitution approach, whereby the amount of 
calcium is reduced in an attempt to substitute silver into the HA crystal lattice [149-
154]. However the drawback with this approach is that if the silver does not readily 
incorporate into the HA phase, calcium-deficient HA is likely to precipitate which 
possesses different properties than stoichiometric HA; particularly its’ thermal 
stability. Many studies do not report the level of silver successfully incorporated into 
the product and therefore it is not possible not know what changes are caused by the 
incorporation of silver and what changes are caused by the production of calcium-
deficient HA. Furthermore the substitution of silver into the HA crystal lattice may limit 
the diffusion and therefore the antimicrobial activity of the silver hydroxyapatite.  
Several researchers use the terms ‘doped’ and ‘substituted’ interchangeably when 
reporting on silver incorporation into HA. It would be beneficial for clarity if 
investigators used ‘substitution’ when silver was attempted to be substituted into the 
lattice and doped when silver was incorporated on the surface. Two reports where 
silver nanoparticles were introduced on the surface of the HA particles used the term 
‘nano composite’ which provided a clear distinction as to what the aim of the methods 
were [155, 156].   
A variety of methods have been used to synthesise silver hydroxyapatite materials 
including the sol-gel method [157, 158] and ionic exchange by immersion of HA in a 
silver salt solution [159]. However the most popular method is the wet precipitation 
method. Several researchers used the chemical precursors of calcium nitrate, silver 
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nitrate and ammonium phosphate [150, 151]. However, this approach may allow the 
formation of highly stable silver ammonium product, thereby limiting the amount of 
silver available for incorporation into the HA phase [160]. Alternatively, chemicals 
including calcium hydroxide and phosphoric acid were used in combination with silver 
nitrate [161]. An interesting approach by Ipekoglu et al. investigated the formation of 
a silver-substituted calcium-deficient HA using rapid microwave assisted processing 
[162]. Other approaches include the synthesis of HA followed by subsequent doping 
with silver nanoparticles [155, 156]. For these investigations TEM images clearly 
display the presence of silver nanoparticles closely associated with the HA particles. 
In the literature, the antimicrobial activity of silver HA powders and coatings have 
been tested against a range of bacteria including E. coli [151, 152, 156], S. aureus 
[149, 161, 163], methicillin-resistant S. aureus [157] and C. albicans [154]. It has been 
widely reported that even very low levels of silver incorporation contribute to an 
effective antimicrobial response. This suggests that low levels of silver may be 
suitable for achieving a suitable antimicrobial response whilst maintaining good levels 
of biocompatibility for host cells.  
However, it should be noted that bacterial genes for silver resistance have been 
identified and concerns have been raised regarding silver-resistant bacteria [164-
166]. In detail, silver resistance is often encoded with plasmid genes. The resistance 
genes can code for proteins which act to transport silver out of the bacterial cell [166]. 
With this in mind, silver is widely used to reduce infections suggesting that the benefits 
of using silver as an antimicrobial agent, particularly the low risk to human health, 
generally outweigh the risks of the evolution of silver-resistant bacteria.  
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2.5.1.3 Hydroxyapatite Standards in Relation to Substituted Nanoscale 
Hydroxyapatite Materials 
No standards were found specifically regarding nHA materials or HA paste materials. 
However, several standards are available regarding the quality of HA required for the 
production of surgical implants, specifically in the form of blocks and coatings [167-
170].  
In terms of allowable limits of elements apart from calcium, phosphorus, oxygen and 
hydrogen, two references were found in the current standards. Firstly, in BS ISO 
13175-3:2012 ‘Implants for surgery – calcium phosphates’ it is specified that any 
impurity with a ratio of more than 1000 mg/kg must be identified and its influence on 
bone healing shall be assessed [169]. The influence on biocompatibility will 
specifically be assessed using ISO 10993-1. Secondly, ISO 13779-6:2015 for HA 
powders used as raw materials for manufacturing of surgical implants or coatings 
stated that any chemical element except for calcium, phosphorus, hydrogen and 
oxygen likely to be present with a mass fraction more than 500 mg/kg shall be 
identified, quantified and indicated on the certificate of compliance on the batch [170]. 
Therefore, for the commercialisation of substituted nHA materials it would be 
necessary to prepare an alternative quality standard system which may be based on 
parts of the currently available standards. Based on the current standards it would be 
necessary to assess the biocompatibility of any substituted nHA material using ISO 
10993-1 to ensure the material was suitable to develop for clinical use.  
2.5.2 Nanoscale Hydroxyapatite Production Methods  
Conventionally, materials may be described as ‘nano’ if one or more of their 
dimensions are less than 100 nm [171]. Nanoscale hydroxyapatite is expected to 
have increased biocompatibility when compared to microcrystalline HA due to its very 
large surface area to volume ratio. Nanoscale hydroxyapatite materials can be 
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considered to be biomimetic since biological apatite is present in the body at the 
nanoscale (see Figure 2.1).  
Research into nanoscale hydroxyapatite materials is a relatively new field with the 
first report of the synthesis of nanocrystalline hydroxyapatite in 1995 using a spray 
dry method [172]. Since then, numerous methods have been employed to synthesise 
nanoscale hydroxyapatite including biomimetic synthesis, mechanochemical  and 
combustion processes [173]. Two prevalent methods are the wet precipitation and 
sol-gel methods. 
Firstly the wet precipitation method usually involves the drop-wise addition of a 
phosphorus solution into a calcium solution or vice versa. An alkaline pH (commonly 
9 or above) is maintained to ensure the formation of hydroxyapatite instead of brushite 
which is thermodynamically favourable at a lower pH. Typical combinations of reagent 
are listed in Table 2.5. Titration by means of a peristaltic pump offers more 
reproducible conditions and better controllability as when compared to the use of a 
burette. The titration step is followed by rigorous stirring and often an ageing step, to 
allow time for the growth of hydroxyapatite crystals. The poor colloidal stability of 
hydroxyapatite results in its precipitation out of the main solution. Typically the 
hydroxyapatite suspension is then washed by centrifugation or filtration, dried and 
sintered. The smallest particle sizes reported in the literature were achieved with use 
of dispersal agents such as Darvan 7 [174] and hexadecyl(cetyl) trimethyl ammonium 
bromide [25]. For instance, spherical nanoscale HA particles of size 80, 40 and 20 
nm were synthesised using 0.6, 0.9 and 1.2 mM of hexadecyl(cetyl) trimethyl 
ammonium bromide respectively. 
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Table 2.5. Typical reagents used in the wet precipitation method to produce 
nanoscale hydroxyapatite. 
Calcium 
precursor 
Phosphorus 
precursor 
Reagent to 
control pH 
References 
Calcium hydroxide 
Orthophosphoric 
acid 
None [89, 90, 174-176] 
Ammonium 
hydroxide 
[177] 
Sodium hydroxide [178] 
Calcium chloride 
Disodium 
hydrogen 
phosphate 
None [25] 
Ammonium 
hydrogen 
phosphate 
Ammonium 
hydroxide 
[179] 
Sodium phosphate Sodium hydroxide [86, 176] 
Calcium nitrate 
Diammonium 
hydrogen 
phosphate 
Ammonium 
hydroxide 
[90, 180, 181] 
Phosphoric acid [182] 
 
The sol-gel method contains similar stages as the wet precipitation method, starting 
with titration and mixing steps. Reagents typically used in the sol-gel method are listed 
in Table 2.6. Calcium nitrate is commonly used as the calcium precursor and the sol-
gel method can involve the use of organic precursors such as triethyl phosphite. 
Inconveniently, the use of triethyl phosphite requires a lengthy hydrolysis stage which 
can be up to 24 h [183]. Unlike the wet precipitation method, the sol-gel method 
involves an intermediate gel phase which is said to promote molecular level mixing of 
the calcium and phosphorus precursors [184]. The gel can develop after a heating 
stage, usually at 60 or 80 °C. As a result the hydroxyapatite powder is said to require 
a lower sintering temperature as when compared to the wet precipitation method 
[183]. The prepared gel is effectively a hydrated network of metal hydroxide bonds. 
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Table 2.6. Typical reagents used in the sol-gel method to produce nanoscale 
hydroxyapatite. 
Calcium 
precursor 
Phosphorus 
precursor 
Reagent to 
control pH 
References 
Calcium nitrate 
Ammonium 
phosphate 
Ammonium 
hydroxide 
[185] 
None [186] 
Triethyl phosphite None [184, 187-189] 
Phosphorus 
pentoxide 
None [88, 190, 191] 
Phosphoric acid Ammonium [192] 
Calcium acetate Triethyl phosphite None [188] 
 
As discussed above, there are a wide variety of papers published in the literature 
regarding the wet precipitation and sol-gel synthesis of nanoscale hydroxyapatite. 
The main advantages of wet precipitation and sol-gel methods are the relative ease 
of production, especially that expensive equipment is not necessarily required. 
Furthermore these methods lend themselves well to the introduction of other ions and 
therefore may be most suitable for the production of substituted nHA materials.  
Unfortunately, the quality of the papers regarding the wet precipitation and sol-gel 
production of nHA is variable. For instance, some papers do not use transmission 
electron microscopy (TEM) which is required to ensure that the synthesised product 
is indeed nanoscale [86, 186]. Similarly, some studies only use a limited amount of 
characterisation techniques which leave the reader unable to understand the precise 
physico-chemistry of the nHA produced [88, 89, 191].  Furthermore, it is often very 
difficult to draw conclusions on how the alteration of particular process parameter 
affects the properties of the nHA produced due to the various synthesis conditions 
used in different papers. Indeed, research recently published by our group has 
demonstrated the physico-chemical differences in nHA produced by different 
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synthesis methods which highlights the need to perform detailed characterisation 
techniques to fully understand the nature of the synthesised product [193]. Therefore, 
for this PhD program it was necessary to review several methods in order to select 
those that may be most suited to the production of (a) nHA, (b) substituted nHA, and 
(c) substituted nHA on an industrial scale.   
2.5.2.1 Material Characterisation of nHA 
A variety of materials characterisation methods have been used to investigate the 
properties of nanoscale hydroxyapatite. Firstly, X-ray diffraction is commonly used to 
detect the crystal phases present in a sample. The technique involves monitoring the 
diffraction of X-rays as they pass through the crystal lattice. Each characteristic lattice 
structure gives rise to a specific XRD pattern. However, difficulties can arise when 
using conventional materials characterisation techniques to analyse nanoscale 
materials. For example, it can be difficult to distinguish between X-ray diffraction 
patterns from very small crystals and amorphous materials, due to both materials not 
possessing long-range order [194]. Specifically, short range order is generally used 
to describe the ordering between an atom and its nearest neighbours. All liquids and 
solids are considered to possess short range order. Long range order however, can 
only be observed in solids or crystalline solids where adjacent crystal lattices provide 
order over a much longer length scale which may be tens or hundreds of atomic 
distances [195]. As a result, alternative characterisation techniques including Raman 
spectroscopy and Fourier-Transform Infrared (FTIR) spectroscopy are increasing in 
popularity as useful tools to investigate such materials [196]. These particular 
techniques provide information on the chemical bonds present in the studied material, 
which can highlight the presence of different chemical structures. The incident 
radiation may interact with the sample in several ways including absorption and 
emission of infrared radiation. However, samples must be kept as dry as possible to 
reduce the intensity of the water band which can obscure spectral features. An 
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alternative mode of FTIR does not require the production of potassium bromide discs; 
instead the powder material may be placed in contact with a crystal with a high 
reflective index (e.g. diamond) when the material is examined using FTIR in 
attenuated total reflectance (FTIR-ATR).  
Other characterisation tests performed on nanoscale HA materials in the literature 
include transmission electron microscopy (TEM), thermogravimetric and differential 
thermal analyses (TG/DTA) and the Brunauer-Emmett-Teller (BET) method [174, 
179]. In TEM an electron beam is used to image nanoscale features of the sample. 
However when performing this technique the nanoscale HA can be damaged with the 
high energy of the electron beam at high intensity. Thermogravimetric analysis 
records the weight of a sample as it is heated to high temperature, typically 1200 or 
1300 °C. On the other hand, differential thermal analysis records the heat flow from 
the sample material which provides information regarding the chemical events that 
occur at elevated temperatures. These techniques can allow for the high temperature 
stability of the nHA to be investigated. The BET method allows measurement of the 
specific surface area of materials by studying the level of gas adsorption.    
Inductively coupled plasma (ICP) techniques including mass spectrometry (MS) and 
atomic absorption spectrometry (AAS) have been used to give quantitative chemical 
compositions of nHA materials [86, 177]. This can also allow for parameters such as 
the calcium: phosphorus ratio to be calculated. This technique requires for the sample 
to be acid digested prior to analysis. Alternatively X-ray fluorescence (XRF) can be 
used for quantitative chemical analysis. XRF involves suspending a powder sample 
in molten glass which is then cooled and analysed for specific elements by monitoring 
the specific fluorescent response of the material to X-ray illumination.  
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2.5.2.2 Biological Characterisation of nHA 
The papers regarding the in vitro biocompatibility of nHA usually test a powder or 
coating form, with very few papers reporting the biological behaviour of injectable 
nHA. However, early evidence suggests that nHA in powder and coating forms 
possesses potent osteoconductive properties. It is believed that the superior 
biological activity of nanoscale HA when compared to micron scale HA is due to 
several factors. Firstly, the higher specific surface area of nHA allows greater levels 
of protein absorption [197]. Specifically, it was reported that nHA absorbed a greater 
amount of vitronectin than micron scale HA [198]. The absorption of protein onto a 
biomaterial allows for cells to subsequently adhere to the surface. Therefore the ability 
of a biomaterial to adhere protein can be a strong indicator of its’ biological response 
especially in terms of integration [197]. It has also been confirmed that nHA surfaces 
can promote cellular attachment. For instance, a study by Guo et al. reported greater 
levels of human osteoblast attachment on nHA when compared to micron scale HA 
[199]. The cellular morphology of attached osteoblasts was more physiologically 
relevant with less cell spreading observed on nHA in combination with a greater 
degree of mineralisation. Therefore it was concluded that nHA has greater bioactivity 
than micron HA. These affects are again potentially due to the greater surface area 
and corresponding protein absorption provided by nHA [199].  
Furthermore, nHA has been reported to upregulate osteogenic gene expression in rat 
mesenchymal stromal cells (MSCs). In detail, alkaline phosphatase (ALP), core 
binding factor alpha 1 (Cbfa1), and the alpha 1 chain of type 1 collagen (COL1A1) 
were upregulated thereby stimulating the osteogenic differentiation of the MSCs. 
Furthermore the osteogenic protein expression of ALP and COL1A1 was higher for 
the cells cultured on nHA compared with a micron HA control [200]. It has also been 
suggested that the biomimetic nature of nHA inherently allows for a better biological 
response and higher levels of osteointegration in turn [14].  
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As well as stimulating cellular attachment and differentiation, nHA has also been 
reported to enhance cellular viability [199]. For example, when mesenchymal stromal 
cells were cultured on microscale and nanoscale particles of hydroxyapatite, greater 
cell viability and proliferation were observed for the cells cultured on the smallest 
nanoscale particles tested (20 nm). Furthermore the growth of osteosarcoma cells 
was found to be inhibited when cultured on the smallest nHA particles [25].   
The majority of recent papers investigating the in vivo response of nHA materials 
involve the production of a polymer nHA composite scaffold or the application of a 
nHA coating. The application of nHA as an implant coating generally improves the 
level of osteointegration to a noticeable degree. For instance, when nHA has been 
applied as a coating to titanium bone screws, it has been found that nHA enhances 
the osteointegration which provides better stabilisation compared with micron HA 
coatings [201]. Similarly, Cheng et al. reported that the application of an nHA coating 
stimulated better osteointegration resulting in higher removal torque values for 
titanium screw implanted in rat tibia compared with no nHA coating [202]. When 
applied to the surface of a PLGA porous scaffold, the nHA coating was found to 
stimulate a higher degree of bone formation than observed with uncoated scaffolds 
[203]. A nanostructured surface design was also found to improve new bone 
formation and mineralisation on macroporous HA scaffolds in rat calvarial defects 
[204]. 
Regarding nHA polymer composite materials, an nHA chitosan composite powder 
had a lower osteogenic potential than nHA powder alone when investigated in vitro 
and in a rat calvarial defect [205].  PLA composites were also improved in terms of 
biocompatibility when nHA was incorporated. Specifically, a lower inflammatory 
response was observed with the increased presence of nHA. This was suggested to 
be due to the slower release of degradation products. The mechanical strength of the 
implants was also improved with nHA addition [206]. 
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For information regarding the in vivo response of nanoscale HA paste materials see 
section 2.4 Nanoscale Hydroxyapatite Bone Augmentation Pastes.  
2.6 Summary of Literature Review  
This review has highlighted the importance of healthy bone for a good quality of life. 
There is clearly a significant socio-economic need for improved bone substitution 
materials since the current gold standard of autologous bone has severe limitations. 
Early evidence suggests that nanoscale hydroxyapatite materials may possess 
superior properties for bone repair in terms of bioactivity and resorbability. 
Furthermore, the advantageous injectability of nanoscale HA paste materials aids the 
minimally invasive placement of the bone graft. These materials have also shown 
promising results in initial in vivo tests in animals and in preliminary clinical trials, 
possibly promoting bone formation to a higher degree than control materials. 
Furthermore, the potential of performing elemental substitutions on nanoscale HA 
materials presents an opportunity to develop novel materials for bone regeneration 
with superior characteristics. Although many nHA production methods have been 
published in the literature, it is unclear which methods may be most suited for the 
production of substituted nHA pastes in an industrial batch process. Relatively few 
papers have been published in the areas of strontium and silver addition to nHA 
systems which have a great potential to impart advantageous properties. This review 
has identified the benefits of developing ‘off the shelf’ novel bone augmentation 
materials with enhanced bioactive and/or antimicrobial properties thereby providing 
direct benefits for the patient and the surgeon.  
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3. Aims and Objectives 
Chapter 2 concluded that nanoscale calcium phosphates have great potential as 
injectable synthetic bone graft substitutes that may promote healing and tissue 
regeneration. While much has been published on the preparation of simple nHA, 
relatively little has been reported on the fabrication of these materials for use as 
injectable bone substitutes, in particular as chemically modified systems to provide 
advanced functionality. The aim of this PhD program was therefore to develop and 
evaluate processes suitable for the production of injectable basic and inorganically 
modified nHA materials, and to assess their biocompatibility and advanced 
functionality for application in regenerative medicine. The specific objectives were: 
1. To compare and contrast published methods for nHA synthesis in order to select 
those that appeared best-suited for chemical modification and commercial scale-up. 
This will involve the production of nHA using a variety of wet chemical precipitation 
and sol-gel methods. The nHA produced will then be characterised using a range of 
techniques including X-ray diffraction (XRD), X-ray fluorescence (XRF) and 
transmission electron microscopy (TEM). From these results, the most promising 
method(s) will be selected for the subsequent development of chemically modified 
compositions. 
2. To further develop the most promising methods identified above in order to 
investigate the effect of process parameters on the nHA produced. Specifically, the 
method parameters will be altered and materials characterisation techniques (XRD 
and TEM) will be carried out in order to ascertain the effects of experimental 
conditions on the chemical nature and morphology of the nHA produced.  
3. To investigate the preparation of strontium-substituted nHA paste and gel. The 
optimised methods developed from objective 2 will be used as the basis to prepare a 
series of strontium-substituted nHA pastes and gels. Comprehensive materials 
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characterisation will be performed including XRD, XRF, TEM and Fourier transform 
infrared spectroscopy in attenuated total reflectance mode (FTIR-ATR). The direct 
and indirect in vitro biocompatibility of the materials will be investigated in order to 
assess their suitability as bone augmentation materials.  
4. To investigate the preparation of silver-substituted and/or doped nHA paste. The 
method developed in objective 2 will also be used to produce a range of silver-doped 
nHA pastes with a range of silver contents. After the silver-doped nHA pastes have 
been characterised using the techniques listed for objective 3, the antibacterial activity 
of the pastes will be investigated using agar diffusion and broth dilution methods.  
Specifically, the ideal strontium content of the paste or gel would be the content at 
which bioactivity is increased to an optimal degree. This may be difficult to conclude 
without in vivo assessment, and it could be that a range of strontium contents promote 
good osteoconductive properties. Similarly, the optimal silver content of the paste 
would be where the paste displays an effective antibacterial response whilst 
possessing a low toxicity to human cells, thereby promoting good bone tissue 
regeneration. 
On completion of this project, methods will have been developed and described in 
detail for the production of chemically modified nanoscale hydroxyapatite pastes.  The 
intention was to add beneficial biological and antibacterial properties, and these will 
have been assessed as part of the experimental programme. This research will 
significantly add to current knowledge in the field, indicating how chemically modified 
nHA paste and gels may have enhanced biological properties and clinical potential.  
This will in turn assist the development of new medical devices with enhanced 
properties for bone tissue regeneration, bringing them closer to commercial 
manufacture and clinical use. 
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4. Materials and Methods 
4.1 Materials 
Table 4.1. Reagents used in synthesis and characterisation of nHA.  
Reagent 
Molecular 
formula 
Molecular weight 
(g.mol-1) 
Supplier 
Ammonium 
hydroxide 28 % 
NH4OH 35.05 Alfa Aesar (UK) 
Ammonium 
phosphate dibasic 
(NH4)2HPO4 132.06 
Sigma Aldrich (UK) 
 
Calcium chloride 
dihydrate 
CaCl2·2H2O 147.01 
Calcium hydroxide Ca(OH)2 74.09 
Calcium nitrate 
tetrahydrate 
Ca(NO3)2·4H2O 236.15 
Distilled water  H2O 18.02 - 
Ethanol C2H6O 46.07 
Fisher Scientific 
(UK) 
Methanol CH3OH 32.04 Alfa Aesar (UK) 
Phosphoric acid 
(85 %) 
H3PO4 98.00 
Sigma Aldrich (UK) 
Potassium 
hydroxide 
KOH 56.11 
Potassium 
phosphate dibasic 
trihydrate 
K2HPO4·3H2O 228.22 
Silver nitrate AgNO3 169.87 
Strontium 
hydroxide 
octahydrate 
Sr(OH)2·8H2O 265.76 
Strontium nitrate Sr(NO3)2 211.63 
Triethyl phosphite (C2H5)3PO4 166.16 
Zinc chloride ZnCl2 189.36 
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Table 4.2. Consumables used in biological characterisation experiments. 
Item Supplier / Manufacturer 
For antibacterial evaluation 
Brain heart infusion (BHI) agar 
Oxoid (UK) 
Brain heart infusion (BHI) broth 
For in vitro biocompatibility 
L-glutamine 
Sigma Aldrich (UK) 
Live/Dead staining kit 
Minimum Essentials Media Eagles (α-
modification) (α-MEM) 
Non-essential amino acid 
Penicillin / streptomycin 
Phosphate buffered saline 
Trypsin EDTA 
Foetal calf serum (FCS) Labtech International Ltd. (UK)  
PrestoBlue® cell viability reagent Fisher Scientific (UK) 
 
4.2 Methods  
4.2.1 Evaluation of Wet Precipitation and Sol-gel Methods for Nanoscale 
Hydroxyapatite Synthesis (Methods 1 - 4) 
4.2.1.1 Wet Precipitation Synthesis of Nanoscale Hydroxyapatite 
Method 1: Acid-base Reaction of Calcium Hydroxide and Phosphoric Acid Based on 
Prakash et al. [176] 
Calcium hydroxide (1.85 g (25 mmol)) was suspended in 250 mL distilled water using 
a hotplate magnetic stirrer set to 400 rpm. Prior to the titration, the calcium hydroxide 
suspension was heated to 60 °C and stirred for 1 h. The hotplate magnetic stirrer was 
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then left on throughout the titration. A phosphoric acid solution was prepared by 
dissolving 1.73 g (15 mmol) of 85 wt. % phosphoric acid in 250 mL distilled water. 
The phosphoric acid solution was then added to the calcium solution at a rate of 3.5 
mL.min-1 with a peristaltic pump.  The solution was stirred for a further 2 h after the 
phosphoric acid addition was completed and then left to cool to room temperature 
overnight. The precipitate which had settled overnight was washed three times by 
pouring off the clear liquid on top of the sediment and adding 500 mL distilled water. 
This procedure was followed by stirring at 400 rpm for 1 min and then the precipitate 
was left to settle over a 2 h period in between washes. Finally the suspension was 
dried at 60 °C in an oven, ground in an agate mortar and pestle and half of the sample 
was sintered. The furnace was programmed to heat at 10 °C.min-1 to a temperature 
of 1000 °C which was maintained for 2 h before the sample cooled to room 
temperature overnight. The resulting nHA powders were then stored in a vacuum 
desiccator. See schematic diagram for overview of method (Figure 4.1). 
Method 2: Reaction of Calcium Chloride and Potassium Phosphate Based on 
Fluidinova Patent Example 3 [207] 
Calcium chloride dihydrate (3.68 g (25 mmol)) was dissolved in 250 mL distilled water 
and stirred at approximately 400 rpm. Meanwhile, 3.42 g (15 mmol) of potassium 
phosphate dibasic trihydrate was dissolved in 250 mL distilled water. A 1 M potassium 
hydroxide solution was made by dissolving 5.57 g potassium hydroxide in distilled 
water to make a volume of 100 mL. The pH of the calcium and the phosphorus 
solutions were adjusted to 11 and 12 respectively by adding the appropriate amount 
of 1 M potassium hydroxide solution. The phosphorus solution was then titrated into 
the stirred calcium solution at approximately 3 mL.min-1 using a peristaltic pump. The 
solution was stirred for 1 h after the titration was completed and then left to settle 
overnight. The solution was washed, ground and sintered using the same process as 
described for method 1. 
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Figure 4.1. Schematic diagram showing production stages for method 1-3.  
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4.2.1.2 Sol-gel Synthesis of Nanoscale Hydroxyapatite 
Method 3: Reaction of Calcium Nitrate and Ammonium Phosphate Based on 
Fluidinova Patent Example 2 [207] 
Calcium nitrate tetrahydrate (5.91 g (25 mmol)) was dissolved in 250 mL distilled 
water and stirred at approximately 400 rpm. Similarly, 1.98 g (15 mmol) of ammonium 
phosphate dibasic was dissolved in 250 mL distilled water. The pH of the calcium and 
the phosphorus solutions were then adjusted to 11 and 12 respectively by adding 1 
M potassium hydroxide solution. The phosphorus solution was titrated into the stirred 
calcium solution at approximately 3 mL.min-1 using a peristaltic pump, followed by 1 
h of stirring at 400 rpm after the titration was completed. The suspension was then 
left to settle overnight. The solution was washed, ground and sintered using the same 
process as described for method 1.  
Method 4: Reaction of Calcium Nitrate and Triethyl Phosphite Based on Liu et al. 
[184] 
Firstly, 22.48 g (95 mmol) of calcium nitrate tetrahydrate was dissolved in 40 mL 
ethanol using a magnetic stirrer. Triethyl phosphite (10 mL (58 mmol)) was dissolved 
in 5.6 mL distilled water and 10 mL ethanol. The solutions were covered and stirred 
for 30 min to allow the phosphite to hydrolyse. The pH of the calcium and phosphorus 
solutions were adjusted to pH 10 using 28 % ammonium hydroxide solution. The 
calcium nitrate solution was then titrated using a peristaltic pump at 3 mL.min-1 into 
the hydrolysed phosphorus solution under vigorous stirring which was continued until 
5 min after the titration. The solution was then aged at room temperature for at least 
24 h. The suspension was dried overnight on a hotplate at 60 °C until a gel was 
obtained. The gel was further dried in an oven at 80 °C. The dried powder was 
crushed with a mortar and pestle before being sintered at 500, 550 or 600 °C for 2 h. 
The powders were then washed to remove any soluble impurities such as ammonium 
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hydroxide or ammonium nitrate. Firstly, each sample was divided between 4 tubes 
and 40 mL distilled water was added to each tube. The powder was shaken until it 
was in suspension and then sonicated for 5 min. The tubes were centrifuged at 3500 
rpm for 10 min. The supernatant was poured off and 40 mL distilled water was added 
again. This sonication-centrifugation cycle was repeated 4 times in total. After the fifth 
rinse approximately 20 mL methanol was added to each tube and the powder 
suspension was poured into Petri dishes and left in a fume hood for the methanol to 
evaporate. After approximately 3 h, powders were placed in oven at 37 °C. Powders 
were then stored in a vacuum desiccator.  
4.2.2 Development of Selected Synthesis Methods (Methods 1 and 3) 
Methods 1 and 3 were selected for further development due to their advantages over 
methods 2 and 4, as discussed in section 6.1 Evaluation of Wet Precipitation and Sol-
gel Methods of Nanoscale Hydroxyapatite Synthesis (Methods 1 - 4). Several 
parameters were altered in an attempt to obtain an optimal nHA product using the 
most simple and cost-effective method.  
4.2.2.1 Method 1: Acid-base Reaction of Calcium Hydroxide and Phosphoric 
Acid  
The synthesis parameters of method 1 (specified in section 4.2.1.1) were then altered 
in order to optimise the nHA obtained. The parameters investigated were: 
1. Phosphoric acid solution addition rate (method 1-B) 
The rate of the phosphorus solution addition was increased by pouring the 
phosphoric acid solution into the calcium hydroxide suspension (addition rate 
of approximately 100 mL.s-1). The results were compared to the previous 
results obtained when the phosphorus solution was titrated into the calcium 
suspension at 3.5 mL.min-1 (method 1-A). This rapid addition rate was then 
used in all subsequent method alterations detailed below. 
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2. Temperature of reaction (method 1-C) 
The temperature of the synthesis was decreased to room temperature and 
compared with the previous results obtained when the reaction was carried 
out at 60 °C. Similarly, all subsequent method alterations listed below were 
also carried out at room temperature. 
3. Concentration of reactants (method 1-D) 
The concentration of the reactants was then increased by suspending 3.70 g 
(50 mmol) of calcium hydroxide in 500 mL distilled water and dissolving 3.46 
g (30 mmol) of phosphoric acid in 250 mL distilled water. For this experiment 
the stirring time of the HA suspension after phosphoric acid addition was 
decreased from 2 h to 1 h. 
4.2.2.2 Method 3: Reaction of Calcium Nitrate and Ammonium Phosphate  
The synthesis parameters of method 3 were then investigated and compared to the 
results obtained using the original method (as specified in section 4.2.1.2). The 
following parameters were investigated: 
1. pH of the calcium and phosphorus solutions (methods 3-B, 3-C and 3-D) 
The pH of the calcium and phosphorus solutions was altered using potassium 
hydroxide solutions to investigate their effect on the nHA produced (Table 
4.3). For all subsequent experiments, the pH of the calcium and phosphorus 
solutions were adjusted to 11 and 12 respectively.  
2. Phosphorus solution addition rate (method 3-E) 
The rate of the phosphorus solution addition was increased by pouring the 
phosphorus solution into the calcium solution (addition rate of approximately 
100 mL.s-1). The results were compared to the previous results obtained when 
the phosphorus solution was titrated into the calcium solution at 3 mL.min-1. 
This rapid addition rate was then used in all subsequent preparations. 
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3. Concentration of reactants (method 3-F) 
The concentration of the reactants was increased by suspending 11.81 g (50 
mmol) of calcium nitrate tetrahydrate in 500 mL distilled water and dissolving 
3.96 g (30 mmol) of ammonium phosphate dibasic in 250 mL distilled water.   
Table 4.3. Calcium and phosphorus solution pH investigated for nHA synthesis using 
method 3. 
Method 
reference 
pH of calcium 
solution 
pH of 
phosphorus 
solution 
Potassium 
hydroxide 
solution used for 
pH adjustment 
(M) 
3-A 11 12 1 
3-B 11 11 1 
3-C 10 10 0.5 
3-D 9 9 0.1 
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4.2.3 Synthesis of Strontium-substituted Nanoscale Hydroxyapatite (Optimised 
Methods 1 and 3) 
When the range of strontium substituted nHA were prepared it was considered which 
substitution levels would be most likely to promote optimal bone regeneration. 
Relatively low levels of strontium substitution (i.e. below 10 at. %) were likely to 
promote a beneficial biological response as suggested in the literature review. 
Furthermore substituted nHA with lower levels of strontium may be easier to progress 
through regulatory barriers due to their relative similarity to hydroxyapatite. However, 
the investigation of more unstable compositions (i.e. 50 at. % Sr) may have more 
clearly demonstrated how differences in solubility affect the properties of the 
biomaterial system. Furthermore, the 100 at. % strontium-substituted nHA was likely 
to have a similarly low level of solubility to the calcium nHA so provided a good 
comparison as to the effects that calcium or strontium alone may have not only on 
the material properties, but also on the precipitation of these materials.  
4.2.3.1 Optimised Method 1 
The substitution of strontium into the calcium hydroxyapatite crystal lattice (0, 2.5, 5, 
10, 50 and 100 at. %) was then performed by adding the appropriate amount of 
strontium hydroxide octahydrate alongside the appropriate amount of calcium 
hydroxide to 500 mL distilled water (Table 4.4). The calcium / strontium hydroxide 
suspension was then stirred for 1 h at 400 rpm prior to the rapid addition of the 30 
mmol (dissolved in 250 mL distilled water) phosphoric acid solution and then stirred 
for 1 h. The strontium-substituted nHA suspensions were washed at least three times 
with 500 mL distilled water. Additional washes were carried out until the conductivity 
was below 15 µS.cm-1. However washing was discontinued if the conductivity did not 
decrease by 10 µS.cm-1 with 4 subsequent washes. The nHA suspensions were then 
dried and sintered in the same method as described in method 1. 
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Table 4.4. Amount of reagents required for the optimised method 1 synthesis of the 
range of strontium-substituted nHA.  
Amount of Sr (at. %) 
Calcium hydroxide 
amount 
Strontium hydroxide 
octahydrate amount 
g mmol g mmol 
0 3.70 50 0 0 
2.5 3.61 48.75 0.33 1.25 
5 3.52 47.5 0.66 2.5 
10 3.33 45 1.33 5 
50 1.85 25 6.64 25 
100 0 0 13.29 50 
 
4.2.3.2. Optimised Method 3 
The substitution of strontium into the calcium hydroxyapatite crystal lattice was then 
performed by dissolving the appropriate amount of strontium nitrate alongside the 
appropriate amount of calcium nitrate tetrahydrate in 500 mL distilled water (Table 
4.5). Ammonium phosphate (3.96 g (30 mmol)) was dissolved in 250 mL distilled 
water.  The pH of the calcium / strontium nitrate solution and the ammonium 
phosphate solution were then adjusted to 11 and 12 respectively using 1 M potassium 
hydroxide solution. The phosphorus solution was poured into the calcium / strontium 
solution which was then stirred for 1 h at 400 rpm and the nHA suspension was left 
to settle overnight. The strontium-substituted nHA suspensions were then washed at 
least three times with 500 mL distilled water. Additional washes were carried out until 
the conductivity was below 15 µS.cm-1. However washing was discontinued if the 
conductivity did not decrease by 10 µS.cm-1 with 4 subsequent washes. The nHA 
suspensions were then dried at 60 °C and ground in a mortar and pestle. Due to 
excessive thermal decomposition at 1000 °C, 100 at. % strontium nHA was sintered 
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at 500, 700 and 850 °C for 2 h in order to investigate its thermal stability. Powders 
were then stored in a vacuum desiccator. 
Table 4.5. Amount of reagents required for the optimised method 3 synthesis of the 
range of strontium-substituted nHA.  
Amount of Sr (at. %) 
Calcium nitrate amount 
Strontium nitrate 
amount 
g mmol g mmol 
0 11.81 50 0 0 
2.5 11.51 48.75 0.26 1.25 
5 11.22 47.5 0.53 2.5 
10 10.63 45 1.06 5 
50 5.90 25 5.29 25 
100 0 0 10.58 50 
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4.2.4 Synthesis of Silver-doped Nanoscale Hydroxyapatite (Altered Method 1) 
To maintain a high level of biocompatibility the silver doping level was kept relatively 
low (i.e. below 10 at. %). However, it was also useful to investigate how the presence 
of silver may have affected the precipitation reaction when the level of silver doping 
was increased. Therefore higher levels, i.e. 10 at. % silver-doping, were also 
investigated in order to understand the sensitivity of the silver-doped nHA 
precipitation.  
4.2.4.1 Altered Method 1 
A range of silver-doped nHA powders (0, 2, 5 and 10 at. %) were prepared by adding 
the appropriate amount of silver nitrate to the 50 mmol calcium hydroxide suspension 
(Table 4.6). The silver / calcium suspension was stirred at 400 rpm and heated to 60 
°C on a hotplate stirrer for 1 h followed by the rapid addition of the 30 mmol phosphoric 
acid solution. The suspension was stirred and heated for a further hour before being 
left to cool and settle overnight. The suspension was washed 3 times with 500 mL 
distilled water. The suspensions were dried and sintered using the same procedure 
as described in method 1. 
Table 4.6. Amount of silver nitrate required for the method 1 synthesis of the range of 
silver-doped nHA. 
Silver dopant level (at. %) 
Silver nitrate amount 
g mmol 
0 0 0 
2 0.17 1 
5 0.42 2.5 
10 0.85 5 
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4.2.5 Characterisation Techniques used for the Evaluation and Development of 
Nanoscale Hydroxyapatite Synthesis Methods 
4.2.5.1 X-ray Diffraction (XRD)  
Nanoscale hydroxyapatite powder samples were prepared for XRD by depositing a 
small amount of PVA glue onto an acetate film. nHA powder was then mixed with the 
PVA glue, and was treated with a hot air gun until dried. Qualitative phase analysis 
was performed on powdered samples using X-ray diffraction (STOE IP, Phillips) with 
Cu Kα1 radiation, λ = 0.15406 nm. The diffractometer was operated at 40 kV and 35 
mA, with a 2θ range of 10-60°. The resulting patterns were analysed using ICDD PDF 
4+ software. See Table 4.7 for XRD database cards used to identify phases present 
in the samples. For the final optimised range of materials the full width at half 
maximum for the (002) diffraction peak before and after high temperature sintering 
was measured by hand in order to demonstrate the change in the crystallite size of 
the samples, in accordance with the Scherrer equation [208]:  
Crystallite size (nm) = 
0.9 λ
FWHM cos θ
 
Where: λ = 0.15406 nm (incident Cu Kα1 x-ray radiation), FWHM = full width half 
maximum of the (002) XRD diffraction peak, θ = Bragg angle. 
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Table 4.7. X-ray diffraction cards used to identify phases observed in nHA XRD 
patterns. Quality rating in descending order: * (high-quality), I (indexed), C 
(calculated). 
Compound Card Quality rating 
Hydroxyapatite (Ca10(PO4)6(OH)2) 9-432 I 
β-tricalcium phosphate  
(β-Ca3(PO4)2) 
04-014-2292 * 
Calcium oxide (CaO) 48-1467 C 
Ammonium nitrate (NH4NO3) 8-452 I 
Brushite (CaHPO4.2H2O) 72-1240 C 
2.4 at. % strontium-substituted hydroxyapatite 
(Ca9.76Sr0.24(PO4)6(OH)2) 
04-016-2959 I 
5 at. % strontium-substituted hydroxyapatite 
(Ca9.5Sr0.5(PO4)6(OH)2) 
04-016-3585 I 
10 at. % strontium-substituted hydroxyapatite 
(Ca9Sr1(PO4)6(OH)2) 
60-0648 I 
50 at. % strontium-substituted hydroxyapatite 
(Ca5Sr5(PO4)6(OH)2) 
34-479 I 
100 at. % strontium-substituted hydroxyapatite 
(Sr10(PO4)6(OH)2) 
33-1348 * 
β-tristrontium phosphate  
(β-Sr3(PO4)2) 
24-1008 * 
Silver phosphate (Ag3PO4) 6-505 * 
Silver (Ag) 4-783 I 
 
4.2.5.2 Transmission Electron Microscopy (TEM) 
Powder samples were placed in ethanol and were prepared for transmission electron 
microscopy by ultrasonic dispersion for 15 min. The ethanol solution was then 
pipetted onto a 400 mesh copper grid coated with a holey thin carbon film (Agar 
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Scientific).  Morphological evaluation of the HA particles was carried out using the FEI 
Tecnai G2 Spirit TEM at an accelerating voltage of 80 kV. TEM was mainly carried 
out on the unsintered samples due to the increase in particle size observed during 
sintering. Increased particle sizes were not desired due to the aim of nanoscale 
material production. However, for method 4, the sintered particles were imaged since 
a HA phase was not detected prior to sintering.  
4.2.5.3 X-ray Fluorescence (XRF) 
0.2 g of sample powder was used for XRF analysis for the initial evaluation of the nHA 
production methods 1 - 4 due to limited sample size. For subsequent XRF analyses 
0.8 g of sample powder was used. The sample powder was combined with 8 g of 
lithium tetraborate (ICPH, Malzéville, France). This mixture was melted into a glass 
disc in a furnace at 1200 °C. The glass discs were analysed in an XRF spectrometer 
(PW2440 Philips) to determine the elemental composition of the samples.  
4.2.5.4 Fourier Transform Infrared Spectroscopy in Attenuated Total 
Reflectance Mode (FTIR-ATR) 
A small amount of powder was placed on top of the diamond in the attenuated total 
reflectance mode adapter and was compressed onto the surface of the diamond. 32 
scans were performed from 4000 – 500 cm-1 with a resolution of 4 cm-1 (Thermo 
Scientific Nikolet Spectrometer, Unicam Ltd. England). 64 background scans were 
initially taken with an empty set up and this scan was then subtracted from all 
subsequent scans.  
4.2.5.5 Radiopacity of Strontium-substituted Nanoscale Hydroxyapatite 
Powders 
0.1 g of powder (0, 2.5, 5, 10, 50, 100 at. % Sr) was placed in a 96 well plate (n = 3). 
An X-ray image was taken with 0.25 s exposure time and developed in a dark room. 
Firstly the films were placed in developer solution for 4 min followed by a 2 min rinse 
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in running water. The films were then placed in a fixative solution for 4 min followed 
by a 30 min rinse in running water. The films were then left to dry overnight before 
being scanned and analysed using Quantity One software to obtain quantitative 
values for the radiopacity of the materials. The radiodensity of the materials was 
expressed in mm of aluminium.     
4.2.6 Production of Nanoscale Hydroxyapatite Paste and Gel Materials  
The different between a gel and a paste is not formally defined in the literature. For 
this project, a gel was defined as a translucent stable suspension which had a higher 
water content that the correspondingly opaque paste. 
4.2.6.1 Strontium-substituted Nanoscale Hydroxyapatite Paste Production 
using Optimised Method 1 
The final production protocol described in section 4.2.2.1 Optimised Method 1:  
Synthesis of Strontium-substituted nHA was used to synthesise the final range of 
strontium-substituted nHA paste materials (0, 2.5, 5, 10, 50 and 100 at. % Sr). Instead 
of the suspensions being dried completely in the oven, the drying was stopped when 
the paste had an approximate water content of 80 wt. %. This water content was 
selected due to the formation of a stable paste suspension which had good injectable 
properties when loaded into a syringe. The water content was confirmed by 
completely drying a small amount of the paste at 80 °C and calculating the mass loss 
% using the equation shown below. The pastes were then stored in sealed universal 
tubes, sterilised by gamma irradiation and were loaded into 1 mL syringes prior to 
use. 
Water content of paste (wt. %) = 
Initial mass of paste − mass of dried paste
Initial mass of paste
×  100 
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4.2.6.2 Strontium-substituted Nanoscale Hydroxyapatite Gel Production using 
Optimised Method 3 
Similarly the final production protocol described in section 4.2.2.2 Optimised Method 
3: Synthesis of Strontium-substituted nHA was used to synthesise the final range of 
strontium-substituted nHA gel materials (0, 2.5, 5, 10, 50 and 100 at. % Sr). The gels 
were dried until a water content of approximately 90 wt. % was obtained. The sol-gel 
optimised method 3 allowed for the formation of a stable gel-like suspension with a 
higher water content (90 wt. %) than any stable suspension which could be produced 
using optimised method 1. This allowed the comparison of injectable nHA materials 
with different water contents. The water content was confirmed and the gels were 
stored in the same manner as described above for the paste materials.  
4.2.6.3 Silver-doped Nanoscale Hydroxyapatite Paste Production using Method 
1 
Silver-doped nHA pastes (0, 2, 5 and 10 at. %) were prepared using the protocol 
described in section 4.2.2.1 Method 1: Synthesis of Silver-doped nHA. These 
materials were dried at 60 °C until a paste of 85 wt. % water content was obtained. 
The water content was confirmed and the pastes were stored in the same manner as 
described in section 4.2.6.1 Strontium-substituted Nanoscale Hydroxyapatite Paste 
Production using Optimised Method 1. 
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4.2.7 Characterisation of Nanoscale Hydroxyapatite Paste and Gel Materials 
4.2.7.1 In Vitro Evaluation of Strontium-substituted Nanoscale Hydroxyapatite 
Paste and Gel Produced using Optimised Methods 1 and 3  
The in vitro biocompatibility of the strontium-substituted nHA paste and gels (0, 2.5, 
5, 10, 50 and 100 at. % Sr) produced using optimised method 1 and method 3 
respectively were investigated; the indirect and direct biocompatibility were assessed 
using light microscopy (Eclipse TS100, Nikon), PrestoBlue® assays and Live/Dead 
fluorescence imaging. Prior to use, all paste and gel materials were sterilised using 
25kGy γ-irradiation from a cobalt 60 source (Swann-Morton Ltd., Sheffield, UK). The 
biocompatibility protocols were provided by the IMCOSS project [209] and were 
based on the ISO 10993-5 biocompatibility testing standard [210].  
The following media was prepared and used for cell culture (v/v %): 87 % α-MEM, 10 
% FCS, 1 % penicillin-streptomycin, 1 % L-glutamine and 1 % non-essential amino 
acids. MG63 human osteosarcoma cell line was grown in T75 flasks. When 70-80 % 
confluent, the flasks were washed twice with 10 mL phosphate buffered saline (PBS) 
used each time. 2 mL trypsin-EDTA was added and the flasks were incubated for 5 
min at 37 °C, 5 % CO2. The detachment of the cells from the flasks was monitored 
using light microscopy. When the cells were detached, 4 mL FCS was added to 
neutralise the trypsin. The cell suspension was placed in a tube and centrifuged for 5 
min at 1000 rpm. The supernatant was carefully removed and the cell pellet was 
resuspended in an appropriate amount of media for cell counting using a 
haemocytometer. The cells were then seeded for experiments or seeded for further 
growth in T75 flasks.  
Firstly, indirect cellular toxicity was investigated by incubating 0.5 mL of Sr nHA paste 
/ gel material (0, 2.5, 5, 10, 50 and 100 at. % Sr) with 5 mL media for 24 h at 37 °C to 
produce pre-conditioned media. Preconditioned media for a commercially available 
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nHA paste (ReproBone novoTM, Ceramisys Ltd.) was prepared following the same 
procedure, and 5 mL of media was also incubated without any material present for a 
non-material control. At the same time, 50,000 MG-63 human osteoblast-like cells in 
1 mL media were seeded in each well of a 24 well plate and incubated for 24 h (n = 
3). After 24 h incubation, the pre-conditioned media was centrifuged at 1000 rpm for 
5 min. The media on the cells was replaced by 1 mL preconditioned media and the 
cells were incubated again for 24 h. Light microscopy images were then obtained to 
assess the growth of the cells in the pre-conditioned medium. A PrestoBlue® assay 
was carried out using a 10 v/v % dilution of the PrestoBlue® in complete media; 1 mL 
of the PrestoBlue® media solution was added to each well. After 1 h, 200 µL was 
taken out of each well and placed in a 96 well plate. The fluorescence of the samples 
was read on a fluorescent plate reader (Infinite M200, Tecan) with 535 nm excitation 
and 590 nm emission wavelengths used. After the PrestoBlue® assay the wells were 
washed twice with 1 mL PBS and 400 µL of Live/Dead stain, prepared according to 
the manufacturer’s instructions, was added to each well and incubated for 15 min at 
37 °C, 5 % CO2. The wells were then washed with PBS before being imaged using a 
fluorescence microscope (Axiovert 200M, Zeiss). The experiment was repeated three 
times to obtain n = 9.  
For direct toxicity assays 100 µL of paste or gel (0, 2.5, 5, 10, 50, and 100 at. % Sr) 
was placed into a 24 well plate (n = 3). Direct cellular viability was also tested for 
ReproBone novoTM (Ceramisys, Ltd.) using the same protocol alongside the paste or 
gel samples. A 1 mL cell suspension containing 50,000 MG63 cells was then added 
to each well alongside control wells containing no material. Paste / gel wells with no 
cells present were also prepared to act as a material control. The 24 well plates were 
then incubated for 48 h at 37 °C, 5 % CO2. After 48 h, light microscopy was used to 
image cells growing alongside the paste / gel materials. Cellular viability was then 
tested using a PrestoBlue® assay. To prevent the disruption and loss of paste or gel 
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from the wells, 100 µL PrestoBlue® reagent was directly added to the wells, after 100 
µL media had been removed. After 1 h, 200 µL of the solution was transferred to a 96 
well plate for fluorescent analysis as detailed above. After the PrestoBlue® assay the 
wells were washed twice with 1 mL PBS and 400 µL of Live/Dead stain was added to 
each well and incubated for 15 min at 37 °C, 5 % CO2. The wells were then washed 
with PBS before being imaged using fluorescent microscopy as described above. 
Unfortunately the dead cells could not be imaged due to red background fluorescence 
from residual PrestoBlue® media solution which had absorbed into the pastes and 
gels.  The experiment was repeated three times to obtain n = 9. 
All PrestoBlue® assays results were expressed as the mean of the three triplicate 
repeats (n = 9). Statistical analyses were tested for significance using a one way 
ANOVA test with Tukey’s multiple comparisons test applied using GraphPad Prism 6 
software.  
4.2.7.2. Antibacterial Evaluation of Silver-doped nHA Paste Produced Using 
Method 1 
Preparation of Brain-heart Infusion (BHI) Agar and Broth 
BHI agar plates were prepared by dissolving 4.7 g BHI agar powder in 100 mL of 
distilled water. The solution was autoclaved and then placed in a water bath at 55 °C 
to cool. The liquid agar was then poured into plastic Petri dishes and left to set, before 
being stored at 4 °C. BHI broth was prepared by dissolving 3.7 g BHI broth powder in 
100 mL distilled water and sterilised in an autoclave.  S. aureus (Oxford strain) and 
P. aeruginosa (clinical isolate SOM-1) were cultured on BHI agar plates at 37 °C, 5 
% CO2. 
Agar Diffusion Assay for Silver-doped nHA Pastes 
10 mL of BHI broth was inoculated with a single colony of S. aureus or P. aeruginosa 
and agitated in a rotary incubator at 37 °C, 5 % CO2 overnight. 400 µL of bacterial 
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suspension with an optical density (O.D) of 1.5 at 600 nm were prepared. The 
bacterial suspensions were then spread over the surface of the agar plate using a 
spreader. 0.15 mL of each of the silver-doped nHA paste materials (0, 2, 5 and 10 at. 
% Ag) were then placed on top of the agar plates before incubation overnight. The 
plates were imaged and 3 agar plugs were removed using a plastic Pasteur pipette 
from the agar directly surrounding each paste material. The plugs were placed in a 
10 mL universal tube with 4 mL distilled water and 40 µL of ultra-pure nitric acid before 
being heated at 70 °C for 2 h to dissolve the agar plugs. The samples were then 
analysed for silver content using inductively coupled plasma-mass spectrometry 
(ICP-MS, Elan DRCII, Perkin Elmer).  
Suspension Culture for Silver-doped nHA Pastes 
10 mL of BHI broth was inoculated with a single colony of S. aureus or P. aeruginosa 
and agitated in a rotary incubator at 37 °C, 5 % CO2 overnight. Bacterial suspensions 
with an optical density (O.D.) of 0.05 at 600 nm were prepared. Paste suspensions 
for each of the silver-doped nHA paste materials (0, 2, 5 and 10 at. % Ag) were then 
prepared by placing 0.2 g paste in an Eppendorf tube with 1 mL BHI broth and 
agitating it using a vortex mixer. 50 µL of BHI broth was placed in all wells of a 96 well 
plate. A serial dilution was then performed by adding 50 µL of paste suspension to 
the first well, mixing and transferring 50 µL of suspension to the next well and so on. 
This process was repeated 11 times, with four repeats for each material. Three of the 
rows were then inoculated with 50 µL bacterial suspension whilst 50 µL BHI broth 
was added to one row to act as a material control. BHI broth acted as a negative 
control and BHI broth inoculated with 50 µL bacterial suspension acted as a positive 
control. The plates were incubated overnight after which the optical density of the 
wells at 600 nm was recorded using a plate reader (POLARstar Galaxy, BMG 
Labtech). The optical density of the material controls were subtracted from the 
suspension cultures. The minimum inhibition concentration (MIC) for the pastes was 
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calculated as the concentration of paste at which the optical density of the culture had 
reduced by 50 %.  
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5. Results 
5.1 Evaluation of Wet Precipitation and Sol-gel Methods for Nanoscale 
Hydroxyapatite Synthesis (Methods 1 - 4) 
5.1.1 Wet Precipitation Synthesis of Nanoscale Hydroxyapatite 
5.1.1.1 Method 1: Acid-base Reaction of Calcium Hydroxide and Phosphoric 
Acid  
XRD patterns showed that HA was the only detectable phase precipitated from 
method 1 (Figure 5.1). However, after sintering treatment at 1000 °C for 2 h a low 
intensity calcium oxide peak was detected alongside a main phase of HA. TEM 
micrographs of the HA produced by method 1 (Figure 5.2) displayed that needle-like 
nHA particles with a high aspect ratio (length of particle / width of particle) of 
approximately 6.5 were produced during the reaction. The nHA particles produced 
were typically 130 nm long and 20 nm wide.  
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Figure 5.1. XRD patterns of nHA powder prepared by method 1. The unsintered 
sample (black) and sample sintered at 1000 °C for 2 h (red) are displayed. Peak 
labels:  hydroxyapatite;  calcium oxide. 
 
Figure 5.2. TEM micrographs of unsintered nHA powder prepared by method 1.  
70.0 
200 nm 100 nm 
Unsintered 
1000 °C 
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 5.1.1.2. Method 2: Reaction of Calcium Chloride and Potassium Phosphate  
XRD patterns displayed that the main phase precipitated using method 2 was HA 
(Figure 5.3). After heat treatment the product was found to completely decompose 
into β-tricalcium phosphate (β-TCP). Needle shaped nHA particles were also 
produced during this reaction (Figure 5.4). However, these particles have a noticeably 
smaller aspect ratio than the particles produced using the method 1. Average particle 
sizes were 110 nm by 30 nm providing an aspect ratio of 3.7.    
 
Figure 5.3. XRD patterns of nHA powder prepared using method 2. The unsintered 
sample (black) and sample sintered at 1000 °C for 2 h (red) are displayed. Peak 
labels:  hydroxyapatite;  β-tricalcium phosphate. 
] 
70.0 
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1000 °C 
Unsintered 
1000 °C 
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Figure 5.4. TEM micrographs of unsintered nHA powder prepared using method 2. 
5.1.2 Sol-gel Synthesis of Nanoscale Hydroxyapatite 
5.1.2.1 Method 3: Reaction of Calcium Nitrate and Ammonium Phosphate  
HA was successfully produced using method 3 as shown by XRD patterns (Figure 
5.5). However, after sintering a minor phase of β-TCP was detected alongside the 
main HA phase. nHA particles produced using method 3 were approximately 30 nm 
by 20 nm and were therefore much smaller and had a lower aspect ratio (1.5) than 
the particles produced using the wet precipitation methods 1 and 2 (Figure 5.6).    
  
200 nm 100 nm 
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Figure 5.5. XRD patterns of nHA powder prepared using method 3. The unsintered 
sample (black) and sample sintered at 1000 °C for 2 h (red) are displayed. Peak 
labels:  hydroxyapatite;  β-tricalcium phosphate. 
 
 
Figure 5.6. TEM micrographs of unsintered nHA powder prepared using method 3. 
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5.1.2.2 Method 4: Reaction of Calcium Nitrate and Triethyl Phosphite  
Prior to sintering, no phases were detected by XRD for the method 4 product 
displaying its amorphous nature (Figure 5.7). After sintering the product at 500, 550 
and 600 °C a main HA phase was detected (Figure 5.8). Ammonium nitrate was 
detected in the sintered samples particularly when sintered at 500 and 550 °C. When 
the product was sintered at 600 °C, β-TCP was detected alongside a decreased 
amount of ammonium nitrate. The nHA particles produced using this method were 
noticeably larger and more rounded than the particles produced using methods 1-3. 
Little variation was observed between the particle sintered at different temperatures; 
typical particle morphology shown in Figure 5.9. The particles were approximately 
100 nm by 80 nm and had an average aspect ratio of 1.25.  
 
Figure 5.7. XRD pattern of unsintered powder prepared using method 4 at pH 10. No 
identifiable crystalline phases were detected.   
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Figure 5.8. XRD patterns of nHA powder prepared using method 4 at pH 10. The 
samples sintered at 500 (black), 550 (red) and 600°C for 2 h (blue) are displayed. 
Peak labels:  hydroxyapatite;  β-tricalcium phosphate;  ammonium nitrate.  
 
Figure 5.9. TEM micrographs of nHA powder sintered at 550 °C prepared using 
method 4 at pH 10. 
200 nm 100 nm 
600 °C 
500 °C 
550 °C 
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5.1.3 X-ray Fluorescence Results for the Evaluation of Production Methods 
(Methods 1 - 4) 
XRF results showed that the HA produced using the different methods tended to vary 
from the stoichiometric calcium to phosphorus ratio of 1.67 (Table 5.1). The method 
1 product had excess calcium present (Ca:P 1.70) whereas the other wet precipitation 
method (method 2) produced HA which was noticeably calcium-deficient (Ca:P 1.38).  
The large variations in the calcium to phosphorus ratios of the materials produced 
using method 4 raised concerns regarding the chemical homogeneity of these 
samples. The samples produced using the method 4 tended towards excess calcium 
rather than calcium deficiency. For example, the samples synthesised at pH 10 had 
Ca:P ratios of 1.75, 1.93 and 1.60 when sintered at 500, 550 and 600 °C respectively. 
Table 5.1. XRF results for nHA production methods 1 – 4. 
Production method 
pH 
Sintering 
temperature 
(°C) 
Calcium: 
phosphorus 
molar ratio 
Ca 
soln 
P 
soln 
Wet precipitation 
Method 1 11.4 1.8 1000 1.70 
Method 2 11 12 1000 1.38 
Sol-gel 
Method 3 11 12 1000 1.51 
Method 4 10 10 
500 1.75 
550 1.93 
600 1.60 
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5.2 Development of Selected Synthesis Methods (Methods 1 and 3) 
5.2.1 Method 1: Acid-base Reaction of Calcium Hydroxide and Phosphoric Acid    
The development of method 1 involved changing the parameters in order to determine 
their effect on the nHA produced. Firstly, it was observed that by increasing the 
phosphoric acid solution addition rate into the calcium hydroxide suspension, no 
calcium oxide was observed in the sintered HA product as seen in method 1-A; 
instead a minor phase of β-TCP was detected (method 1-B) (Table 5.2). There was 
also a change in the particle morphology when the phosphoric acid addition rate was 
increased, i.e. rapid mixing (method 1-B), with the particle aspect ratio decreasing 
from approximately 6.5 to 1.3. When the temperature was decreased with rapid 
mixing (method 1-C) there was a noticeable reduction in the conductivity of the nHA 
suspension prior to washing (Table 5.3), which suggested that less residual calcium 
hydroxide was present.  No other phase or particle morphology changes were 
observed for the other incremental method alterations including the increase in 
reactant concentration (method 1-D) (Figure 5.10).  
Table 5.2. Summary of XRD analysis on method 1 development. 
Method 
reference 
Method details 
Phases 
detected in 
XRD pattern 
of 
unsintered 
sample 
Phases 
detected in 
XRD pattern 
of sample 
sintered at 
1000 °C for  
2 h 
Addition rate 
of 
phosphoric 
acid solution 
Reaction 
temperature 
(°C) 
Reactant concentrations 
Calcium 
hydroxide 
(mmol) / 
suspended 
in volume 
of distilled 
water (mL) 
Phosphoric 
acid 
(mmol) / 
dissolved 
in volume 
of distilled 
water (mL) 
1-A 3.5 mL.min-1 60 25 / 250 15 / 250 HA HA + CaO 
1-B 100 mL.s-1 60 25 / 250 15 / 250 HA HA + βTCP 
1-C 100 mL.s-1 25 25 / 250 15 / 250 HA HA + βTCP 
1-D 100 mL.s-1 25 50 / 500 30 / 250 HA HA + βTCP 
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Table 5.3. Effect of temperature on conductivity of suspensions prepared using 
phosphoric acid addition rate of 100 mL.s-1 with reactant concentrations of 25 / 250 
and 15 / 250 (mmol.mL-1) for the calcium hydroxide suspension and phosphoric acid 
solution respectively. 
Sample reference 
Reaction temperature 
(°C) 
Conductivity of nHA 
suspension prior to 
washing (µS.cm-1) 
1-B 60 161 
1-C 25 21 
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Figure 5.10. TEM micrographs showing particle morphology when incremental 
changes were made using method 1: (A) original method (1-A); (B) Phosphoric acid 
solution addition rate increased (1-B); (C) Reaction performed at room temperature 
(1-C); (D) Increased concentration of reaction (1-D). 
5.2.2 Method 3: Reaction of Calcium Nitrate and Ammonium Phosphate  
The development of method 3 showed that a high pH was critical to produce a pure 
HA precipitated product with high thermal stability. The level of thermal stability was 
assessed by the relative intensity of the β-TCP peaks when compared to the HA 
peaks, which indicated the proportion of the HA which had decomposed into β-TCP. 
Indeed, the amount of β-TCP detected in the sintered product increased as the pH 
A B 
C D 
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was decreased. When the calcium and phosphorus solution pH was adjusted to 9 
(method 3-D), the main phase of the sintered product was β-TCP (Table 5.4). The 
increase in phosphorus solution addition rate and concentration of reactants did not 
have an effect on the phases produced (method 3-E compared to method 3-A). The 
particle size increased slightly for the increased phosphorous solution addition rate 
(Figure 5.11). Specifically the average particle size was 30 x 20 nm for the original 
method 3-A and 40 x 20 nm for method 3-E. The particle size further increased to 50 
x 30 nm with an increase in the reactant concentration (method 3-F). 
Table 5.4. Summary of XRD analysis on method 3 development. 
Method 
reference 
Method details 
Phases 
detected in 
XRD 
pattern of 
unsintered 
sample 
Phases 
detected in 
XRD 
pattern of 
sample 
sintered at 
1000 °C for 
2 h 
pH 
Phosphorus 
solution 
addition rate 
Reactant concentrations 
Calcium 
solution 
Phosphorus 
solution 
Calcium 
nitrate 
(mmol) / 
dissolved 
in volume 
of 
distilled 
water 
(mL) 
Ammonium 
phosphate 
(mmol) / 
dissolved 
in volume 
of distilled 
water (mL) 
3-A 11 12 3 mL.min-1 25 / 250 15 / 250 HA HA + β-TCP 
3-B 11 11 3 mL.min-1 25 / 250 15 / 250 HA HA + β-TCP 
3-C 10 10 3 mL.min-1 25 / 250 15 / 250 HA HA + β-TCP 
3-D 9 9 3 mL.min-1 25 / 250 15 / 250 
HA + 
brushite 
β-TCP + HA 
3-E 11 12 100 mL.s-1 25 / 250 15 / 250 HA HA + β-TCP 
3-F 11 12 100 mL.s-1 50 / 500 30 / 250 HA HA + β-TCP 
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Figure 5.11. TEM micrographs displaying particle morphology when incremental 
changes were made using method 3: (A) Original method (3-A); (B) Phosphorus 
solution addition rate increased (3-E); (C) Increased concentration of reactants (3-F).  
  
A B C 
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5.3 Synthesis of Strontium-substituted Nanoscale Hydroxyapatite 
(Optimised Methods 1 and 3) 
5.3.1 Optimised Method 1: Synthesis of Strontium-substituted Nanoscale 
Hydroxyapatite  
The addition of strontium into optimised method 1 caused a peak shift to lower 
degrees 2θ in the XRD patterns for the apatite phase produced when greater amounts 
of strontium were used in the method (Figure 5.12 and Figure 5.13). This peak shift 
to lower degrees 2θ was also observed for the minor phase of strontium-substituted 
β-tricalcium phosphate which was present only after high temperature treatment.  
 
Figure 5.12. XRD patterns of unsintered strontium-substituted HA powders (0, 2.5, 5, 
10, 50 and 100 at. % Sr) produced using optimised method 1. Peak labels:  
hydroxyapatite;  strontium hydroxyapatite.  
 
Caroline Wilcock - Results 
108 
 
 
Figure 5.13. XRD patterns of strontium-substituted HA powders (0, 2.5, 5, 10, 50 and 
100 at. % Sr) produced using optimised method 1 sintered at 1000 °C for 2 h. Peak 
labels:  hydroxyapatite;  β-tricalcium phosphate; strontium hydroxyapatite;  β-
tristrontium phosphate. 
The full width half maximum of the (002) XRD peak for the sintered strontium-
substituted nHA samples was consistently lower than for the corresponding 
unsintered samples, except for the sample with 100 % strontium (Table 5.5). This 
demonstrated the sharpening of the diffraction peaks for the majority of the sintered 
samples. The reduction of the FWHM corresponds with an increase in crystallite size, 
in accordance with the Scherrer equation [208]. 
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Table 5.5. Full width half maximum (FWHM) values for (002) XRD peak located 
between 24 and 26 degrees 2θ of strontium-substituted nHA produced using 
optimised method 1.  
Sr (at. %) 
FWHM of (002) XRD peak (Degrees 2θ) 
Unsintered Sintered 
0 0.37 0.20 
2.5 0.35 0.20 
5 0.38 0.19 
10 0.36 0.23 
50 0.40 0.25 
100 0.24 0.24 
 
Particles of 100 at. % strontium-substituted hydroxyapatite had a larger aspect ratio 
(4.5) than any other level of strontium substitution (e.g. 0 at. % Sr nHA particles had 
an aspect ratio of 1.7). The particles produced using 2.5, 5, 10 and 50 at. % Sr 
appeared to be composed of smaller crystallites which were agglomerated together. 
This was in contrast the particles produced at 0 and 100 at. % Sr which had well 
defined edges (Figure 5.14).  
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Figure 5.14. TEM micrographs of unsintered strontium-substituted HA powders (0, 
2.5, 5, 10, 50 and 100 at. % Sr) produced using optimised method 1. 
XRF data showed the accurate incorporation of strontium into the product, with the 
product Sr / (Sr+Ca) close to the attempted substitution level (Table 5.6). However 
the calcium and strontium to phosphorus ratios were lower than expected particularly 
for the 100 % strontium sample, which had a Sr:P ratio of 1.50. The sample with 0 at. 
% Sr had the calcium to phosphorus ratio (1.63) that was closest to the stoichiometric 
value (1.67).  
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Table 5.6. XRF results for strontium-substituted nHA powders produced using 
optimised method 1. 
Experimental 
Sr / (Sr + Ca) molar % 
Sr / (Sr + Ca) molar % 
calculated from XRF 
data 
(Ca + Sr) / P molar ratio 
0 0.02 1.63 
2.5 2.45 1.57 
5 4.83 1.57 
10 9.55 1.56 
50 49.67 1.58 
100 99.79 1.50 
 
The FTIR-ATR spectra of the range of unsintered strontium-substituted nHA powders 
displayed the presence of the characteristic bands for hydroxyapatite [11, 211]: 3750 
cm-1 (OH- stretch νOH); 1086 and 1022 cm-1 (PO43- ν3); 962 cm-1 (PO43- ν1); 630 cm-1 
(OH- libration δOH); 600 and 570 cm-1 (PO43- ν4). Additional band allocation for the 
unsintered samples: broad peak centred around 3400 cm-1 (absorbed water 
molecules); 1455 and 1410 cm-1 (CO32- ν3); 880 cm-1 (CO32- ν2). The band at around 
880 cm-1 may also be associated with hydrogen phosphate (P-OH ν2), but it is 
generally accepted that the strong CO32- ν2 band obscures this activity [212]. The 
absorbed water and carbonate groups (Figure 5.15 and Figure 5.16) were removed 
during high temperature sintering (Figure 5.17 and Figure 5.18). There was a clear 
shift in the position of the phosphate group bands (1086, 1022 and 962 cm-1) to a 
lower wavenumber when increased amount of strontium were incorporated. 
Specifically, the highest degree of band wavenumber shift was observed for the 100 
at. % strontium sample, followed by the lower amount of strontium incorporation levels 
respectively (Figure 5.16 A and Figure 5.18 A). Shoulders on the phosphate group 
bands were observed for the sintered samples which corresponded to the presence 
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of β-TCP or β-tristrontium phosphate (β-TSP) [211]; approximate positions of 990 cm-
1 (for 0 at. % Sr), 974 cm-1 (for 2.5 and 5 at. % Sr) and 1023 cm-1 (for 100 at. % Sr). 
The bands for the phosphate group activity for the 50 at. % Sr nHA were not as clearly 
defined (i.e. not as sharp) as the other Sr contents. This was observed for both the 
unsintered and sintered samples. The carbonate bands for the 50 and 100 at. % Sr 
nHA samples were also less defined when compared to the other Sr contents (Figure 
5.16 B).  
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Figure 5.15. FTIR-ATR spectra of unsintered strontium-substituted nHA powders (0, 
2.5, 5, 10, 50 and 100 at. % Sr) produced using optimised method 1. 
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Figure 5.16.  FTIR-ATR spectra of unsintered strontium-substituted nHA powders (0, 
2.5, 5, 10, 50 and 100 at. % Sr) produced using optimised method 1. (A) 1150 – 900 
cm-1: phosphate group bands. (B) 1550 - 1350 cm-1: carbonate group bands.  
B 
A 
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Figure 5.17. FTIR-ATR spectra of strontium-substituted nHA powders (0, 2.5, 5, 10, 
50 and 100 at. % Sr) sintered at 1000 °C for 2 h produced using optimised method 1. 
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Figure 5.18. FTIR-ATR spectra of strontium-substituted nHA powders (0, 2.5, 5, 10, 
50 and 100 at. % Sr) sintered at 1000 °C for 2 h produced using optimised method 1. 
(A) 1150 – 900 cm-1: phosphate group bands. (B) 1550 - 1350 cm-1: carbonate group 
bands.  
A 
B 
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The radiopacity of the strontium-substituted nHA powders increased with increasing 
strontium content in a non-linear manner (Figure 5.20). 
 
 
Figure 5.19. Radiograph of strontium-substituted nHA powders (0, 2.5, 5, 10, 50 and 
100 at. % Sr) produced using optimised method 1, n=3, with aluminium step wedge 
used for quantification. Scale bar = 1 cm. 
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Figure 5.20. Quantification of radiopacity of strontium-substituted nHA powders (0, 
2.5, 5, 10, 50 and 100 at. % Sr) produced using optimised method 1, n=3. Error bars: 
± S.D. 
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5.3.2 Optimised Method 3: Synthesis of Strontium-substituted Nanoscale 
Hydroxyapatite  
XRD patterns for the range of strontium-substituted nHA powders (0, 2.5, 5, 10, 50 
and 100 at. % Sr) produced using optimised method 3 displayed the same peak shift 
relationship (Figure 5.21) as the Sr nHA produced using optimised method 1; i.e. the 
XRD peaks shifted to lower degrees 2θ for increased amounts of Sr. The thermal 
stability of the calcium nHA produced using optimised method 3 was relatively high, 
with only minor traces of β-TCP observed when sintered at 1000 °C (Table 5.4, 
method 3-F). This was in contrast to the 100 at. % Sr nHA produced which underwent 
significant thermal decomposition at 700 °C and almost complete thermal 
decomposition at 850 °C (Figure 5.22). Therefore there was no suitable single 
sintering temperature which could be used to increase the sharpness of the diffraction 
peaks of the entire range of strontium-substituted nHA without causing excessive 
thermal decomposition. 
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Figure 5.21. XRD patterns of unsintered strontium-substituted nHA powders (0, 2.5, 
5, 10, 50 and 100 at. % Sr) produced using optimised method 3. Peak labels:  
hydroxyapatite; strontium hydroxyapatite. 
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Figure 5.22. XRD patterns of 100 at. % strontium-substituted nHA powder produced 
using optimised method 3: unsintered and sintered at 500, 700 and 850 °C. Peak 
labels: strontium hydroxyapatite;  β-tristrontium phosphate.  
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The increase in the aspect ratio for the 100 at. % strontium-substituted HA produced 
using optimised method 3 (Figure 5.23) was more pronounced than observed for 
optimised method 1 (Figure 5.14). Specifically, the aspect ratio for the nHA produced 
using optimised method 3 increased from 2.5 for the sample with 0 at. % Sr to 6 for 
the 100 at. % Sr sample. 
 
Figure 5.23. TEM micrographs of unsintered strontium-substituted HA powders (0, 
2.5, 5, 10, 50 and 100 at. % Sr) produced using optimised method 3. 
XRF data displayed the successful incorporation of strontium into the HA in a similar 
ratio to that which was used in the method (Table 4.1). The (Ca+Sr)/P molar ratios 
were again lower than the stoichiometric value of 1.67, with the 0 at. % strontium 
sample (1.59) closest to the stoichiometric value.   
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Table 5.7. XRF results for strontium-substituted nHA produced using optimised 
method 3.  
Experimental  
Sr / (Sr + Ca) molar % 
Sr / (Sr + Ca) molar % 
calculated from XRF 
data 
(Ca + Sr) / P molar ratio 
0 0.01 1.59 
2.5 2.32 1.56 
5 4.81 1.50 
10 9.01 1.54 
50 45.11 1.48 
100 99.91 1.52 
 
FTIR-ATR spectra (Figure 5.24 and Figure 5.25) confirmed the presence of an 
apatite-like phase with characteristic bands for hydroxyapatite as listed in section 
5.3.1 Optimised Method 1: Synthesis of Strontium-substituted Nanoscale 
Hydroxyapatite. Absorbed water and carbonate group activity were also observed in 
these samples alongside the characteristic hydroxyapatite phosphate and hydroxyl 
group activity. As observed for the Sr nHA produced using optimised method 1, there 
was a clear shift to a lower wavenumber of the phosphate group bands (1086, 1022 
and 962 cm-1) when increasing amounts of strontium were present (Figure 5.25 A). 
Similarly for the results obtained for the optimised method 1, the peaks for the 
phosphate group band for the 50 at. % Sr nHA were not as defined as the other Sr 
contents. Also the carbonate group bands for the 50 and 100 % at. Sr nHA samples 
were less defined when compared to the other Sr contents (Figure 5.25 B). 
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Figure 5.24. FTIR-ATR spectra of unsintered strontium-substituted nHA powders (0, 
2.5, 5, 10, 50 and 100 at. % Sr) produced using optimised method 3.  
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Figure 5.25. FTIR-ATR spectra of unsintered strontium-substituted nHA powders (0, 
2.5, 5, 10, 50 and 100 at. % Sr) produced using optimised method 3. (A) 1150 – 900 
cm-1: phosphate group bands. (B) 1550 - 1350 cm-1: carbonate group bands. 
A 
B 
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The radiopacity of the strontium-substituted nHA powders increased in a non-linear 
manner (Figure 5.27) as seen for the powders produced using optimised method 1. 
The radiopacity values recorded were slightly higher than those found for the powders 
produced using optimised method 1. For instance, the radiopacity values recorded 
for the samples produced using optimised method 1 ranged from 2.0 to 6.6 mm of Al, 
whereas the powders produced using optimised method 3 ranged from 3.4 to 7.7 mm 
of Al.  
 
Figure 5.26. Radiograph of strontium-substituted nHA powders (0, 2.5, 5, 10, 50 and 
100 at. % Sr) produced using optimised method 3, n=3, with aluminium step wedge 
used for quantification. Scale bar = 1 cm. 
Sr (at. %):  0        2.5        5        10        50      100 
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Figure 5.27. Quantification of radiopacity of strontium-substituted nHA powders (0, 
2.5, 5, 10, 50 and 100 at. % Sr) produced using optimised method 3, n=3. Error bars: 
± S.D. 
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5.4 Synthesis of Silver-doped Nanoscale Hydroxyapatite (Altered Method 
1)  
XRD patterns showed the precipitation of a HA phase for the 0, 2 and 5 at. % silver-
doped samples (Figure 5.28). However, when the level of silver-doping was increased 
to 10 at. %, silver phosphate was detected alongside the HA phase. Furthermore, an 
increase in the relative intensity at around 10 degrees 2θ indicated an increase 
amorphous residue, with a higher degree of amorphous residue observed with 
increasing silver content. After high temperature treatment, increasing amounts of β-
TCP were detected as the amount of silver-doping was increased (Figure 5.29). For 
the 5 and 10 at. % silver-doped samples, metallic silver was detected after sintering.  
 
Figure 5.28. XRD patterns of unsintered silver-doped nHA powders (0, 2, 5 and 10 
at. % Ag) produced using altered method 1. Peak labels:  hydroxyapatite;  silver 
phosphate. 
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Figure 5.29. XRD patterns of silver-doped nHA powders (0, 2, 5 and 10 at. % Ag) 
produced using altered method 1 sintered at 1000 °C for 2 h. Peak labels:  
hydroxyapatite;  β-tricalcium phosphate;  silver. 
The full width half maximum of the (002) XRD peak for the sintered silver-doped nHA 
samples were consistently lower than for the unsintered samples (Table 5.8). As 
stated previously, based on the Scherrer equation the reduction in the FWHM 
corresponds with an increase in the crystallite size after sintering. 
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Table 5.8. Full width half maximum (FWHM) values for the (002) XRD peak located 
at approximately 26 degrees 2θ of silver-doped nHA produced using altered method 
1.  
Ag (at. %) 
FWHM of (002) XRD peak (Degrees 2θ) 
Unsintered Sintered 
0 0.32 0.23 
2 0.30 0.20 
5 0.32 0.22 
10 0.31 0.21 
 
TEM micrographs (Figure 5.30) showed no major morphological changes in the nHA 
particles when different levels of silver-doping were introduced. However, dark spots 
were observed on some particles in the 5 and 10 at. % silver-doped samples.  
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Figure 5.30. TEM micrographs of unsintered silver-doped nHA powders (0, 2, 5 and 
10 at. % Ag) produced using altered method 1. 
XRF data showed that the silver to calcium molar ratio of the products were lower 
than the amount of silver used in the method (Table 5.9). However, the relative silver 
to calcium molar ratio increased as more silver was used in the method.  
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Table 5.9. XRF results for unsintered 0, 2, 5 and 10 at. % silver-doped nHA samples 
produced using altered method 1. 
Experimental Ag:Ca molar ratio  
(mol. %) 
Ag:Ca molar ratio from XRF (mol. %) 
0 0 
2 1.69 
5 3.34 
10 6.72 
 
All FTIR-ATR spectra for the unsintered silver-doped powders displayed the 
characteristic bands of phosphate and hydroxyl groups associated with 
hydroxyapatite (Figure 5.31) (as listed in section 5.3.1 Optimised Method 1: Synthesis 
of Strontium-substituted Nanoscale Hydroxyapatite). Unsintered samples displayed 
the bands of absorbed water and carbonate groups (Figure 5.32). The high 
temperature sintering process removed the water and carbonate groups and also 
resolved the spectral hydroxyl group bands (Figure 5.33 and Figure 5.34). A peak 
shift to a higher wave number was observed only for the 10 at. % silver-doped sample 
for the unsintered and sintered samples (Figure 5.32 and Figure 5.34). It can also be 
seen that the phosphate group bands were poorly defined for the 10 at. % silver-
doped sample compared to the other formulations. Shoulders were observed in the 
phosphate group activity (1150 – 900 cm-1) for the sintered samples indicating the 
presence of β-TCP [211], particularly for 2, 5 and 10 at. % Ag; approximate positions 
1126, 990 and 945 cm-1. 
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Figure 5.31. FTIR-ATR spectra of unsintered silver-doped nHA powders (0, 2, 5 and 
10 at. % Ag) produced using altered method 1.  
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Figure 5.32. FTIR-ATR spectra of unsintered silver-doped nHA powders (0, 2, 5 and 
10 at. % Ag) produced using altered method 1. (A) 1150 – 900 cm-1: phosphate group 
bands. (B) 1550 - 1350 cm-1: carbonate group bands. 
A 
B 
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Figure 5.33. FTIR-ATR spectra of silver-doped nHA powders (0, 2, 5 and 10 at. % 
Ag) sintered at 1000 °C for 2 h produced using altered method 1. 
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Figure 5.34. FTIR-ATR spectra of silver-doped nHA powders (0, 2, 5 and 10 at. % 
Ag) sintered at 1000 °C for 2 h produced using altered method 1. (A) 1150 – 900 cm-
1: phosphate group bands. (B) 1550 - 1350 cm-1: carbonate group bands. 
A 
B 
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5.5 Nanoscale Hydroxyapatite Paste and Gel Characterisation  
5.5.1 In Vitro Biocompatibility of Strontium-substituted Nanoscale 
Hydroxyapatite Pastes and Gels Produced by Optimised Methods 1 and 3 
In vitro evaluation using cultured cells has the potential to predict the behaviour of 
materials prior to clinical use, or can be used to investigate some specific cell-
mediated interactions. Indirect and direct assays were carried out on the strontium-
substituted pastes and gels to evaluate the potential biocompatibility of the materials 
as described in section 4.2.7.1 In Vitro Evaluation of Strontium-substituted Nanoscale 
Hydroxyapatite Paste and Gel Produced using Optimised Methods 1 and 3.  
For the indirect assays, the 2.5, 5 and 10 at. % Sr nHA paste showed a significantly 
lower viability than the cells cultured with 0 and 100 at. % Sr nHA pastes (Figure 
5.35). Moreover, the 0 and 100 at. % Sr nHA pastes showed the same viability as the 
cells cultured on tissue culture plastic. Variable amount of nHA particles were 
observed in the preconditioned media between different materials tested despite all 
media undergoing centrifugation prior to application. Live/Dead fluorescence images 
showed that the majority of cells were alive, with few dead cells observed (Figure 
5.36). 
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Figure 5.35. PrestoBlue® viability assay results at 24 h for MG63 cells cultured 
indirectly with strontium-substituted nHA pastes produced using optimised method 1 
(0, 2.5, 5, 10, 50 and 100 at. % Sr), control paste (ReproBone novoTM) and with no 
material present (n = 9). Error bars ± standard error of the mean. Significance level: 
*: p< 0.05, **: p< 0.01, ***: p< 0.001, ****: p< 0.0001. 
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Figure 5.36. Live/Dead fluorescence imaging for MG63 cells cultured indirectly with 
strontium-substituted nHA pastes produced using optimised method 1 (0, 2.5, 5, 10, 
50 and 100 at. % Sr), control paste (ReproBone novoTM) and with no material present. 
Scale bar = 200 µm. 
0 at. % 
5 at. % 
2.5 at. % 
10 at. % 
100 at. % 50 at. % 
Control paste No material 
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The cells cultured alongside the nHA paste with 5 at. % Sr content had a significantly 
lower viability than the 0, 2.5, 10 and 50 at. % Sr nHA pastes (Figure 5.37). It was 
also observed that the 5 at. % Sr nHA pastes had a greater tendency to fragment 
during the 48 h incubation than the pastes with other Sr contents (Figure 5.38). The 
cells cultured directly with the 0 at. % Sr nHA paste had statistically greater viability 
than the cells cultured with the 100 at. % Sr nHA paste. This was in contrast to the 
indirect viability assays where the cells cultured with preconditioned media from the 
0 and 100 at. % Sr nHA pastes had the same viability (Figure 5.35). Light microscopy 
and fluorescence microscopy showed the survival and morphology of the cells in 
direct contact with the paste (Figure 5.39 and Figure 5.40). For the fluorescence 
microscopy images, some cells close to the paste had a rounded morphology which 
may have displayed the growth of cells inside the pastes (Figure 5.40). 
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Figure 5.37. PrestoBlue® viability assay results at 48 h for MG63 cells cultured directly 
with strontium-substituted nHA pastes produced using optimised method 1 (0, 2.5, 5, 
10, 50 and 100 at. % Sr), control paste (ReproBone novoTM) and with no material (n 
= 9). Error bars ± standard error of the mean. Significance level: *: p< 0.05, **: p< 
0.01, ***: p< 0.001.  
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Figure 5.38. Image of 24 well plate after 48 h incubation of MG63 cells with strontium-
substituted nHA pastes produced using optimised method 1 (0, 2.5, 5, 10, 50 and 100 
at. % Sr), control paste (ReproBone novoTM) and with no material present after 48 h 
incubation with MG63 cells. All samples in triplicate. Scale bar = 2 cm. 
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Figure 5.39. Light microscopy images for MG63 cells cultured directly with strontium-
substituted nHA pastes produced using optimised method 1 (0, 2.5, 5, 10, 50 and 100 
at. % Sr), control paste (ReproBone novoTM) and with no material present. Scale bar 
= 200 µm. 
0 at. % 
5 at. % 
2.5 at. % 
10 at. % 
100 at. % 50 at. % 
Control paste No material 
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Figure 5.40. Live/Dead fluorescence imaging for MG63 cells cultured directly with 
strontium-substituted nHA pastes produced using optimised method 1 (0, 2.5, 5, 10, 
50 and 100 at. % Sr), control paste (ReproBone novoTM) and with no material present. 
Only green channel shown. Scale bar = 200 µm. 
0 at. % 
5 at. % 
2.5 at. % 
10 at. % 
100 at. % 50 at. % 
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Preconditioned media produced by incubation with the strontium gels had no 
detrimental effect on the viability of the cells (Figure 5.41). nHA particles were also 
observed in the preconditioned media after centrifugation, as observed for the paste 
preconditioned media. Live/Dead fluorescence images showed good cell survival, 
with few dead cells observed (Figure 5.42).  
 
 
Figure 5.41. PrestoBlue® viability assay results at 24 h for MG63 cells cultured 
indirectly with strontium-substituted nHA gels produced using optimised method 3 (0, 
2.5, 5, 10, 50 and 100 at. % Sr), control paste (ReproBone novoTM) and with no 
material (n = 9). Error bars ± standard error of the mean. No significant difference 
was observed between the materials tested. 
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Figure 5.42. Live/Dead fluorescence imaging for MG63 cells cultured indirectly with 
strontium-substituted nHA gels produced using optimised method 3 (0, 2.5, 5, 10, 50 
and 100 at. % Sr), control paste (ReproBone novoTM) and with no material present. 
Scale bar = 200 µm. 
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Cells grown with 0 and 100 at. % Sr nHA gels had significantly reduced viability 
compared with 50 at. % Sr nHA gel, the control paste and cells on tissue culture 
plastic (Figure 5.43). Furthermore, cells cultured with 2.5 at. % Sr nHA gel had a lower 
viability than those cultured with 50 at. % Sr nHA gel and the control paste. The nHA 
gels were observed to fragment considerably during the 48 h incubation period 
(Figure 5.44). Microscopy images displayed the growth of cells in direct contact with 
paste (Figure 5.45). Similarly to the Live/Dead fluorescence images for the nHA 
pastes, cells with a rounded morphology were observed at the edges of the gels, 
which may have been evidence of cells growing within the gels (Figure 5.46).  
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Figure 5.43. PrestoBlue® viability assay results at 48 h for MG63 cells cultured directly 
with strontium-substituted nHA gels produced using optimised method 3 (0, 2.5, 5, 
10, 50 and 100 at. % Sr), control paste (ReproBone novoTM) and with no material (n 
= 9). Error bars ± standard error of the mean. Significance level: *: p< 0.05, **: p< 
0.01, ***: p< 0.001. 
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Figure 5.44. Image of 24 well plate after 48 h incubation of MG63 cells with strontium-
substituted nHA gels produced using optimised method 3 (0, 2.5, 5, 10, 50 and 100 
at. % Sr), control paste (ReproBone novoTM) and with no material present. All samples 
in triplicate. Scale bar = 2 cm.  
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Figure 5.45. Light microscopy images for MG63 cells cultured directly with strontium-
substituted nHA gels produced using optimised method 1 (0, 2.5, 5, 10, 50 and 100 
at. % Sr), control paste (ReproBone novoTM) and with no material present. Scale bar 
= 200 µm. 
0 at. % 
5 at. % 
2.5 at. % 
10 at. % 
100 at. % 50 at. % 
Control paste No material 
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Figure 5.46. Live/Dead fluorescence imaging for MG63 cells cultured directly with 
strontium-substituted nHA gels produced using optimised method 3 (0, 2.5, 5, 10, 50 
and 100 at. % Sr), control paste (ReproBone novoTM) and with no material present. 
Only green channel shown. Scale bar = 200 µm. 
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The comparison of the indirect and direct biocompatibility results for the strontium-
substituted nHA pastes and gels (Figure 5.47) showed that the viability data for the 
indirect paste and gel cultures followed the same pattern, with a reduction in viability 
observed from 0 at. % to 5 at. % Sr nHA. The viability then increased for the cells 
cultured indirectly with the 5 at. % to 100 at. % Sr nHA pastes and gels. Direct viability 
results showed a reduction in viability for 100 % at. Sr nHA paste and gel compared 
with the highest direct viability results for the pastes (0 at. % Sr) and gels (50 at. % 
Sr) respectively. Similarly to the indirect assays, the direct paste assays showed a 
reduction in viability for the 5 at. % Sr paste.  
 
Figure 5.47. PrestoBlue® viability assay results at 48 h for MG63 cells cultured 
directly and indirectly with strontium-substituted (0, 2.5, 5, 10, 50 and 100 at. % Sr) 
nHA pastes produced using optimised method 1 and gels produced using optimised 
method 3. All data was normalised to the experimental cell control with no material 
present. Error bars ± standard error of the mean.  
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5.5.2 Antibacterial Activity of Silver-doped Nanoscale Hydroxyapatite Pastes 
Produced by Altered Method 1 
Agar diffusion assays to investigate the antibacterial activity of the silver-doped nHA 
pastes against S. aureus and P. aeruginosa displayed a clear growth inhibition zone 
surrounding the silver-doped materials (Figure 5.48). There was no zone of inhibition 
observed around the nHA paste that was not silver-doped. For the agar diffusion 
assay involving S. aureus, silver was observed to have chemically reduced on the 
surface of the silver-doped pastes whilst no chemically reduced silver was observed 
on the surface of the pastes for the P. aeruginosa agar diffusion assay. ICP results 
confirmed the presence of silver ions in the agar adjacent to the paste materials with 
the higher silver-doped materials allowing greater diffusion of silver ions into the agar 
gel (Figure 5.49). The amount of silver detected in the agar when the paste were 
incubated with S. aureus was consistently lower than when the pastes were incubated 
with P. aeruginosa.  
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Figure 5.48. Agar diffusion assay of 0, 2, 5 and 10 at. % silver-doped nHA paste 
incubated overnight with S. aureus and P. aeruginosa, scale bars = 0.5 cm.     
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Figure 5.49. ICP-MS quantification of silver concentration in agar plugs surrounding 
the silver-doped nHA paste materials for agar diffusion assays with S. aureus and P. 
aeruginosa, n=2, difference between experiments did not exceed 1.5 ng.mg-1.   
When the bacteria were cultured in suspension with the pastes there was a reduction 
in bacterial growth observed for the paste with no silver-doping as the concentration 
of the paste was increased (Figure 5.50). However, the silver-doped pastes showed 
a greater level of growth inhibition in a dose dependent manner with the 10 at. % 
silver-doped paste inhibiting bacterial growth the most followed by the 5 and the 2 at. 
% silver-doped nHA pastes respectively. This was clearly shown by the increasing 
MIC for the silver-doped pastes with a higher silver-doping level (Table 5.10). There 
was also an increase in the optical density for the highest concentrations of the 10 at. 
% silver-doped paste when investigated in suspension culture against S. aureus, 
which was not observed as clearly when P. aeruginosa was cultured with the 10 at. 
% silver-doped material.   
Caroline Wilcock - Results 
156 
 
 
 
Figure 5.50. Optical density of S. aureus (A) and P. aeruginosa (B) in suspension 
culture at 20 h incubated with 0, 2, 5 and 10 at. % silver-doped nHA paste (paste 
material control subtracted) (n = 9). Error bars ± standard error of the mean.  
A 
B 
Caroline Wilcock - Results 
157 
 
Table 5.10. Minimum inhibition concentration (MIC) of silver-doped nHA pastes in 
mg.mL-1.  
Organism Level of silver-doping in nHA paste (at. %) 
0 2 5 10 
S. aureus >50 12 9 2.5 
P. aeruginosa 35 29 8 3.5 
 
  
Caroline Wilcock - Discussion 
158 
 
6. Discussion 
6.1 Evaluation of Wet Precipitation and Sol-gel Methods of Nanoscale 
Hydroxyapatite Synthesis (Methods 1 - 4) 
During the evaluation of the nHA synthesis methods, the wet precipitation method 
proved to be a reliable and convenient method for the production of nHA particles 
with a high aspect ratio (i.e. needle shaped). Method 1, involving the reaction of 
calcium hydroxide and phosphoric acid, was particularly advantageous due to the 
simple acid-base nature of the reaction which avoided the formation of chemical by-
products. Indeed, the high alkalinity of calcium hydroxide allowed for the reaction pH 
to be ‘self-controlled’ [127], thereby simplifying the preparation by removing the need 
for additional pH control. However, the major concern with this method was the 
presence of residual calcium hydroxide which was expected to have a detrimental 
effect on the pH when the product was placed in an aqueous environment. This, in 
turn, could compromise the biocompatibility of the material. XRF data (Table 5.1) 
suggested that the presence of calcium hydroxide was minor, with the Ca:P ratio only 
increasing by 1.8 % from the stoichiometric HA value of 1.67.  
For the wet precipitation method 2 (reaction of calcium chloride and potassium 
phosphate), the complete thermal decomposition and the low Ca:P ratio (1.38) 
suggested that the precipitated nHA was particularly calcium-deficient (Figure 5.3 and 
Table 5.1). For this reaction, the main factor in the production of calcium-deficient HA 
was likely to be too low a pH which led to the incorporation of HPO4 groups. However, 
since the pH had already been adjusted to 11 and 12 prior to the titration for the 
calcium and phosphorus solutions respectively, this method was deemed to be 
difficult for the large scale production of nHA due to the strong basic pH that would 
be required to produce a stoichiometric nHA and ensure that no other calcium 
phosphate phases were produced. The thermal decomposition of nHA below 1000 
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°C, prepared using the wet precipitation method, has been reported elsewhere [86, 
175]. It is recognised that the decomposition temperature of HA is strongly dependent 
on the synthesis conditions [86, 88] such as the amount of solution ageing time and 
the solution pH. It has been well documented that the main cause for low temperature 
thermal decomposition is the formation of calcium-deficient HA. For instance, Gibson 
et al. reported decomposition temperatures between 710-740 °C for calcium-deficient 
HA [213]. The XRD reference cards of calcium-deficient HA and stoichiometric HA 
are remarkable similar and this makes phase identification extremely difficult 
particularly especially on unsintered samples with low crystallinity.  
Sol-gel method 3, involving the reaction of calcium nitrate and ammonium phosphate, 
was found to successfully produce low aspect ratio nanoscale HA particles with good 
thermal stability; only minor decomposition was observed when the product was 
sintered at 1000 °C (Figure 5.5 and Figure 5.6). The low stoichiometric Ca:P ratio 
(1.51) was again likely to contribute to the lower thermal stability of this calcium-
deficient sample. The thermal decomposition of HA synthesised using the sol-gel 
method has been widely reported [88, 184, 214]. Indeed, sol-gel nanoscale HA 
sintered at temperatures as low as 600 °C has been found to contain β-TCP [190]. In 
the literature, the reaction between calcium nitrate and ammonium phosphate to 
produce hydroxyapatite has been referred to both as a sol-gel [184-186, 215] and a 
precipitation method [90, 180, 181, 216, 217]. The sol-gel classification was adopted 
for this thesis due to the formation of a gel during the drying process.     
In contrast to all of the other nHA preparation methods, there were no detectable 
crystalline phases prior to sintering for sol-gel method 4 (reaction of calcium nitrate 
and triethyl phosphite) (Figure 5.7). The presence of β-TCP when the product was 
sintered demonstrated a deviation from stoichiometry. These XRD results displayed 
that a sintering temperature of 600 °C was required to achieve a detectable level of 
β-TCP in the XRD patterns (Figure 5.8). Sol-gel powders with a high thermal 
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sensitivity were also reported by Fathi et al. [88]; hydroxyapatite was the only phase 
present when the sample was sintered at 600 °C, whereas β-TCP and CaO were 
present after sintering at 700 °C. For hydroxyapatite prepared using sol-gel methods, 
lower sintering temperature are required to densify the ceramics compared to 
powders produced using wet precipitation. The lower sintering temperature required 
has been attributed to the higher reactivity of the sol-gel powders [218] and the 
smaller particle size formed by the sol-gel method [190]. The XRF results for these 
samples were varied suggesting that the chemical homogeneity of the sample was 
poor, which was surprising since the sol-gel method is said to promote molecular level 
mixing resulting in high chemical homogeneity [184]. The detection of ammonium 
nitrate in the sintered samples showed that the washing stages were inadequate to 
remove this by-product from the reaction. Furthermore, it can be seen that a sintering 
temperature above 600 °C is necessary to thermally decompose all of the residual 
ammonium nitrate.  
The nHA particles produced using method 4 were the largest obtained from all the 
methods due to the high temperature treatment which causes particle growth by 
diffusion (sintering) (Figure 5.8). The additional steps of washing with centrifugation 
were also time consuming and a considerable disadvantage of the method, when 
compared to the previous methods. Furthermore, the requirement to sinter the 
material prior to obtaining a HA phase was considered unsuitable for the production 
of an injectable nHA paste or gel. Instead it was deemed preferable not to dry the 
nHA suspension fully to prevent agglomeration. Therefore, to produce the paste and 
gel materials the drying of the nHA suspensions was stopped when an appropriate 
water content was obtained. For the evaluation of the initial methods, FTIR analysis 
would have been useful in determining how the presence of carbonate and hydrogen 
phosphate groups may have affected the thermal stability of the nHA prepared.  
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From these initial methods, 1 and 3 were selected for further development due to their 
favourable properties. The major advantages associated with each method were the 
relative ease of nHA production and the absence of by-products for method 1. The 
good chemical stoichiometry and small nanoscale dimensions of the products were 
also favourable, as well as the possible production of a nHA gel using method 3. The 
major difference between methods 1 and 3 was the solubility of the calcium reagent 
which may have contributed to the different particle morphologies obtained.  
Calcium hydroxide has a very low solubility and therefore only a limited amount of 
calcium is available for conversion into hydroxyapatite at any one time. In contrast, 
the high solubility of calcium nitrate allows for a high availability of calcium which 
greatly affects the precipitation kinetics. As discussed by Prakash et al. [176], the 
effect of temperature on nHA particle morphology is completely opposite for systems 
involving calcium hydroxide and more soluble calcium salts such as calcium nitrate 
or calcium chloride. It was reported that, during nHA synthesis with calcium hydroxide 
and phosphoric acid, an increased reaction temperature was found to yield particles 
with a lower aspect ratio (i.e. more rounded). Conversely, an increase in reaction 
temperature increased the particle aspect ratio (i.e. became more needle-like) when 
investigated for calcium chloride and sodium phosphate. Since a higher precipitation 
rate results in particles with a high aspect ratio, the final crystal morphology can 
highlight the differences in the precipitation kinetics. Indeed, the difference in the 
Gibbs free energy is the stimulating factor for precipitation which depends upon the 
concentration of the ions and the temperature of the reaction among other 
thermodynamic factors. The simple control of particle morphology by temperature is 
an advantage due to the ability to yield different nHA morphologies and in turn 
behaviours. As well as physicochemical, rheological and mechanical differences, the 
bioactivity of nHA is likely to be affected by its particle morphology. Therefore, the 
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production of different nHA morphology may provide optimised particles for different 
applications.  
6.2 Development of Selected Synthesis Methods (Methods 1 and 3) 
6.2.1 Development of Method 1 
The rate of the phosphoric acid addition was found to have the greatest effect of all 
the synthesis parameters investigated, in terms of chemical composition and particle 
morphology of the product (Table 5.2 and Figure 5.10). When the phosphoric acid 
was poured into the calcium hydroxide suspension, the rapid decrease in the pH of 
the solution was likely to have contributed to the successful conversion of the poorly 
soluble calcium hydroxide into hydroxyapatite by encouraging the dissolution of 
calcium hydroxide. Since the main intensity XRD peak of calcium hydroxide overlaps 
with the (202) HA peak at 34.1° degrees 2θ, it is only in the sintered sample that the 
presence of calcium hydroxide in the precipitated product can be inferred from the 
detection of its thermal decomposition product, calcium oxide [174]. The elimination 
of the calcium hydroxide residue by the increase in addition rate can clearly be seen 
from the XRD results, with no calcium oxide residue in the rapidly mixed sintered 
product (method 1-B) as opposed to its presence in the product prepared using slow 
titration (method 1-A). These results were in contrast to those reported by Bouyer et 
al. [174]; in their study, calcium oxide was detected in the XRD pattern at the highest 
phosphoric acid addition rate (2.4 L.min-1) which indicated the presence of calcium 
hydroxide in the precipitated product. It is possible that the calcium hydroxide used 
by Bouyer et al. was composed of larger particles than that used in this project, which 
could explain the increased solubility of calcium hydroxide observed in the current 
investigations. Several other strategies have been suggested to eliminate the calcium 
hydroxide residue including increased stirring, using a lower minimum adjusted pH 
level and adding extra acid [177]. 
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It is likely that the low pH caused by the rapid addition of phosphoric acid contributed 
to the incorporation of HPO4 groups into the HA, which caused the precipitation of a 
calcium-deficient product with a lower thermal stability. This hypothesis is supported 
by the lower than stoichiometric Ca:P ratio (1.63) obtained for the nHA prepared using 
the optimised route 1 method. It has been suggested that the hydroxyl ions in the 
calcium hydroxide suspension are rapidly neutralised when the phosphoric acid 
solution is added quickly, which lowers the pH in the majority of the suspension but 
not at the surface of the calcium hydroxide particles [177].  A similar effect was also 
reported by Osaka [219] where a high phosphoric acid addition rate caused the 
precipitation of HA with a lower thermal stability. As mentioned previously, it is well 
established that calcium-deficient HA (CDHA) has a lower thermal decomposition 
temperature than stoichiometric HA [213, 220-222]. In detail, it is believed that the 
increased thermal instability of calcium-deficient HA is due to the condensation of the 
HPO42- ions and the subsequent reaction of P2O74- ion with the OH- ion [221]. Using 
a combination of XRD and FTIR, Gibson et al. were able to identify structural changes 
between 500 and 1100 °C during the thermal decomposition of CDHA [213]. In this 
study, CDHA with a Ca:P ratio of 1.5 was found to decompose over 710 – 740 °C. 
The thermal stability of CDHA is likely to be dependent on the degree of calcium 
deficiency, however it is difficult to make comparison between different studies due 
to the different processing parameters used. As discussed by Gibson et al., the 
different decomposition temperatures reported by various researchers may be due to 
the different sintering times used [213].  
The noticeable effect of the phosphoric acid addition rate on the nHA particle 
morphology could clearly been seen in TEM images (Figure 5.10). The changes in 
particle morphology can be attributed to the difference in the precipitation rate [175, 
176]. Interestingly, the rapid addition of phosphoric acid caused a reduction in the 
precipitation rate resulting in particles with a decreased aspect ratio, whereas the 
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particles with a higher aspect ratio correspond with a faster precipitation rate. This 
can also be explained by considering the energy of particle growth verses the energy 
of new particle nucleation. As discussed by Bouyer et al., when the rate of crystal 
nucleation becomes higher than the rate of crystal growth, the specific surface area 
increases typically resulting in a larger number of smaller particles [174]. Similar 
results were reported by Afshar et al. with a slower acid addition rate contributing to 
the growth of larger particles [177].   
The lower solubility of calcium hydroxide at an increased temperature was likely to 
have contributed to the presence of residual calcium hydroxide in the titrated nHA 
product when the calcium hydroxide suspension was heated (method 1-A). However, 
it was observed that no residual calcium hydroxide was present after the rapid 
phosphoric acid addition rate was employed even at an elevated temperature 
(method 1-B). Despite this, the increased conductivity of the nHA suspension when 
the reaction was carried out at a higher temperature (Table 5.3) may be due to the 
presence of trace amounts of residual calcium hydroxide. Although not detectable on 
the XRD pattern, this is an important parameter to consider for obtaining a product 
with optimal biocompatibility as even the presence of trace amounts of basic calcium 
hydroxide may detrimentally alter the in vivo response through a lowering of pH.   
It was difficult to compare the precise effects of temperature change on particle 
morphology with those reported by other researchers due to the difference in 
phosphoric acid solution addition rates. Despite the reported effect that temperature 
has been found to have on nHA morphology, for this project the effect was clearly 
overshadowed by the notable change caused by the rate of phosphoric acid addition. 
As described elsewhere for titration reactions, the aspect ratio of the nHA particles 
increases with increasing temperature. Bouyer et al. reported a maximum in crystallite 
size at 60 °C due to the balance of two thermodynamic effects. It was discussed that 
although the temperature rise increases the crystallinity of the HA, it also limits the 
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growth along the c axis due to the nanoscale crystals tending to a monocrystalline 
phase [174]. For the development of the paste it was decided that a platelet shaped 
nHA would have superior rheological properties to promote high injectability. There is 
evidence to suggest that nHA particles with a high aspect ratio have a poorer 
flowability and pronounced shear thinning effects due to the alignment of the needles 
under conditions of flow [223, 224]. As this is an important factor for the preparation 
of injectable nHA systems, it has been highlighted as an area for future work in 
Chapter 8. 
When the concentration of the reactants was increased there were no noticeable 
changes in the chemical composition or morphology of the nHA (method 1-D 
compared with method 1-C). Presumably, there exists a maximum concentration at 
which the chemical diffusion is limited which prevents the successful conversion of 
the reagents into the products. At certain levels, the precipitation of nHA is likely to 
be heavily influenced by the reactant concentration due the thermodynamic 
alterations to the system. For example, the change in the Gibbs free energy, which is 
the driving force for precipitation, is directly proportional to the ionic concentrations in 
the solution. The precipitation of nHA is a relatively complex due to the many factors 
which govern the process. Although relationships on the effect of a particular variable 
on particle morphology can be made, under different conditions the reverse can be 
true. This is clearly demonstrated by the effect of temperature which has the opposite 
effect on aspect ratio for systems with low and high solubility calcium reagents.     
In terms of scaling up the method for industrial application, the main consideration 
should be the effective mixing of the suspension to ensure that the product has good 
chemical homogeneity. Indeed, it was concluded by Afshar et al. that powerful high 
speed stirring is beneficial in maintaining a homogenous media for the precipitation 
of a consistent HA product [177].   
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6.2.2 Development of Method 3 
The product formed using method 3 and the thermal stability of the nHA was found to 
be highly dependent on the pH of the initial calcium and phosphorous solutions (Table 
5.4). When the pH was too low, the state of the orthophosphate ions was not suitable 
for stoichiometric HA preparation. This was due to the incorporation of HPO42- ions 
into the HA crystal structure which caused the formation of calcium-deficient HA [219]. 
This theory was supported by the reduced Ca:P ratio (1.59) obtained using XRF on 
the optimised method 3 product.  As described for method 1, the preparation of a 
calcium-deficient nHA decreased the thermal stability of the product. For method 3 
there was a clear increase in β-TCP in the sintered product when the pH was lowered 
(methods 3-B, 3-C and 3-D), thereby demonstrating the thermal stability dependence 
on the preparation pH. Furthermore, brushite was formed when the pH of the calcium 
and phosphorus solutions was 9 prior to titration. Brushite is known to form at a lower 
pH than hydroxyapatite, and has a reported pH stability range of 2.0 – 6.0 compared 
to 9.5 – 12 reported for hydroxyapatite [225].   
No considerable differences were found between the nHA produced when the 
phosphate solution addition rate was increased (Table 5.4 and Figure 5.11, method 
3-A compared with method 3-E), which was in complete contrast to method 1 where 
chemical and morphological changes were detected. This may be due to the highly 
soluble nature of the reactants used in method 3, which differs significantly from the 
sparingly soluble calcium hydroxide used in method 1. The difference in solubility has 
understandably had an effect on nHA crystal morphology. The presence of small 
platelet shaped crystals suggests that the precipitation rate was relatively slow and 
the rate of new particle nucleation was faster than the rate of particle growth.  When 
the concentration of reactants was increased, slightly larger particles were obtained 
(method 3-F), which suggests that the crystal growth rate was increased by the higher 
concentration of reactants. As described by Liu et al. the precipitation of HA from 
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solutions of calcium nitrate and ammonium phosphate is a fairly complex multistage 
process. Initially, octacalcium phosphate is formed which rapidly converts to 
amorphous calcium phosphate. This is followed by the formation of calcium-deficient 
HA which then converts to HA. The speed of this process was reported to be 
temperature dependent, with an increased rate found at higher temperatures [216].   
No ammonium nitrate was detected in the dried products demonstrating that the by-
product of the reaction had successfully been removed during the washing stages. 
This was an important factor to consider since the presence of ammonium nitrate may 
detrimentally affect the biocompatibility of the synthesised gel [226]. Other 
approaches have included sintering the product to remove the ammonium nitrate 
[215]. However, this was unsuitable for the production of a nHA gel due to the 
increase in particle size obtained during high temperature treatment and the 
agglomeration of nHA particles when the product is dried completely.  
The pH was also observed to have an effect on the settling of the nHA suspension. 
The lower the pH, the lower the settling level of the nHA which in turn affected its’ 
ability to form a stable gel. This was likely to be due to the change in pH affecting the 
colloidal nature of the settled suspension. In general, the sol-gel method produces a 
colloidal solution which has been hypothesised to have an oligometric structure. The 
nHA particles are suspended in the gel phase by the presence of metal hydroxide 
bonds. During the drying process the particles consolidate through van der Waals 
attractions [183]. The surface charge of the particles is a key factor in the stability of 
the solution. Indeed, the decreasing surface charge of the particles characterises the 
change from a solution into a gel [14]. The pH is likely to affect the nHA particle 
surface charge and in turn the agglomeration of the particles in the colloidal 
suspension. The use of a high pH therefore allowed the formation of a stable nHA gel 
composed of 90 wt. % water.  
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Considering injectable nHA systems, there is a very limited amount of publications 
regarding nHA gels. The majority of published work has been focussed on nHA 
poly(vinyl alcohol) (PVA) hydrogels, which contain molecular chains of PVA cross 
linked by irradiation. These gels are generally developed with the view to use for 
articular cartilage repair [227-229]. Other nHA gels have been based on collagen and 
alginate [230], or collagen and chitosan [231] gel networks. The polymer gel networks 
add extra complexity to the production and processing of these materials for use as 
medical devices. However, providing the product has been washed of by-products 
which may be detrimental to the biocompatibility, the ‘gel’ stage of the sol-gel process 
may provide a simple nHA gel material composed of nHA particles suspended in 
water suitable for bone tissue augmentation. Although not formally defined, it could 
be suggested that paste and gels differ in their water content and appearance with 
translucent gels possessing a higher water content than the corresponding opaque 
paste materials.  
6.3 Production and Characterisation of Strontium-substituted Nanoscale 
Hydroxyapatite (Optimised Methods 1 and 3) 
The substitution of strontium for calcium in the HA crystal lattice had a variety of 
physicochemical effects which were detected using a range of materials 
characterisation techniques. Firstly, the increase in the unit cell parameters for the 
strontium-substituted nHA was evident in the peak shift to lower degrees 2θ displayed 
in the XRD patterns (Figure 5.12, Figure 5.13 and Figure 5.21). Indeed, increased 
peak shift was observed for a higher amount of strontium substitution for both 
optimised methods. The larger ionic radius of strontium when compared to calcium 
was responsible for the increase in lattice parameters. As reported by O’Donnell et 
al., the increase in the lattice parameters, unit cell volume and density were linear 
over the whole range of strontium substitution (0 – 100 at. %) [124]. It was observed 
that the XRD pattern for the 100 at. % strontium HA had the highest intensity peaks. 
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This effect may be due to the greater electron density of strontium which allows for 
the efficient scattering of X-rays [124].   
It has been reported that strontium is able to substitute into both calcium sites within 
the HA crystal lattice, with some reports suggesting a preference for strontium 
substitution into the M(II) site [124]. It has also been found that at very low strontium 
content (at. %) a slight preference for the M(I) site exists. In detail, for strontium 
incorporation below 1 at. % a preference for the M(I) site was observed. Since HA 
contains six M(II) sites and four M(I) sites, the ideal statistical occupancy can be 
described as M(II)/M(I) equating to 1.5. This ratio was achieved for compositions 
around 5 at. %. At higher strontium substitutions the preference for the M(II) site was 
confirmed [232]. Similar results were reported by Bigi et al. with a preference for the 
M(I) site found for 5 at. % compared to a preference for the M(II) site for 10 and 50 
at. % [125]. Theoretical analysis suggested that strontium substitution caused a 
strong local distortion on the HA crystal lattice, with more distortion encountered at 
the M(II) site. Specifically the metal oxygen bond structures at the metal sites cause 
lattice disorder [232]. The M(II) site has been described as ‘larger’ than M(I) to signify 
the increased preference for the larger strontium ion to occupy this site. This is due 
to the ability of the M(II) atoms to form staggered equilateral triangles, compared to 
the constrained columns of the M(I) sites aligned parallel to the c-axis. The preference 
for the M(I) site at lower concentrations may be explained by the longer M(I)-O 
distances when few strontium atoms are present [125].  
Sr nHA produced using optimised method 1 displayed greater thermal instability with 
the co-presence of strontium and calcium in the crystal, since the lowest intensity 
breakdown product peaks were observed for 100 at. % calcium nHA and 100 at. % 
strontium nHA (Figure 5.13). This is likely to be due to strain exerted on the crystal 
lattice due to the size difference between the two atoms. For instance, it was reported 
that 50 at. % strontium-substituted nHA had the smallest crystallite size over the 
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range of 0 – 100 at. % strontium substitution due to the greater amount of disorder in 
the crystals [124]. A similar effect was reported elsewhere with a low content of 
strontium decreasing the crystallite size whilst a higher content of strontium 
significantly increased the crystallinity of the product [125]. The decrease in 
crystallinity was reported to be caused by the incorporation of strontium increasing 
the length of the metal hydroxyl bond which also decreased the lattice energy [128]. 
The decrease in the crystallite size can be observed by the broadening of the XRD 
peaks, with the unsintered 50 at. % Sr samples produced using both methods having 
the broadest peaks (Figure 5.12 and Figure 5.21). Further evidence for the reduced 
crystallite size of the strontium and calcium mixed apatite was observed in the FTIR-
ATR spectra (Figure 5.16, Figure 5.18 and Figure 5.25), where the phosphate group 
bands were broader for the 50 at. % strontium hydroxyapatite compared with all the 
other compositions (0, 2.5, 5, 10 and 100 Sr at. %) produced using both optimised 
methods. Other researchers have correlated the reduction in phosphate group band 
definition with a decreased product crystallinity [208, 233]. The measurement of the 
FWHM (Table 5.5) of the (002) XRD peak showed the increase in crystallite size as 
the products were sintered. However, no measureable change in the FWHM for the 
100 at. % Sr sample was detected. This may be due to the high intensity diffraction 
pattern already observed for the unsintered 100 at. % Sr nHA material.  
The noticeable difference between the thermal stability of the strontium-substituted 
nHA produced by the different optimised methods suggested that the optimised 
method 3 product had a greater degree of calcium / strontium deficiency (Figure 5.13 
and Figure 5.22). However, it is interesting to note that the 100 at. % strontium-
substituted sample produced using optimised method 3 ((Ca+Sr)/P of 1.52) had a 
much lower thermal stability than the 100 at. % strontium-substituted sample 
produced using optimised method 1 ((Ca+Sr)/P of 1.50) (Table 5.6). 
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It has been reported that the presence of B-type carbonate substitution stabilises the 
apatitic structure due to the presence of water in two types of vacancies [234]. The 
vacancies are present due to the negative charge deficiency when the CO32- ion 
substitutes for the PO43- ion [235]. Therefore B-type carbonate substitution may have 
contributed to the increased thermal stability for the 100 at. % strontium 
hydroxyapatite produced using the optimised method 1. However, it should be noted 
that B-type carbonate substitution bands were less defined for the 50 and 100 at. % 
Sr nHA produced using both optimised methods. Therefore it is difficult to conclude 
whether this effect could have contributed to the increased thermal stability observed 
for the 100 at. % Sr nHA produced using optimised method 1. From the TEM 
micrographs it can be seen that the 100 at. % strontium nHA produced using 
optimised method 3 (Figure 5.23) has much straighter edges and sharper vertices 
than the 100 at. % Sr nHA produced using optimised method 1 (Figure 5.14). This 
could suggest a higher surface energy of the 100 at. % Sr nHA produced using 
optimised method 3, which in turn could contribute to its lower thermal stability.   
The XRF results showed a general decrease in (Ca+Sr)/P ratio as the strontium 
content was increased, which was unexpected due to the high thermal stability of the 
100 at. % strontium-substituted produced using optimised method 1 (Table 5.6). This 
raised concerns over the reliability of the XRF data, and it may be that the accuracy 
limitations of the technique have provided conflicting data.  
TEM images clearly displayed the noticeable effect strontium had on the crystal 
growth of the nHA particles. Although much more pronounced in optimised method 3 
(Figure 5.23), it was still clear in optimised method 1 that the 100 at. % strontium-
substituted nHA was composed of particles with a higher aspect ratio than the 100 at. 
% calcium nHA (Figure 5.14). This provided insights to the effect that strontium has 
on the precipitation of the nHA. In detail, the change in particle aspect ratio suggested 
that the presence of strontium instead of calcium caused a change in the precipitation 
Caroline Wilcock - Discussion 
172 
 
rate, due to the energy of crystal growth being lower than energy required for new 
crystal nucleation. These effects promoted growth along the c axis [174] which 
resulted in the large aspect ratio particles for the 100 at. % strontium nHA particles. 
It can be seen that the nHA particles for the mixed calcium-strontium nHA particles 
are generally composed of smaller sub particles with ill-defined edges, particularly for 
the optimised method 1 products. Similar effects were reported elsewhere and 
corresponded with a lower degree of crystallinity [125]. It could be proposed that the 
co-presence of calcium and strontium slowed down the crystal growth rate resulting 
in a larger number of smaller particles, probably due to the increased difficulty to 
accommodate both atoms in the crystal lattice. Furthermore, an increase in particle 
aspect ratio for increased strontium content has also been reported for strontium-
substituted nHA produced using the same reagents as optimised method 3 [125].  
XRF results demonstrated that the level of incorporation of strontium into the products 
was generally very close to the attempted substitution level, albeit in a calcium / 
strontium deficient product (Table 5.6 and Table 5.7). This showed the readiness of 
strontium to substitute into the nHA crystal lattice and was probably aided by the 
isoelectric nature of the substitution of divalent calcium ions for divalent strontium 
ions.  
The presence of strontium in the nHA had a clear effect on the phosphate group 
bands as showed by the peak shift to a lower wavenumber, observed in the FTIR-
ATR spectra (Figure 5.16, Figure 5.18 and Figure 5.25). This change in the chemical 
environment is likely to be due to the larger strontium atom creating a modified crystal 
lattice which in turn allows for different vibrational and stretching energies for the 
chemical groups. As described for Raman spectroscopy by O’Donnell et al. the 
frequency of the bands are dependent on the lattice vibrational energies; this is the 
same case for FTIR spectroscopy. Therefore, the position of the vibration is defined 
by the masses of the atoms present and the strength of the forces between them 
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[124]. As discussed in detail for strontium substitution in HA by Bigi et al., the FTIR 
phosphate peaks shifts can be attributed to the increased size of strontium compared 
to calcium. The presence of a larger atom caused a decrease in the anionic repulsion 
of the PO43- groups and, in combination with an increased anionic separation, caused 
the change in energies observed in the spectra [125].   
The FTIR-ATR spectra showed modest levels of carbonate substitution for the 
strontium-substituted nHA produced using both optimised methods (Figure 5.16 and 
Figure 5.25). The bands at around 1450 and 1420 cm-1 can be attributed to the B-
type substitution of carbonate groups for phosphate groups. In contrast, no bands for 
the A-type substitution of carbonate for hydroxyl groups were observed, which are 
generally present at around 1550 cm-1 [86, 236, 237]. A possible explanation for the 
carbonate substitution may be that the alkalinity of the precipitation solutions allowed 
for dissolution of atmospheric carbon dioxide. The carbonate groups observed for the 
unsintered optimised method 1 product are removed during the sintering treatment at 
1000 °C (Figure 5.18). As described by Rau et al. the loss of carbonate groups from 
HA can begin at relatively low temperatures e.g. 400 °C. However it was found that 
the preparation conditions had a significant effect on the loss of carbonate during 
thermal treatment, with different carbonated HA displaying vastly different carbonate 
loss regimes [238].  
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Based on the evidence of the characterisation results, the strontium-substituted nHA 
prepared during these investigations may have the following chemical formula (i.e. 
calcium / strontium deficient and carbonate substituted): 
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x = Sr at. % / 10 
0 ≤ x ≤ 10 
0 ≤ y ≤ 1 
0 ≤ z ≤ 1 
Since the natural form of nHA is carbonated and calcium-deficient, the production of 
non-stoichiometric HA actually presents a more biomimetic approach which may 
possess greater bioactivity. For example, research on biomimetic calcium-deficient 
carbonated nHA has shown it is able to stimulate proliferation and the alkaline 
phosphatase activity of murine preosteoblast cells to a greater degree than 
conventional nHA [239]. 
The increase in radiopacity with increasing strontium content was expected due to 
the higher atomic mass of strontium compared to calcium. This allows strontium to 
absorb more X-ray energy [240]. Therefore, for the same mass of dried powder an 
increase of radiopacity was clearly observed with increasing strontium content (Figure 
5.20 and Figure 5.27). The density of the different powders may have contributed to 
the difference seen between powders produced by the different methods, as for the 
same strontium content, a higher radiopacity was observed for the powders produced 
using optimised method 3. The difference in density may be linked to the amount of 
absorbed water present in the powders. No published studies have been found on 
the radiopacity of strontium hydroxyapatite powder alone and therefore more 
investigations are required to better understand an optimal strontium content for the 
effective detection of strontium-substituted HA in vivo. However, the increased 
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radiopacity of strontium hydroxyapatite bone cements have also been reported [122, 
123].  
The in vitro biocompatibility results highlighted the sensitivity of cultured cells to 
different forms of substituted nHA. Indeed, any significant differences in cellular 
viability observed in these experiments (Figure 5.47) may have been due to a change 
in chemistry or particle morphology or a combination of the two effects.  
For the indirect assays, variable amounts of particles were observed in the 
preconditioned media prepared using pastes or gels with different strontium contents, 
despite identical media preparation. However, it was interesting to note that the 
indirect paste assays showed significant variances in viability (Figure 5.35) whereas 
no significant differences were observed for the indirect gel assays (Figure 5.41). The 
gels were observed to consistently fragment (Figure 5.44) which may have allowed 
for similar particle content during the preparation of the preconditioned media for the 
indirect assays. Since the 5 at. % Sr nHA paste displayed the greatest fragmentation 
when cultured directly with the cells (Figure 5.38), this may have allowed for a greater 
surface area for the release of nHA particles during the preparation of the 
preconditioned media. This effect might have contributed to the decreased viability of 
the cells cultured with preconditioned media prepared using the 5 at. % Sr nHA paste. 
The cells cultured indirectly with the 0 and 100 at. % Sr nHA pastes showed the 
greatest viability, which implied that the strontium-substituted nHA pastes containing 
calcium and strontium had a detrimental effect on cellular viability. It could be 
suggested that the increased solubility, expected for the strontium-substituted 
samples containing strontium and calcium, caused a high concentration of dissolved 
ions which may have reduced the viability of the cells through osmotic effects or other 
mechanisms. The presence of the larger strontium ion has been proposed to 
contribute to the increased solubility of strontium-substituted nHA samples due to a 
destabilising effect on the crystal structure [241]. 
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For the direct assays, the fragmentation of the 5 at. % Sr nHA paste was likely to 
have reduced the surface area of the well plate where cells could grow in an 
unconstrained manner, thereby reducing the overall viability.  No significant 
differences in viability were observed for the 0, 2.5, 10 and 50 at. % Sr nHA pastes 
(Figure 5.41) suggesting that for these samples, the increased amount of strontium 
was not detrimental to the cells. The fragmentation of the gels may have also 
contributed to the variable viability observed between gels of different strontium 
contents (Figure 5.43). The reduced viability of cells cultured with 0 and 100 at. % Sr 
nHA gels suggested that for these experiments, the co-presence of strontium and 
calcium were beneficial for cellular viability, with the 50 at. % Sr nHA gel showing the 
highest level of viability. This was in contrast to the results for the indirect paste assay 
where the 0 and 100 at. % Sr nHA samples had a beneficial effect on cellular viability 
compared to the strontium-substituted samples (Figure 5.35).   
The difference between biocompatibility investigations observed for the pastes and 
gels may have been affected by the different water contents of the two materials, 
since the gel was composed of 90 wt. % water and the paste had an 80 wt. % water 
content. Therefore, the paste culture samples would have been subjected to a higher 
dose of nHA particles and presumably a higher dose of any ions released from the 
materials. Furthermore, the gel material may have released more water into the media 
which may have affected the cellular response.  
The greatest difference in particle morphology was observed for the 100 at. % 
strontium-substituted nHA prepared by both methods (Figure 5.14 and Figure 5.23). 
For the pastes prepared using optimised method 1, the 0 at. % Sr nHA paste had a 
significantly higher viability level than the 100 at. % strontium nHA paste when the 
direct biocompatibility was compared. However, for the gels prepared using optimised 
method 3 there was no significant difference in the direct viability between 0 and 100 
at. % Sr nHA. This makes it difficult to conclude whether particle morphology has a 
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distinct effect on cell viability. As mentioned previously, the combination of chemical 
and morphological changes can make it difficult to ascertain which changes have the 
greatest effect of cellular viability.    
The strontium-substituted nHA particles produced by the two different methods had 
a similar morphology when samples containing the same Sr content were compared.  
For the direct biocompatibility assays, the co-presence of strontium and calcium in 
the gel had a beneficial effect on cellular viability; for the paste investigations the 
samples with strontium and calcium generally did not have a detrimental effect on the 
cells. These results suggest that the materials are not cytotoxic and are therefore 
promising biomaterials.  
As discussed in section 2.5.1.1 Substitutions Intended to Enhance the Bioactivity of 
Hydroxyapatite, few detailed reports are published regarding the biocompatibility of 
strontium-substituted nHA. However, those which have been published have 
concluded a variety of optimal strontium concentrations. It must be noted that different 
strontium content ranges are often considered which makes it difficult to compare 
between studies. Furthermore, the investigations of different forms of material and 
different particle morphologies can further complicate the results due to their distinct 
effects on cellular behaviour.  
Several experiments with MG63 cells tested on Sr nHA have reported that the 
presence of Sr has a positive effects on cellular viability [115, 132, 242]. In contrast, 
other investigations have found that SrHA has no significant effect on cellular viability 
for MSCs [134] or for L929 fibroblasts [243]. These results highlight the limitations of 
in vitro biocompatibility testing, as different results may be obtained using different 
cells types. For instance, Crawford et al. have reported that nHA particles have a 
cytotoxic effect for a range of cell types, with two dimensional cultures showing 
increased sensitivity compared to three dimensional systems [244]. It was found that 
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some nHA particles had been internalised by the cells which may have contributed to 
the toxicity.  
The investigation of the full compositional range of strontium-substituted nHA 
produced by different preparation methods in this thesis has highlighted the sensitivity 
of in vitro biocompatibility testing; similar materials produced using different methods 
have significantly different results. Without the presence of the complex in vivo 
processes it is not possible to fully conclude which materials may be more beneficial 
to encourage bone healing. Due to the limitations of in vitro testing it is necessary to 
investigate the biocompatibility of the materials in an in vivo model as outlined in 
Chapter 8 Future Work.  
This report has demonstrated the successful production of strontium-substituted nHA 
pastes and gels using relatively simple, low cost methodologies. The current evidence 
suggests that these materials are likely to have a beneficial biological response. 
Therefore, these investigations are of great interest for the development of the next 
generation of nHA pastes. Few reports in the literature investigate the production of 
injectable strontium-substituted nHA systems and therefore these studies 
considerably add to the prior knowledge, which can be used to develop superior 
biomaterials with enhanced functionality.   
6.4 Production and Characterisation of Silver-doped Nanoscale 
Hydroxyapatite (Altered Method 1) 
The successful formation of nHA in all the silver-doped samples was displayed by X-
ray diffraction (Figure 5.28) and confirmed by FTIR-ATR analysis (Figure 5.31). The 
presence of silver phosphate when 10 at. % silver doping was attempted highlighted 
the sensitive balance of the precipitation system; when present in high levels the 
formation of silver phosphate effectively removed phosphorous from the solution 
which should ensure that any precipitated HA is not calcium-deficient. This is due to 
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the effective increase in the calcium: phosphorus ratio. The greater amount of β-TCP 
observed for the higher silver-doped samples demonstrated that increased amounts 
of silver had a destabilising effect on the HA crystal lattice (Figure 5.29). Indeed, the 
increased thermal decomposition of the silver-doped samples suggested that either 
the presence of silver aided the thermal decomposition of the samples or that a more 
unstable nHA was precipitated.  
The majority of investigations reported in the literature used a substitution approach 
where the amount of calcium in the method was reduced in order to allow silver to 
substitute readily into the crystal lattice. However, this approach makes it difficult to 
conclude whether the decreased thermal stability was due to silver substitution or the 
precipitation of a calcium-deficient apatite which has been reported to have a lower 
thermal stability [89, 213]. In this study, since a constant amount of calcium hydroxide 
was used regardless of the level of silver nitrate addition, it was unlikely that an 
excessively calcium-deficient HA was precipitated, especially considering the 
effective increase in calcium: phosphorous ratio caused by the silver phosphate 
formation for the 10 at. % silver-doped sample. It is possible that trace amounts of 
silver phosphate were formed in the 2 and 5 at. % samples, which were undetectable 
by XRD due to their small quantities.  
The decreased thermal stability of the silver-doped samples may be due to the partial 
substitution of silver for calcium atoms in the HA structure as suggested by other 
researchers [152, 157, 161]. Specifically, the hydroxyl vacancy was reported to 
contribute to the increased thermal decomposition caused by the difference in charge 
between Ag+ and Ca2+ [157]. The increased ionic radius of Ag+ (0.128 nm) when 
compared to Ca2+ (0.099 nm) was also reported to increase the unit cell parameters 
of the silver substituted nHA. Alternatively, silver may be present on the surface of 
the nHA crystal or may be in the form of free ions in the aqueous paste. The presence 
of a metallic silver phase in the sintered silver-doped samples demonstrated that the 
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high temperature treatment may have caused the dissociation of silver from the nHA. 
Otherwise, the silver may be present due to the decomposition of silver phosphate or 
residual silver nitrate.   
The peak shift observed in the phosphate group bands in the FTIR-ATR spectra for 
the unsintered and sintered 10 at. % silver-doped sample may indicate that silver 
substitution has taken place (Figure 5.32 A and Figure 5.34 A). As seen for the 
strontium-substituted samples, a peak shift indicates a change in the phosphate 
environment, which may potentially be due to the incorporation of the larger silver ion. 
However, no significant peak shift was observed for the XRD patterns suggesting that 
the substitution of silver had a minor effect on the unit cell parameters, perhaps due 
to a very low level of incorporation into the unit cell.  
The precipitated nHA had a small crystallite size as demonstrated by the broad XRD 
peaks and quantified by the relatively large FWHM of the (002) XRD peak (Table 5.9). 
The decrease in FWHM after high temperature sintering corresponded with an 
increase in the sample crystallite size. It was reported elsewhere that HA samples 
with an increased silver content had a lower crystallinity, which in turn increased the 
solubility [154]. In this project, although the XRD patterns of the nHA samples with 
different amount of silver doping were similar, the hydroxyl and phosphate peaks of 
the FTIR-ATR spectra were less defined for the higher silver-doped samples. Other 
reports have correlated these changes in FTIR spectra with a lower HA crystallinity 
[208, 233]. 
XRF results demonstrated the incorporation of silver into the product albeit with a 
decreased silver: calcium molar ratio than that was used in the method (Table 5.9). 
The lower levels were potentially due to silver being washed away during the washing 
of the silver-doped nHA suspensions. The difficulty of silver incorporation was also 
demonstrated by the precipitation of a silver phosphate phase. Other reports have 
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also reported lower levels of silver incorporation than attempted. For instance, the 
highest incorporation level of 10 wt. % silver attempted by Lim et al. only resulted in 
1.1 wt. % silver content in the product when analysed using XRF [161]. However, it 
should also be noted that the sublimation of nanometer-sized has been reported at 
950 K (677 °C) [245] which could also have affected the silver: calcium molar ratios 
during the XRF analysis.   
TEM analysis displayed no noticeable changes in the size or shape of the nHA 
particles obtained from the wet precipitation with different amounts of silver doping 
(Figure 5.30). Several papers also reported no significant changes in nHA 
morphology with the addition of silver [149, 152, 154]. However, small dark particles 
were observed on the 5 and 10 at. % samples in this project. This observation 
corresponded with the TEM carried out by other researchers who had attempted the 
addition of silver nanoparticles to nHA [155, 156]. These reports clearly showed the 
presence of small silver particles which were noticeably darker that the nHA particles 
when observed using TEM. This may demonstrate that part of the silver content is 
not substituted in the lattice; instead the silver is present on the surface of the 
particles. However, this may be in the form of silver phosphate which was detected in 
the XRD analysis (Figure 5.28).    
The clear zones of inhibition surrounding the silver-doped nHA pastes in the agar 
diffusion assay displayed the diffusion limited nature of the antibacterial activity 
(Figure 5.48). Furthermore, ICP-MS analysis of the agar surrounding the pastes 
demonstrated that the antibacterial activity of the pastes was at least partially due to 
the action of diffusible silver ions (Figure 5.49). The diffusion limited mobility of the 
silver ions is likely to be beneficial for the in vivo activity of the pastes. Indeed, it was 
reported by Peetsch et al. that the cytotoxic effects of silver-doped calcium 
phosphates observed in vitro were due to the rapid release of silver ions [246]. In this 
study it was also suggested that in vivo, the diffusion limited nature of the silver 
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release combined with the rapid dilution of silver ions would reduce the cytotoxic 
effects to the host cells; it was believed that this approach would maintain a potent 
antibacterial effect at the site of implantation for antibacterial nanoparticle coatings on 
calcium phosphate [247]. Therefore in our studies, the low levels of silver detected in 
the agar, with the maximum reading of 7 ng.mg-1, showed that the silver beneficially 
remained in close association with the nHA phase during incubation at 37 °C.  
The reduction of metallic silver on the surface of the silver-doped nHA pastes during 
incubation with S. aureus, whilst no reduction was observed when the pastes was 
incubated with P. aeruginosa, demonstrated the unusual behaviour of the pastes in 
the presence of different bacteria (Figure 5.48). It was noted that the reduction of the 
silver may have limited the diffusion potential of the silver ions into the agar (Figure 
5.49), thereby maintaining a high level of antibacterial effectiveness at the paste site. 
Whilst there is no definite explanation for the surface reduction of the silver, this effect 
may have been caused by a reaction with intracellular contents or metabolites.           
When investigated in suspension culture, the apparent antibacterial activity of the 
nHA with no silver-doping was attributed to the probable adhesion of bacteria to the 
nHA, causing agglomeration and aggregation, thus reducing the optical density of the 
suspension (Figure 5.50). This effect was likely to be aided by the high surface area 
to volume ratio of the nHA particles with a similar effect being reported by Ciobanu et 
al. [149]. In detail, Ciobanu et al. found statistically lower levels of adherence of S. 
aureus on the silver-doped nHA powders investigated when compared to undoped 
nHA powders. This demonstrated the strong affinity of bacteria to adhere to nHA and 
therefore the need for antibacterial consideration when designing implantable nHA 
materials. The antibacterial activity of the silver-doped samples was noticeably higher 
and therefore was evidently an effect of silver incorporation, with an increased growth 
reduction effect observed for the nHA pastes with a higher silver content. This was 
clearly shown by the decreasing MIC with increasing silver content (Table 5.10). The 
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unexpected increase in optical density observed for the highest concentrations of the 
10 at. % silver-doped nHA paste may have been due to the reduction of silver by the 
bacteria as observed in the agar diffusion assays.    
Potent antibacterial activity of silver HA powders and coatings have been reported by 
other researchers. Typically, dose dependent antibacterial activity was observed with 
higher levels of silver incorporation contributing to a more effective bactericidal 
response [154, 161]. In a study by Stanic et al. the antimicrobial properties of silver-
doped nHA powders were studied using E.coli, S. aureus and C. albicans. Using 
atomic force microscopy, it was found that incubation with the silver-doped materials 
had caused changes in cellular morphology for all organisms investigated which may 
have contributed to cell death. Low levels of haemolysis demonstrated good blood 
compatibility suggesting that these materials have promising biocompatibility [154].   
Silver is a particularly potent antibacterial agent due to its multiple modes of action on 
the bacterial cell, and acts primarily with exposed sulfhydryl complexes to form S-Ag 
groups [165]. This reaction has extensive toxic effects including membrane potential 
disruption and the inhibition of adenosine triphosphate production [165, 166]. 
Furthermore, the membrane integrity of the cells is compromised, and the action of 
silver causes the denaturation of key metabolic enzymes. The production of free-
radicals and the interaction of silver with DNA further compound the toxicity of silver. 
In detail, pyrimidine dimerization disrupts DNA replication, which prevents bacterial 
reproduction [165]. Indeed it is these multiple modes of action that makes silver a 
promising element to combat the rise of antibiotic resistant bacteria. For instance, it 
was reported by Samani et al. that silver-doped HA coatings had effective 
antibacterial activity against methicillin-resistant S. aureus (MRSA) in terms of 
reducing the proliferation rate [157].  
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The potent antibacterial activity of the silver-doped nHA pastes produced in this thesis 
support the antibacterial effectiveness of silver reported elsewhere. Therefore, these 
materials are very promising for reducing the incidence of implant associated 
infections whilst maintaining an injectable form which can allow for minimally invasive 
surgery to be performed.   
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7. Conclusions 
Although hydroxyapatite has been used extensively for bone augmentation, relatively 
little research has been directed at the development of nHA for use as a medical 
device.  As well as having injectable properties to allow for minimally invasive surgical 
intervention, a combination of inorganically modified nHA and water has the potential 
to offer enhanced biofunctionality. As outlined in Chapter 3, the aim of this project 
was therefore to develop methods to produce modified nHA pastes and gels, and to 
characterise the resulting materials to better understand the chemical processes 
underpinning their preparation and properties. The conclusions of this research may 
be summarised as: 
1. Of the nHA production methods investigated, the reaction of calcium hydroxide and 
phosphoric acid (method 1) was identified as the most promising route for the wet 
precipitation of nHA with a close chemical similarity to stoichiometric HA. Further 
advantages included the lack of noxious chemical by-products, obviously attractive in 
the preparation of a biomaterial. The nHA sol-gel production method based on the 
reaction of calcium nitrate and ammonium phosphate (method 3) was also selected 
for further development due to its ability to form a stable gel during the drying process. 
2. Development of these two selected methods showed that the alteration of synthesis 
parameters had a marked effect on nHA chemistry and morphology. These 
investigations demonstrated that rapid mixing methods may be implemented which 
allowed for the preparation of nHA with biomimetic features, specifically carbonate-
substituted and calcium-deficient nHA.  For method 1, the rapid addition of phosphoric 
acid into the calcium hydroxide suspension eliminated the calcium hydroxide residue 
that was observed with a slower addition rate. The increase in phosphoric acid 
solution addition rate also decreased the aspect ratio of the nHA particles. For method 
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3, a high pH was critical for the formation of nHA with a high thermal stability and also 
for the formation of a stable gel product. 
3. A range of strontium-substituted nHA (0, 2.5, 5, 10, 50 and 100 at. % Sr) was 
successfully produced using optimised methods 1 and 3. Both methods allowed for 
an accurate incorporation of strontium into the product, with the synthesised nHA 
containing an amount of strontium close to attempted substitution level. When fully 
substituted (i.e. 100 at. %) strontium hydroxyapatite was prepared, the particle aspect 
ratio was increased. This was thought to be most likely due to changes in the 
precipitation rate during production. The strontium-substituted nHA had a higher 
radiopacity that was proportional to its strontium content. Initial in 
vitro biocompatibility tests suggested that the majority of the Sr nHA pastes and gels 
supported the growth of osteoblastic-like cells in direct and indirect contact. 
4. Silver-doped nHA (0, 2, 5 and 10 at. %) pastes were also produced using a modified 
method 1. The detection of a silver phosphate phase when 10 at. % silver-doped nHA 
was attempted, highlighted the sensitivity of the reaction and suggested that the 
maximum level of silver-doping had been exceeded. Although the amount of silver 
incorporated in the product was lower than the attempted level, all the silver-doped 
pastes had potent antibacterial properties. The antibacterial activity of the silver-
doped nHA paste was found to be dependent on the silver content of the paste, with 
higher levels of silver doping having a greater antibacterial response. Diffusible silver 
ions were at least partially responsible for the antibacterial activity of the pastes, and 
the low level of diffusion suggested that the materials could beneficially maintain a 
high level of antibacterial activity at the site of implantation. 
The investigations reported in this thesis are the first detailed reports of methods that 
have successfully produced strontium-substituted nHA pastes and gels, and silver-
doped nHA pastes which are promising materials with enhanced functionality for bone 
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augmentation. These materials are expected to be particularly useful due to the 
enhanced bioactivity and potent antibacterial activity of strontium-substituted and 
silver-doped nHA respectively. Therefore, this work has great potential to aid the 
development of novel biomaterials with improved functionality. The further work 
required for future clinical product development is detailed in the next chapter. 
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8. Future Work 
Several aspects of this project should be considered for future development of 
injectable bone augmentation materials: 
1. Firstly the scale up of the optimised production methods are likely to affect the 
material properties and therefore the biological properties of the synthesised 
materials.  This is due to the sensitive nature of the precipitated nHA with the chemical 
nature and morphology particularly affected by solution pH and reactant addition rate. 
Therefore, in order to commercialise these materials it would be necessary to 
carefully consider how the scale up of such methods may affect the physicochemical 
properties of the materials. For example, effective mixing would be required to 
achieve an appropriate reactant distribution which in turn should ensure the 
successful conversion of the reactants into nHA.   
2. In these investigations, variable results were obtained regarding the in vitro 
biocompatibility of the strontium-substituted nHA pastes and gels. In combination with 
scale up methods, an optimal strontium content should be investigated in order to 
fully optimise the biomaterial biological behaviour. Specifically, this could be initially 
investigated using quantitative PCR in order to better understand the effect of 
strontium-substituted nHA on the gene expression and in turn the biological behaviour 
of the material on the differentiation and activity of bone cells. Furthermore, the in vivo 
response of the strontium-substituted nHA materials should be investigated due to 
the limitations of in vitro experiments when analysing nHA paste and gel materials. In 
detail, the early bone regeneration response should be monitored in order to better 
understand the bone regeneration capacity of these materials.      
3. The promising antibacterial activity of the silver-doped nHA paste suggested that 
this material might be useful for the prevention and treatment of deep bone infections. 
However, investigations must be carried out in order to ascertain the potential 
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cytotoxic effects of the silver-doped material. Firstly, the silver-doped paste materials 
should be screened in vitro in order to balance the antibacterial response with 
acceptable levels of cellular viability. Once determined, optimal silver concentrations 
should be screened in vivo in order to ensure the safety of these materials. The potent 
antibacterial activity of the silver-doped pastes suggested that perhaps a low level of 
silver-doping could be utilised in order to reduce potential mammalian cytotoxicity 
effects whilst maintaining antibacterial properties.  
4. As well as enhancing the chemical composition, the paste and gels should be 
optimised in terms of water content as this parameter is likely to have an effect on the 
biological response. Furthermore, the water content has a direct effect on the 
rheological properties and in turn the injectability of the pastes and gels which must 
be optimised for clinical use. Greater injectability is required to treat deep bone voids 
and the surgeon must be able to easily deliver the materials to the required site. For 
example, excessive shear thinning behaviour would be undesirable for the controlled 
delivery of the paste or gel. This is due to the requirement of a large force to 
commence delivery, but once the material starts to flow, the force required for 
continued injection decreases. The shear thinning rheological behaviour of the 
materials should therefore be investigated and optimised.  
5. Further developments could be to combine strontium and silver in order to 
synthesise a material with bioactive and antibacterial properties. Alternatively, 
biomimetic multi-substitutions such as carbonate, magnesium and strontium could be 
employed in order to promote in vivo resorption which in turn may promote optimal 
tissue regeneration.   
6. Other interesting designs to consider could be the development of different 
products to suit different groups of patients. By considering the needs of individual 
patients, bone tissue regeneration may be truly optimised by matching the specific 
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requirements of the patient with a particular optimised product. This stratified design 
approach may be the most effective option to fulfil the needs of the patient whilst 
satisfying socio-economic demands.   
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